fbpx
Wikipedia

Alzheimer's disease

January 29, 2023

"Alzheimer" redirects here. For other uses, see Alzheimer (disambiguation).

Alzheimer's disease (AD) is a neurodegenerative disease that usually starts slowly and progressively worsens.[2] It is the cause of 60–70% of cases of dementia.[2][11] The most common early symptom is difficulty in remembering recent events.[1] As the disease advances, symptoms can include problems with language, disorientation (including easily getting lost), mood swings, loss of motivation, self-neglect, and behavioral issues.[2] As a person's condition declines, they often withdraw from family and society.[12] Gradually, bodily functions are lost, ultimately leading to death.[13] Although the speed of progression can vary, the typical life expectancy following diagnosis is three to nine years.[9][14]

Alzheimer's disease
Diagram of a normal brain compared to the brain of a person with Alzheimer's
Pronunciation
  • ˈaltshʌɪməz
SpecialtyNeurology
SymptomsMemory loss, problems with language, disorientation, mood swings[1][2]
ComplicationsDehydration and pneumonia in the terminal stage[3]
Usual onsetOver 65 years old[4]
DurationLong term[2]
CausesPoorly understood[1]
Risk factorsGenetics, head injuries, depression, hypertension[1]
Diagnostic methodBased on symptoms and cognitive testing after ruling out other possible causes[5]
Differential diagnosisNormal aging,[1] Lewy body dementia,[6] Trisomy 21.[7]
MedicationAcetylcholinesterase inhibitors, NMDA receptor antagonists (small benefit)[8]
PrognosisLife expectancy 3–9 years[9]
Frequency50 million (2020)[10]

The cause of Alzheimer's disease is poorly understood.[12] There are many environmental and genetic risk factors associated with its development. The strongest genetic risk factor is from an allele of APOE.[15][16] Other risk factors include a history of head injury, clinical depression, and high blood pressure.[1] The disease process is largely associated with amyloid plaques, neurofibrillary tangles, and loss of neuronal connections in the brain.[13] A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes.[5] Initial symptoms are often mistaken for normal aging.[12] Examination of brain tissue is needed for a definite diagnosis, but this can only take place after death.[13] Good nutrition, physical activity, and engaging socially are known to be of benefit generally in aging, and these may help in reducing the risk of cognitive decline and Alzheimer's; in 2019 clinical trials were underway to look at these possibilities.[13] There are no medications or supplements that have been shown to decrease risk.[17]

No treatments stop or reverse its progression, though some may temporarily improve symptoms.[2] Affected people increasingly rely on others for assistance, often placing a burden on the caregiver.[18] The pressures can include social, psychological, physical, and economic elements.[18] Exercise programs may be beneficial with respect to activities of daily living and can potentially improve outcomes.[19] Behavioral problems or psychosis due to dementia are often treated with antipsychotics, but this is not usually recommended, as there is little benefit and an increased risk of early death.[20][21]

As of 2020, there were approximately 50 million people worldwide with Alzheimer's disease.[10] It most often begins in people over 65 years of age, although up to 10% of cases are early-onset affecting those in their 30s to mid-60s.[13][4] It affects about 6% of people 65 years and older,[12] and women more often than men.[22] The disease is named after German psychiatrist and pathologist Alois Alzheimer, who first described it in 1906.[23] Alzheimer's financial burden on society is large, with an estimated global annual cost of US$1 trillion.[10] Alzheimer's disease is currently ranked as the seventh leading cause of death in the United States.[24]

Signs and symptoms

The course of Alzheimer's is generally described in three stages, with a progressive pattern of cognitive and functional impairment.[25][13] The three stages are described as early or mild, middle or moderate, and late or severe.[25][13] The disease is known to target the hippocampus which is associated with memory, and this is responsible for the first symptoms of memory impairment. As the disease progresses so does the degree of memory impairment.[13]

First symptoms

 
Stages of atrophy in Alzheimer's

The first symptoms are often mistakenly attributed to aging or stress.[26] Detailed neuropsychological testing can reveal mild cognitive difficulties up to eight years before a person fulfills the clinical criteria for diagnosis of Alzheimer's disease.[27] These early symptoms can affect the most complex activities of daily living.[28] The most noticeable deficit is short term memory loss, which shows up as difficulty in remembering recently learned facts and inability to acquire new information.[27]

Subtle problems with the executive functions of attentiveness, planning, flexibility, and abstract thinking, or impairments in semantic memory (memory of meanings, and concept relationships) can also be symptomatic of the early stages of Alzheimer's disease.[27] Apathy and depression can be seen at this stage, with apathy remaining as the most persistent symptom throughout the course of the disease.[29][30] Mild cognitive impairment (MCI) is often found to be a transitional stage between normal aging and dementia. MCI can present with a variety of symptoms, and when memory loss is the predominant symptom, it is termed amnestic MCI and is frequently seen as a prodromal stage of Alzheimer's disease.[31] Amnestic MCI has a greater than 90% likelihood of being associated with Alzheimer's.[32]

Early stage

In people with Alzheimer's disease, the increasing impairment of learning and memory eventually leads to a definitive diagnosis. In a small percentage, difficulties with language, executive functions, perception (agnosia), or execution of movements (apraxia) are more prominent than memory problems.[33] Alzheimer's disease does not affect all memory capacities equally. Older memories of the person's life (episodic memory), facts learned (semantic memory), and implicit memory (the memory of the body on how to do things, such as using a fork to eat or how to drink from a glass) are affected to a lesser degree than new facts or memories.[34][35]

Language problems are mainly characterised by a shrinking vocabulary and decreased word fluency, leading to a general impoverishment of oral and written language.[33][36] In this stage, the person with Alzheimer's is usually capable of communicating basic ideas adequately.[33][36][37] While performing fine motor tasks such as writing, drawing, or dressing, certain movement coordination and planning difficulties (apraxia) may be present, but they are commonly unnoticed.[33] As the disease progresses, people with Alzheimer's disease can often continue to perform many tasks independently, but may need assistance or supervision with the most cognitively demanding activities.[33]

Middle stage

Progressive deterioration eventually hinders independence, with subjects being unable to perform most common activities of daily living.[33] Speech difficulties become evident due to an inability to recall vocabulary, which leads to frequent incorrect word substitutions (paraphasias). Reading and writing skills are also progressively lost.[33][37] Complex motor sequences become less coordinated as time passes and Alzheimer's disease progresses, so the risk of falling increases.[33] During this phase, memory problems worsen, and the person may fail to recognise close relatives.[33] Long-term memory, which was previously intact, becomes impaired.[33]

Behavioral and neuropsychiatric changes become more prevalent. Common manifestations are wandering, irritability and emotional lability, leading to crying, outbursts of unpremeditated aggression, or resistance to caregiving.[33] Sundowning can also appear.[38] Approximately 30% of people with Alzheimer's disease develop illusionary misidentifications and other delusional symptoms.[33] Subjects also lose insight of their disease process and limitations (anosognosia).[33] Urinary incontinence can develop.[33] These symptoms create stress for relatives and caregivers, which can be reduced by moving the person from home care to other long-term care facilities.[33][39]

Late stage

 
A normal brain on the left and a late-stage Alzheimer's brain on the right

During the final stage, known as the late-stage or severe stage, there is complete dependence on caregivers.[13][25][33] Language is reduced to simple phrases or even single words, eventually leading to complete loss of speech.[33][37] Despite the loss of verbal language abilities, people can often understand and return emotional signals. Although aggressiveness can still be present, extreme apathy and exhaustion are much more common symptoms. People with Alzheimer's disease will ultimately not be able to perform even the simplest tasks independently; muscle mass and mobility deteriorates to the point where they are bedridden and unable to feed themselves. The cause of death is usually an external factor, such as infection of pressure ulcers or pneumonia, not the disease itself.[33]

Causes

Proteins fail to function normally. This disrupts the work of the brain cells affected and triggers a toxic cascade, ultimately leading to cell death and later brain shrinkage.[40]

Alzheimer's disease is believed to occur when abnormal amounts of amyloid beta (Aβ), accumulating extracellularly as amyloid plaques and tau proteins, or intracellularly as neurofibrillary tangles, form in the brain, affecting neuronal functioning and connectivity, resulting in a progressive loss of brain function.[41][42] This altered protein clearance ability is age-related, regulated by brain cholesterol,[43] and associated with other neurodegenerative diseases.[44][45]

Advances in brain imaging techniques allow researchers to see the development and spread of abnormal amyloid and tau proteins in the living brain, as well as changes in brain structure and function.[24] Beta-amyloid is a fragment of a larger protein. When these fragments cluster together, a toxic effect appears on neurons and disrupt cell-to-cell communication. Larger deposits called amyloid plaques are thus further formed.[40]

Tau proteins are responsible in neuron's internal support and transport system to carry nutrients and other essential materials. In Alzheimer's disease, the shape of tau proteins is altered and thus organize themselves into structures called neurofibrillary tangles. The tangles disrupt the transport system and are toxic to cells.

The cause for most Alzheimer's cases is still mostly unknown,[10] except for 1–2% of cases where deterministic genetic differences have been identified.[15] Several competing hypotheses attempt to explain the underlying cause; the two predominant hypotheses are the amyloid beta (Aβ) hypothesis and the cholinergic hypothesis.[10]

The oldest hypothesis, on which most drug therapies are based, is the cholinergic hypothesis, which proposes that Alzheimer's disease is caused by reduced synthesis of the neurotransmitter acetylcholine.[10] The loss of cholinergic neurons noted in the limbic system and cerebral cortex, is a key feature in the progression of Alzheimer's.[31] The 1991 amyloid hypothesis postulated that extracellular amyloid beta (Aβ) deposits are the fundamental cause of the disease.[46][47] Support for this postulate comes from the location of the gene for the amyloid precursor protein (APP) on chromosome 21, together with the fact that people with trisomy 21 (Down syndrome) who have an extra gene copy almost universally exhibit at least the earliest symptoms of Alzheimer's disease by 40 years of age.[7] A specific isoform of apolipoprotein, APOE4, is a major genetic risk factor for Alzheimer's disease.[11] While apolipoproteins enhance the breakdown of beta amyloid, some isoforms are not very effective at this task (such as APOE4), leading to excess amyloid buildup in the brain.[48]

Genetic

Only 1–2% of Alzheimer's cases are inherited (autosomal dominant). These types are known as early onset familial Alzheimer's disease, can have a very early onset, and a faster rate of progression.[15] Early onset familial Alzheimer's disease can be attributed to mutations in one of three genes: those encoding amyloid-beta precursor protein (APP) and presenilins PSEN1 and PSEN2.[32] Most mutations in the APP and presenilin genes increase the production of a small protein called amyloid beta (Aβ)42, which is the main component of amyloid plaques.[49] Some of the mutations merely alter the ratio between Aβ42 and the other major forms—particularly Aβ40—without increasing Aβ42 levels.[50] Two other genes associated with autosomal dominant Alzheimer's disease are ABCA7 and SORL1.[51]

Most cases of Alzheimer's are not inherited and are termed sporadic Alzheimer's disease, in which environmental and genetic differences may act as risk factors. Most cases of sporadic Alzheimer's disease in contrast to familial Alzheimer's disease are late-onset Alzheimer's disease (LOAD) developing after the age of 65 years. Less than 5% of sporadic Alzheimer's disease have an earlier onset.[15] The strongest genetic risk factor for sporadic Alzheimer's disease is APOEε4.[16] APOEε4 is one of four alleles of apolipoprotein E (APOE). APOE plays a major role in lipid-binding proteins in lipoprotein particles and the epsilon4 allele disrupts this function.[52] Between 40 and 80% of people with Alzheimer's disease possess at least one APOEε4 allele.[53] The APOEε4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes.[54] Like many human diseases, environmental effects and genetic modifiers result in incomplete penetrance. For example, certain Nigerian populations do not show the relationship between dose of APOEε4 and incidence or age-of-onset for Alzheimer's disease seen in other human populations.[55][56]

Alleles in the TREM2 gene have been associated with a 3 to 5 times higher risk of developing Alzheimer's disease.[57]

A Japanese pedigree of familial Alzheimer's disease was found to be associated with a deletion mutation of codon 693 of APP.[58] This mutation and its association with Alzheimer's disease was first reported in 2008,[59] and is known as the Osaka mutation. Only homozygotes with this mutation have an increased risk of developing Alzheimer's disease. This mutation accelerates Aβ oligomerization but the proteins do not form the amyloid fibrils that aggregate into amyloid plaques, suggesting that it is the Aβ oligomerization rather than the fibrils that may be the cause of this disease. Mice expressing this mutation have all the usual pathologies of Alzheimer's disease.[60]

Other hypotheses

 
In Alzheimer's disease, changes in tau protein lead to the disintegration of microtubules in brain cells.

The tau hypothesis proposes that tau protein abnormalities initiate the disease cascade.[47] In this model, hyperphosphorylated tau begins to pair with other threads of tau as paired helical filaments. Eventually, they form neurofibrillary tangles inside nerve cell bodies.[61] When this occurs, the microtubules disintegrate, destroying the structure of the cell's cytoskeleton which collapses the neuron's transport system.[62]

A number of studies connect the misfolded amyloid beta and tau proteins associated with the pathology of Alzheimer's disease, as bringing about oxidative stress that leads to chronic inflammation.[63] Sustained inflammation (neuroinflammation) is also a feature of other neurodegenerative diseases including Parkinson's disease, and ALS.[64] Spirochete infections have also been linked to dementia.[10] DNA damages accumulate in AD brains; reactive oxygen species may be the major source of this DNA damage.[65]

Sleep disturbances are seen as a possible risk factor for inflammation in Alzheimer's disease. Sleep problems have been seen as a consequence of Alzheimer's disease but studies suggest that they may instead be a causal factor. Sleep disturbances are thought to be linked to persistent inflammation.[66] The cellular homeostasis of biometals such as ionic copper, iron, and zinc is disrupted in Alzheimer's disease, though it remains unclear whether this is produced by or causes the changes in proteins.[10][67] Smoking is a significant Alzheimer's disease risk factor.[1] Systemic markers of the innate immune system are risk factors for late-onset Alzheimer's disease.[68] Exposure to air pollution may be a contributing factor to the development of Alzheimer's disease.[10]

One hypothesis posits that dysfunction of oligodendrocytes and their associated myelin during aging contributes to axon damage, which then causes amyloid production and tau hyper-phosphorylation as a side effect.[69][70]

Retrogenesis is a medical hypothesis that just as the fetus goes through a process of neurodevelopment beginning with neurulation and ending with myelination, the brains of people with Alzheimer's disease go through a reverse neurodegeneration process starting with demyelination and death of axons (white matter) and ending with the death of grey matter.[71] Likewise the hypothesis is, that as infants go through states of cognitive development, people with Alzheimer's disease go through the reverse process of progressive cognitive impairment.[72]

The association with celiac disease is unclear, with a 2019 study finding no increase in dementia overall in those with CD, while a 2018 review found an association with several types of dementia including Alzheimer's disease.[73][74]

Pathophysiology

 
Histopathologic images of Alzheimer's disease, in the CA3 area of the hippocampus, showing an amyloid plaque (top right), neurofibrillary tangles (bottom left), and granulovacuolar degeneration bodies (bottom center)

Neuropathology

Alzheimer's disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions. This loss results in gross atrophy of the affected regions, including degeneration in the temporal lobe and parietal lobe, and parts of the frontal cortex and cingulate gyrus.[75] Degeneration is also present in brainstem nuclei particularly the locus coeruleus in the pons.[76] Studies using MRI and PET have documented reductions in the size of specific brain regions in people with Alzheimer's disease as they progressed from mild cognitive impairment to Alzheimer's disease, and in comparison with similar images from healthy older adults.[77][78]

Both Aβ plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those with Alzheimer's disease,[79] especially in the hippocampus.[80] However, Alzheimer's disease may occur without neurofibrillary tangles in the neocortex.[81] Plaques are dense, mostly insoluble deposits of beta-amyloid peptide and cellular material outside and around neurons. Tangles (neurofibrillary tangles) are aggregates of the microtubule-associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves. Although many older individuals develop some plaques and tangles as a consequence of aging, the brains of people with Alzheimer's disease have a greater number of them in specific brain regions such as the temporal lobe.[82] Lewy bodies are not rare in the brains of people with Alzheimer's disease.[83]

Biochemistry

Main article: Biochemistry of Alzheimer's disease
 
 
 
Enzymes act on the APP (amyloid-beta precursor protein) and cut it into fragments. The beta-amyloid fragment is crucial in the formation of amyloid plaques in Alzheimer's disease.

Alzheimer's disease has been identified as a protein misfolding disease, a proteopathy, caused by the accumulation of abnormally folded amyloid beta protein into amyloid plaques, and tau protein into neurofibrillary tangles in the brain.[84] Plaques are made up of small peptides, 39–43 amino acids in length, called amyloid beta (Aβ). Amyloid beta is a fragment from the larger amyloid-beta precursor protein (APP) a transmembrane protein that penetrates the neuron's membrane. APP is critical to neuron growth, survival, and post-injury repair.[85][86] In Alzheimer's disease, gamma secretase and beta secretase act together in a proteolytic process which causes APP to be divided into smaller fragments.[87] One of these fragments gives rise to fibrils of amyloid beta, which then form clumps that deposit outside neurons in dense formations known as amyloid plaques.[79][88]

Alzheimer's disease is also considered a tauopathy due to abnormal aggregation of the tau protein. Every neuron has a cytoskeleton, an internal support structure partly made up of structures called microtubules. These microtubules act like tracks, guiding nutrients and molecules from the body of the cell to the ends of the axon and back. A protein called tau stabilises the microtubules when phosphorylated, and is therefore called a microtubule-associated protein. In Alzheimer's disease, tau undergoes chemical changes, becoming hyperphosphorylated; it then begins to pair with other threads, creating neurofibrillary tangles and disintegrating the neuron's transport system.[89] Pathogenic tau can also cause neuronal death through transposable element dysregulation.[90]

Disease mechanism

Exactly how disturbances of production and aggregation of the beta-amyloid peptide give rise to the pathology of Alzheimer's disease is not known.[91][92] The amyloid hypothesis traditionally points to the accumulation of beta-amyloid peptides as the central event triggering neuron degeneration. Accumulation of aggregated amyloid fibrils, which are believed to be the toxic form of the protein responsible for disrupting the cell's calcium ion homeostasis, induces programmed cell death (apoptosis).[93] It is also known that Aβ selectively builds up in the mitochondria in the cells of Alzheimer's-affected brains, and it also inhibits certain enzyme functions and the utilisation of glucose by neurons.[94]

Various inflammatory processes and cytokines may also have a role in the pathology of Alzheimer's disease. Inflammation is a general marker of tissue damage in any disease, and may be either secondary to tissue damage in Alzheimer's disease or a marker of an immunological response.[95] There is increasing evidence of a strong interaction between the neurons and the immunological mechanisms in the brain. Obesity and systemic inflammation may interfere with immunological processes which promote disease progression.[96]

Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain-derived neurotrophic factor (BDNF) have been described in Alzheimer's disease.[97][98]

Diagnosis

See also: Early-onset Alzheimer's disease § Diagnosis
 
PET scan of the brain of a person with Alzheimer's disease showing a loss of function in the temporal lobe

Alzheimer's disease can only be definitively diagnosed with autopsy findings; in the absence of autopsy, clinical diagnoses of AD are "possible" or "probable", based on other findings.[99][100][101] Up to 23% of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD.[100]

AD is usually clinically diagnosed based on the person's medical history, history from relatives, and behavioral observations. The presence of characteristic neurological and neuropsychological features and the absence of alternative conditions supports the diagnosis.[needs update][102][103] Advanced medical imaging with computed tomography (CT) or magnetic resonance imaging (MRI), and with single-photon emission computed tomography (SPECT) or positron emission tomography (PET), can be used to help exclude other cerebral pathology or subtypes of dementia.[104] Moreover, it may predict conversion from prodromal stages (mild cognitive impairment) to Alzheimer's disease.[105] FDA-approved radiopharmaceutical diagnostic agents used in PET for Alzheimer's disease are florbetapir (2012), flutemetamol (2013), florbetaben (2014), and flortaucipir (2020).[106] Because many insurance companies in the United States do not cover this procedure, its use in clinical practice is largely limited to clinical trials as of 2018.[107]

Assessment of intellectual functioning including memory testing can further characterise the state of the disease.[1] Medical organizations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians. Definitive diagnosis can only be confirmed with post-mortem evaluations when brain material is available and can be examined histologically for senile plaques and neurofibrillary tangles.[107][108]

Criteria

There are three sets of criteria for the clinical diagnoses of the spectrum of Alzheimer's disease: the 2013 fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5); the National Institute on Aging-Alzheimer's Association (NIA-AA) definition as revised in 2011; and the International Working Group criteria as revised in 2010.[32][107] Three broad time periods, which can span decades, define the progression of Alzheimer's disease from the preclinical phase, to mild cognitive impairment (MCI), followed by Alzheimer's disease dementia.[109]

Eight intellectual domains are most commonly impaired in AD—memory, language, perceptual skills, attention, motor skills, orientation, problem solving and executive functional abilities, as listed in the fourth text revision of the DSM (DSM-IV-TR).[110]

The DSM-5 defines criteria for probable or possible Alzheimer's for both major and mild neurocognitive disorder.[111][112][101] Major or mild neurocognitive disorder must be present along with at least one cognitive deficit for a diagnosis of either probable or possible AD.[111][113] For major neurocognitive disorder due to Alzheimer's disease, probable Alzheimer's disease can be diagnosed if the individual has genetic evidence of Alzheimer's[114] or if two or more acquired cognitive deficits, and a functional disability that is not from another disorder, are present.[115] Otherwise, possible Alzheimer's disease can be diagnosed as the diagnosis follows an atypical route.[116] For mild neurocognitive disorder due to Alzheimer's, probable Alzheimer's disease can be diagnosed if there is genetic evidence, whereas possible Alzheimer's disease can be met if all of the following are present: no genetic evidence, decline in both learning and memory, two or more cognitive deficits, and a functional disability not from another disorder.[111][117]

The NIA-AA criteria are used mainly in research rather than in clinical assessments.[118] They define Alzheimer's disease through three major stages: preclinical, mild cognitive impairment (MCI), and Alzheimer's dementia.[119][120] Diagnosis in the preclinical stage is complex and focuses on asymptomatic individuals;[120][121] the latter two stages describe individuals experiencing symptoms.[120] The core clinical criteria for MCI is used along with identification of biomarkers,[122] predominantly those for neuronal injury (mainly tau-related) and amyloid beta deposition.[118][120] The core clinical criteria itself rests on the presence of cognitive impairment[120] without the presence of comorbidities.[123][124] The third stage is divided into probable and possible Alzheimer's disease dementia.[124] In probable Alzheimer's disease dementia there is steady impairment of cognition over time and a memory-related or non-memory-related cognitive dysfunction.[124] In possible Alzheimer's disease dementia, another causal disease such as cerebrovascular disease is present.[124]

Techniques

 
Cognitive tests such as the Mini–Mental State Examination (MMSE) can help in the diagnosis of Alzheimer's disease. In this test instructions are given to copy drawings like the one shown, remember some words, read, and subtract numbers serially.

Neuropsychological tests including cognitive tests such as the Mini–Mental State Examination (MMSE), the Montreal Cognitive Assessment (MoCA) and the Mini-Cog are widely used to aid in diagnosis of the cognitive impairments in AD.[125] These tests may not always be accurate, as they lack sensitivity to mild cognitive impairment, and can be biased by language or attention problems;[125] more comprehensive test arrays are necessary for high reliability of results, particularly in the earliest stages of the disease.[126][127]

Further neurological examinations are crucial in the differential diagnosis of Alzheimer's disease and other diseases.[26] Interviews with family members are used in assessment; caregivers can supply important information on daily living abilities and on the decrease in the person's mental function.[128] A caregiver's viewpoint is particularly important, since a person with Alzheimer's disease is commonly unaware of their deficits.[129] Many times, families have difficulties in the detection of initial dementia symptoms and may not communicate accurate information to a physician.[130]

Supplemental testing can rule out other potentially treatable diagnoses and help avoid misdiagnoses.[131] Common supplemental tests include blood tests, thyroid function tests, as well as tests to assess vitamin B12 levels, rule out neurosyphilis and rule out metabolic problems (including tests for kidney function, electrolyte levels and for diabetes).[131] MRI or CT scans might also be used to rule out other potential causes of the symptoms – including tumors or strokes.[125] Delirium and depression can be common among individuals and are important to rule out.[132]

Psychological tests for depression are used, since depression can either be concurrent with Alzheimer's disease (see Depression of Alzheimer disease), an early sign of cognitive impairment,[133] or even the cause.[134][135]

Due to low accuracy, the C-PIB-PET scan is not recommended as an early diagnostic tool or for predicting the development of Alzheimer's disease when people show signs of mild cognitive impairment (MCI).[136] The use of 18F-FDG PET scans, as a single test, to identify people who may develop Alzheimer's disease is not supported by evidence.[137]

Prevention

 
Intellectual activities such as playing chess or regular social interaction have been linked to a reduced risk of Alzheimer's disease in epidemiological studies, although no causal relationship has been found.

There are no disease-modifying treatments available to cure Alzheimer's disease and because of this, AD research has focused on interventions to prevent the onset and progression.[138] There is no evidence that supports any particular measure in preventing Alzheimer's,[1] and studies of measures to prevent the onset or progression have produced inconsistent results. Epidemiological studies have proposed relationships between an individual's likelihood of developing AD and modifiable factors, such as medications, lifestyle, and diet. There are some challenges in determining whether interventions for Alzheimer's disease act as a primary prevention method, preventing the disease itself, or a secondary prevention method, identifying the early stages of the disease.[17] These challenges include duration of intervention, different stages of disease at which intervention begins, and lack of standardization of inclusion criteria regarding biomarkers specific for Alzheimer's disease.[17] Further research is needed to determine factors that can help prevent Alzheimer's disease.[17]

Medication

Cardiovascular risk factors, such as hypercholesterolaemia, hypertension, diabetes, and smoking, are associated with a higher risk of onset and worsened course of AD.[139][140] The use of statins to lower cholesterol may be of benefit in Alzheimer's.[141] Antihypertensive and antidiabetic medications in individuals without overt cognitive impairment may decrease the risk of dementia by influencing cerebrovascular pathology.[1][142] More research is needed to examine the relationship with Alzheimer's disease specifically; clarification of the direct role medications play versus other concurrent lifestyle changes (diet, exercise, smoking) is needed.[1]

Depression is associated with an increased risk for Alzheimer's disease; management with antidepressants may provide a preventative measure.[143]

Historically, long-term usage of non-steroidal anti-inflammatory drugs (NSAIDs) were thought to be associated with a reduced likelihood of developing Alzheimer's disease as it reduces inflammation; however, NSAIDs do not appear to be useful as a treatment.[107] Additionally, because women have a higher incidence of Alzheimer's disease than men, it was once thought that estrogen deficiency during menopause was a risk factor. However, there is a lack of evidence to show that hormone replacement therapy (HRT) in menopause decreases risk of cognitive decline.[144]

Lifestyle

Further information: Neurobiological effects of physical exercise

Certain lifestyle activities, such as physical and cognitive exercises, higher education and occupational attainment, cigarette smoking, stress, sleep, and the management of other comorbidities, including diabetes and hypertension, may affect the risk of developing Alzheimer's.[143]

Physical exercise is associated with a decreased rate of dementia,[145] and is effective in reducing symptom severity in those with AD.[146] Memory and cognitive functions can be improved with aerobic exercises including brisk walking three times weekly for forty minutes.[147] It may also induce neuroplasticity of the brain.[148] Participating in mental exercises, such as reading, crossword puzzles, and chess have shown a potential to be preventative.[143] Meeting the WHO recommendations for physical activity is associated with a lower risk of AD.[149]

Higher education and occupational attainment, and participation in leisure activities, contribute to a reduced risk of developing Alzheimer's,[150] or of delaying the onset of symptoms. This is compatible with the cognitive reserve theory, which states that some life experiences result in more efficient neural functioning providing the individual a cognitive reserve that delays the onset of dementia manifestations.[150] Education delays the onset of Alzheimer's disease syndrome without changing the duration of the disease.[151]

Cessation in smoking may reduce risk of developing Alzheimer's' disease, specifically in those who carry APOE ɛ4 allele.[152][143] The increased oxidative stress caused by smoking results in downstream inflammatory or neurodegenerative processes that may increase risk of developing AD.[153] Avoidance of smoking, counseling and pharmacotherapies to quit smoking are used, and avoidance of environmental tobacco smoke is recommended.[143]

Alzheimer's disease is associated with sleep disorders but the precise relationship is unclear.[154][155] It was once thought that as people get older, the risk of developing sleep disorders and AD independently increase, but research is examining whether sleep disorders may increase the prevalence of AD.[154] One theory is that the mechanisms to increase clearance of toxic substances, including Aβ, are active during sleep.[154][156] With decreased sleep, a person is increasing Aβ production and decreasing Aβ clearance, resulting in Aβ accumulation.[157][154][155] Receiving adequate sleep (approximately 7–8 hours) every night has become a potential lifestyle intervention to prevent the development of AD.[143]

Stress is a risk factor for the development of Alzheimer's.[143] The mechanism by which stress predisposes someone to development of Alzheimer's is unclear, but it is suggested that lifetime stressors may affect a person's epigenome, leading to an overexpression or under expression of specific genes.[158] Although the relationship of stress and Alzheimer's is unclear, strategies to reduce stress and relax the mind may be helpful strategies in preventing the progression or Alzheimer's disease.[159] Meditation, for instance, is a helpful lifestyle change to support cognition and well-being, though further research is needed to assess long-term effects.[148]

Management

There is no cure for Alzheimer's disease; available treatments offer relatively small symptomatic benefits but remain palliative in nature.[10][160] Treatments can be divided into pharmaceutical, psychosocial, and caregiving.

Pharmaceutical

 
Three-dimensional molecular model of donepezil, an acetylcholinesterase inhibitor used in the treatment of Alzheimer's disease symptoms
 
Molecular structure of memantine, a medication approved for advanced Alzheimer's disease symptoms

Medications used to treat the cognitive problems of Alzheimer's disease include: four acetylcholinesterase inhibitors (tacrine, rivastigmine, galantamine, and donepezil) and memantine, an NMDA receptor antagonist. The acetylcholinesterase inhibitors are intended for those with mild to severe Alzheimer's, whereas memantine is intended for those with moderate or severe Alzheimer's disease.[107] The benefit from their use is small.[161][162][163][11]

Reduction in the activity of the cholinergic neurons is a well-known feature of Alzheimer's disease.[164] Acetylcholinesterase inhibitors are employed to reduce the rate at which acetylcholine (ACh) is broken down, thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons.[165] There is evidence for the efficacy of these medications in mild to moderate Alzheimer's disease,[166][161] and some evidence for their use in the advanced stage.[161] The use of these drugs in mild cognitive impairment has not shown any effect in a delay of the onset of Alzheimer's disease.[167] The most common side effects are nausea and vomiting, both of which are linked to cholinergic excess. These side effects arise in approximately 10–20% of users, are mild to moderate in severity, and can be managed by slowly adjusting medication doses.[168] Less common secondary effects include muscle cramps, decreased heart rate (bradycardia), decreased appetite and weight, and increased gastric acid production.[166]

Glutamate is an excitatory neurotransmitter of the nervous system, although excessive amounts in the brain can lead to cell death through a process called excitotoxicity which consists of the overstimulation of glutamate receptors. Excitotoxicity occurs not only in Alzheimer's disease, but also in other neurological diseases such as Parkinson's disease and multiple sclerosis.[169] Memantine is a noncompetitive NMDA receptor antagonist first used as an anti-influenza agent. It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate.[169][170] Memantine has been shown to have a small benefit in the treatment of moderate to severe Alzheimer's disease.[171] Reported adverse events with memantine are infrequent and mild, including hallucinations, confusion, dizziness, headache and fatigue.[172][173] The combination of memantine and donepezil[174] has been shown to be "of statistically significant but clinically marginal effectiveness".[175]

An extract of Ginkgo biloba known as EGb 761 has been used for treating Alzheimer's and other neuropsychiatric disorders.[176] Its use is approved throughout Europe.[177] The World Federation of Biological Psychiatry guidelines lists EGb 761 with the same weight of evidence (level B) given to acetylcholinesterase inhibitors and memantine. EGb 761 is the only one that showed improvement of symptoms in both Alzheimer's disease and vascular dementia. EGb 761 may have a role either on its own or as an add-on if other therapies prove ineffective.[176] A 2016 review concluded that the quality of evidence from clinical trials on Ginkgo biloba has been insufficient to warrant its use for treating Alzheimer's disease.[178]

Atypical antipsychotics are modestly useful in reducing aggression and psychosis in people with Alzheimer's disease, but their advantages are offset by serious adverse effects, such as stroke, movement difficulties or cognitive decline.[179] When used in the long-term, they have been shown to associate with increased mortality.[180] Stopping antipsychotic use in this group of people appears to be safe.[181]

Psychosocial

Psychosocial interventions are used as an adjunct to pharmaceutical treatment and can be classified within behavior-, emotion-, cognition- or stimulation-oriented approaches.[needs update][182]

Behavioral interventions attempt to identify and reduce the antecedents and consequences of problem behaviors. This approach has not shown success in improving overall functioning,[183] but can help to reduce some specific problem behaviors, such as incontinence.[184] There is a lack of high quality data on the effectiveness of these techniques in other behavior problems such as wandering.[185][186] Music therapy is effective in reducing behavioral and psychological symptoms.[187]

Emotion-oriented interventions include reminiscence therapy, validation therapy, supportive psychotherapy, sensory integration, also called snoezelen, and simulated presence therapy. A Cochrane review has found no evidence that this is effective.[188] Reminiscence therapy (RT) involves the discussion of past experiences individually or in group, many times with the aid of photographs, household items, music and sound recordings, or other familiar items from the past. A 2018 review of the effectiveness of RT found that effects were inconsistent, small in size and of doubtful clinical significance, and varied by setting.[189] Simulated presence therapy (SPT) is based on attachment theories and involves playing a recording with voices of the closest relatives of the person with Alzheimer's disease. There is partial evidence indicating that SPT may reduce challenging behaviors.[190]

The aim of cognition-oriented treatments, which include reality orientation and cognitive retraining, is the reduction of cognitive deficits. Reality orientation consists of the presentation of information about time, place, or person to ease the understanding of the person about its surroundings and his or her place in them. On the other hand, cognitive retraining tries to improve impaired capacities by exercising mental abilities. Both have shown some efficacy improving cognitive capacities.[191]

Stimulation-oriented treatments include art, music and pet therapies, exercise, and any other kind of recreational activities. Stimulation has modest support for improving behavior, mood, and, to a lesser extent, function. Nevertheless, as important as these effects are, the main support for the use of stimulation therapies is the change in the person's routine.[182]

Caregiving

Further information: Caring for people with dementia and Palliative care

Since Alzheimer's has no cure and it gradually renders people incapable of tending to their own needs, caregiving is essentially the treatment and must be carefully managed over the course of the disease.

During the early and moderate stages, modifications to the living environment and lifestyle can increase safety and reduce caretaker burden.[192][193] Examples of such modifications are the adherence to simplified routines, the placing of safety locks, the labeling of household items to cue the person with the disease or the use of modified daily life objects.[182][194][195] If eating becomes problematic, food will need to be prepared in smaller pieces or even puréed.[196] When swallowing difficulties arise, the use of feeding tubes may be required. In such cases, the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members.[197][198] The use of physical restraints is rarely indicated in any stage of the disease, although there are situations when they are necessary to prevent harm to the person with Alzheimer's disease or their caregivers.[182]

During the final stages of the disease, treatment is centred on relieving discomfort until death, often with the help of hospice.[199]

Diet

Diet may be a modifiable risk factor for the development of Alzheimer's disease. The Mediterranean diet, and the DASH diet are both associated with less cognitive decline. A different approach has been to incorporate elements of both of these diets into one known as the MIND diet.[200] Studies of individual dietary components, minerals and supplements are conflicting as to whether they prevent AD or cognitive decline.[200][201][202]

Prognosis

The early stages of Alzheimer's disease are difficult to diagnose. A definitive diagnosis is usually made once cognitive impairment compromises daily living activities, although the person may still be living independently. The symptoms will progress from mild cognitive problems, such as memory loss through increasing stages of cognitive and non-cognitive disturbances, eliminating any possibility of independent living, especially in the late stages of the disease.[33]

Life expectancy of people with Alzheimer's disease is reduced.[203] The normal life expectancy for 60 to 70 years old is 23 to 15 years; for 90 years old it is 4.5 years.[204] Following Alzheimer's disease diagnosis it ranges from 7 to 10 years for those in their 60s and early 70s (a loss of 13 to 8 years), to only about 3 years or less (a loss of 1.5 years) for those in their 90s.[203]

Fewer than 3% of people live more than fourteen years.[205] Disease features significantly associated with reduced survival are an increased severity of cognitive impairment, decreased functional level, history of falls, and disturbances in the neurological examination. Other coincident diseases such as heart problems, diabetes, or history of alcohol abuse are also related with shortened survival.[206][207][208] While the earlier the age at onset the higher the total survival years, life expectancy is particularly reduced when compared to the healthy population among those who are younger.[209] Men have a less favourable survival prognosis than women.[205][3]

Pneumonia and dehydration are the most frequent immediate causes of death brought by Alzheimer's disease, while cancer is a less frequent cause of death than in the general population.[3]

Epidemiology

Two main measures are used in epidemiological studies: incidence and prevalence. Incidence is the number of new cases per unit of person-time at risk (usually number of new cases per thousand person-years); while prevalence is the total number of cases of the disease in the population at any given time.

 
Deaths per million persons in 2012 due to dementias including Alzheimer's disease
  0–4
  5–8
  9–10
  11–13
  14–17
  18–24
  25–45
  46–114
  115–375
  376–1266

Regarding incidence, cohort longitudinal studies (studies where a disease-free population is followed over the years) provide rates between 10 and 15 per thousand person-years for all dementias and 5–8 for Alzheimer's disease,[210][211] which means that half of new dementia cases each year are Alzheimer's disease. Advancing age is a primary risk factor for the disease and incidence rates are not equal for all ages: every 5 years after the age of 65, the risk of acquiring the disease approximately doubles, increasing from 3 to as much as 69 per thousand person years.[210][211] Females with Alzheimer's disease are more common than males, but this difference is likely due to women's' longer life spans. When adjusted for age, both sexes are affected by Alzheimer's at equal rates.[11] In the United States, the risk of dying from Alzheimer's disease in 2010 was 26% higher among the non-Hispanic white population than among the non-Hispanic black population, and the Hispanic population had a 30% lower risk than the non-Hispanic white population.[212] However, much Alzheimer's research remains to be done in minority groups, such as the African American and the Hispanic/Latino populations.[213][214] Studies have shown that these groups are underrepresented in clinical trials and do not have the same risk of developing Alzheimer's when carrying certain genetic risk factors (i.e. APOE4), compared to their caucasian counterparts.[214][215][216]

The prevalence of Alzheimer's disease in populations is dependent upon factors including incidence and survival. Since the incidence of Alzheimer's disease increases with age, prevalence depends on the mean age of the population for which prevalence is given. In the United States in 2020, Alzheimer's dementia prevalence was estimated to be 5.3% for those in the 60–74 age group, with the rate increasing to 13.8% in the 74–84 group and to 34.6% in those greater than 85.[217] Prevalence rates in some less developed regions around the globe are lower.[218][219] As the incidence and prevalence are steadily increasing, the prevalence itself is projected to triple by 2050.[clarification needed][220] As of 2020, 50 million people globally have AD, with this number expected to increase to 152 million by 2050.[10]

See also: Alzheimer's disease in African Americans

History

 
Alois Alzheimer's patient Auguste Deter in 1902. Hers was the first described case of what became known as Alzheimer's disease.

The ancient Greek and Roman philosophers and physicians associated old age with increasing dementia.[23] It was not until 1901 that German psychiatrist Alois Alzheimer identified the first case of what became known as Alzheimer's disease, named after him, in a fifty-year-old woman he called Auguste D. He followed her case until she died in 1906 when he first reported publicly on it.[221] During the next five years, eleven similar cases were reported in the medical literature, some of them already using the term Alzheimer's disease.[23] The disease was first described as a distinctive disease by Emil Kraepelin after suppressing some of the clinical (delusions and hallucinations) and pathological features (arteriosclerotic changes) contained in the original report of Auguste D.[222] He included Alzheimer's disease, also named presenile dementia by Kraepelin, as a subtype of senile dementia in the eighth edition of his Textbook of Psychiatry, published on 15 July, 1910.[223]

For most of the 20th century, the diagnosis of Alzheimer's disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia. The terminology changed after 1977 when a conference on Alzheimer's disease concluded that the clinical and pathological manifestations of presenile and senile dementia were almost identical, although the authors also added that this did not rule out the possibility that they had different causes.[224] This eventually led to the diagnosis of Alzheimer's disease independent of age.[225] The term senile dementia of the Alzheimer type (SDAT) was used for a time to describe the condition in those over 65, with classical Alzheimer's disease being used to describe those who were younger. Eventually, the term Alzheimer's disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic common symptom pattern, disease course, and neuropathology.[226]

The National Institute of Neurological and Communicative Disorders and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA, now known as the Alzheimer's Association) established the most commonly used NINCDS-ADRDA Alzheimer's Criteria for diagnosis in 1984,[227] extensively updated in 2007.[228][131] These criteria require that the presence of cognitive impairment, and a suspected dementia syndrome, be confirmed by neuropsychological testing for a clinical diagnosis of possible or probable Alzheimer's disease. A histopathologic confirmation including a microscopic examination of brain tissue is required for a definitive diagnosis. Good statistical reliability and validity have been shown between the diagnostic criteria and definitive histopathological confirmation.[229]

Society and culture

See also: Alzheimer's disease organizations

Social costs

Dementia, and specifically Alzheimer's disease, may be among the most costly diseases for societies worldwide.[230] As populations age, these costs will probably increase and become an important social problem and economic burden.[231] Costs associated with AD include direct and indirect medical costs, which vary between countries depending on social care for a person with AD.[230][232][233] Direct costs include doctor visits, hospital care, medical treatments, nursing home care, specialized equipment, and household expenses.[230][231] Indirect costs include the cost of informal care and the loss in productivity of informal caregivers.[231]

In the United States as of 2019, informal (family) care is estimated to constitute nearly three-fourths of caregiving for people with AD at a cost of US$234 billion per year and approximately 18.5 billion hours of care.[230] The cost to society worldwide to care for individuals with AD is projected to increase nearly ten-fold, and reach about US$9.1 trillion by 2050.[232]

Costs for those with more severe dementia or behavioral disturbances are higher and are related to the additional caregiving time to provide physical care.[233]

Caregiving burden

Further information: Caregiving and dementia

The role of the main caregiver is often taken by the spouse or a close relative.[234] Alzheimer's disease is known for placing a great burden on caregivers which includes social, psychological, physical, or economic aspects.[18][235][236] Home care is usually preferred by people with Alzheimer's disease and their families.[237] This option also delays or eliminates the need for more professional and costly levels of care.[237][238] Nevertheless, two-thirds of nursing home residents have dementias.[182]

Dementia caregivers are subject to high rates of physical and mental disorders.[239] Factors associated with greater psychosocial problems of the primary caregivers include having an affected person at home, the carer being a spouse, demanding behaviors of the cared person such as depression, behavioral disturbances, hallucinations, sleep problems or walking disruptions and social isolation.[240][241] Regarding economic problems, family caregivers often give up time from work to spend 47 hours per week on average with the person with Alzheimer's disease, while the costs of caring for them are high. Direct and indirect costs of caring for somebody with Alzheimer's average between $18,000 and $77,500 per year in the United States, depending on the study.[242][234]

Cognitive behavioral therapy and the teaching of coping strategies either individually or in group have demonstrated their efficacy in improving caregivers' psychological health.[18][243]

Media

Main article: Alzheimer's disease in the media

Alzheimer's disease has been portrayed in films such as: Iris (2001), based on John Bayley's memoir of his wife Iris Murdoch;[244] The Notebook (2004), based on Nicholas Sparks's 1996 novel of the same name;[245] A Moment to Remember (2004); Thanmathra (2005);[246] Memories of Tomorrow (Ashita no Kioku) (2006), based on Hiroshi Ogiwara's novel of the same name;[247] Away from Her (2006), based on Alice Munro's short story The Bear Came over the Mountain;[248] Still Alice (2014), about a Columbia University professor who has early onset Alzheimer's disease, based on Lisa Genova's 2007 novel of the same name and featuring Julianne Moore in the title role. Documentaries on Alzheimer's disease include Malcolm and Barbara: A Love Story (1999) and Malcolm and Barbara: Love's Farewell (2007), both featuring Malcolm Pointon.[249][250][251]

Alzheimer's disease has also been portrayed in music by English musician the Caretaker in releases such as Persistent Repetition of Phrases (2008), An Empty Bliss Beyond This World (2011), and Everywhere at the End of Time (2016–2019).[252][253][254] Paintings depicting the disorder include the late works by American artist William Utermohlen, who drew self-portraits from 1995 to 2000 as an experiment of showing his disease through art.[255][256]

Research directions

Additional research on the lifestyle effect may provide insight into neuroimaging biomarkers and better understanding of the mechanisms causing both Alzheimer's disease and early-onset AD.[257]

Emerging theories

Alzheimer’s disease is associated with neuroinflammation and loss of function of microglia, the resident immune cells of the central nervous system.[258] Microglia become progressively dysfunctional following exposure to amyloid plaques, and exposure to pro-inflammatory cytokines (e.g., TNFα, IL-1β, IL-12) has been hypothesized to sustain this dysfunction. Aberrant synaptic pruning via microglial phagocytosis may also contribute to AD pathology[259].The complement system, which is involved in some forms of typical microglial pruning during development,[260] is implicated in animal models of AD by way of dysregulation of the activation (e.g. C1q; C3b) and terminal (e.g. MAC) pathways in synapses with proximity to amyloid plaques.[261] [4]

Astrocytes may also contribute to AD pathology via their reactive states. Under typical conditions, astrocytes can surround amyloid beta plaques and can function to remove these species, which may be dysregulated under pathological conditions. Additionally, the activation of astrocytes following the release of APOE has been found to be vitally important in microglia function, especially in their ability to remove amyloid beta. In AD disease pathology, atrophy of astrocytes may prevent these functions, and further contribute to the prevalence of AD pathological species such as amyloid beta plaques. [258]

Treatment and prevention

There is ongoing research examining the role of specific medications in reducing the prevalence (primary prevention) and/or progression (secondary prevention) of Alzheimer's disease.[262] The research trials investigating medications generally impact Aβ plaques, inflammation, APOE, neurotransmitter receptors, neurogenesis, epigenetic regulators, growth factors and hormones.[262][263][264] These studies have led to a better understanding of the disease, but none identified a prevention strategy.[262][263] Experimental models are commonly used by researchers in order to understand disease mechanisms as well develop and test novel therapeutics aimed at treating Alzheimer's disease.

Antibodies are being developed that may have the ability to alter the disease course by targeting amyloid beta, such as donanemab and aducanumab. Aducanumab was approved by the FDA in 2021, but its use and effectiveness remain unclear and controversial.[265] Although it received FDA approval, aducanumab failed to show effectiveness in people who already had Alzheimer's symptoms.[266]

References

  1. ^ a b c d e f g h i j k Knopman DS, Amieva H, Petersen RC, et al. (May 2021). "Alzheimer disease". Nat Rev Dis Primers. 7 (1): 33. doi:10.1038/s41572-021-00269-y. PMC 8574196. PMID 33986301.
  2. ^ a b c d e f "Dementia Fact sheet". World Health Organization. September 2020.
  3. ^ a b c Ganguli M, Dodge HH, Shen C, Pandav RS, DeKosky ST (May 2005). "Alzheimer disease and mortality: a 15-year epidemiological study". Archives of Neurology. 62 (5): 779–784. doi:10.1001/archneur.62.5.779. PMID 15883266.
  4. ^ a b Mendez MF (November 2012). "Early-onset Alzheimer's disease: nonamnestic subtypes and type 2 AD". Archives of Medical Research. 43 (8): 677–685. doi:10.1016/j.arcmed.2012.11.009. PMC 3532551. PMID 23178565.
  5. ^ a b (PDF). National Institute for Health and Care Excellence (NICE). Archived from the original (PDF) on 5 December 2014. Retrieved 30 November 2014.
  6. ^ Gomperts SN (April 2016). "Lewy Body Dementias: Dementia With Lewy Bodies and Parkinson Disease Dementia". Continuum (Review). 22 (2 Dementia): 435–463. doi:10.1212/CON.0000000000000309. PMC 5390937. PMID 27042903.
  7. ^ a b Lott IT, Head E (March 2019). "Dementia in Down syndrome: unique insights for Alzheimer disease research". Nat Rev Neurol. 15 (3): 135–147. doi:10.1038/s41582-018-0132-6. PMC 8061428. PMID 30733618.
  8. ^ Commission de la transparence (June 2012). "Drugs for Alzheimer's disease: best avoided. No therapeutic advantage" [Drugs for Alzheimer's disease: best avoided. No therapeutic advantage]. Prescrire International. 21 (128): 150. PMID 22822592.
  9. ^ a b Querfurth HW, LaFerla FM (January 2010). "Alzheimer's disease". The New England Journal of Medicine. 362 (4): 329–344. doi:10.1056/NEJMra0909142. PMID 20107219. S2CID 205115756.
  10. ^ a b c d e f g h i j k Breijyeh Z, Karaman R (December 2020). "Comprehensive Review on Alzheimer's Disease: Causes and Treatment". Molecules (Review). 25 (24): 5789. doi:10.3390/molecules25245789. PMC 7764106. PMID 33302541.
  11. ^ a b c d Simon RP, Greenberg DA, Aminoff MJ (2018). Clinical neurology (Tenth ed.). [New York]: McGraw Hill. p. 111. ISBN 978-1-259-86173-4. OCLC 1012400314.
  12. ^ a b c d Burns A, Iliffe S (February 2009). "Alzheimer's disease". BMJ. 338: b158. doi:10.1136/bmj.b158. PMID 19196745. S2CID 8570146.
  13. ^ a b c d e f g h i "Alzheimer's Disease Fact Sheet". National Institute on Aging. Retrieved 25 January 2021.
  14. ^ Todd S, Barr S, Roberts M, Passmore AP (November 2013). "Survival in dementia and predictors of mortality: a review". International Journal of Geriatric Psychiatry. 28 (11): 1109–1124. doi:10.1002/gps.3946. PMID 23526458. S2CID 25445595.
  15. ^ a b c d Long JM, Holtzman DM (October 2019). "Alzheimer Disease: An Update on Pathobiology and Treatment Strategies". Cell. 179 (2): 312–339. doi:10.1016/j.cell.2019.09.001. PMC 6778042. PMID 31564456.
  16. ^ a b "Study reveals how APOE4 gene may increase risk for dementia". National Institute on Aging. Retrieved 17 March 2021.
  17. ^ a b c d Hsu D, Marshall GA (2017). "Primary and secondary prevention trials in Alzheimer disease: looking back, moving forward". Curr Alzheimer Res. 14 (4): 426–440. doi:10.2174/1567205013666160930112125. PMC 5329133. PMID 27697063.
  18. ^ a b c d Thompson CA, Spilsbury K, Hall J, Birks Y, Barnes C, Adamson J (July 2007). "Systematic review of information and support interventions for caregivers of people with dementia". BMC Geriatrics. 7: 18. doi:10.1186/1471-2318-7-18. PMC 1951962. PMID 17662119.
  19. ^ Forbes D, Forbes SC, Blake CM, Thiessen EJ, Forbes S (April 2015). "Exercise programs for people with dementia". The Cochrane Database of Systematic Reviews (Submitted manuscript). 132 (4): CD006489. doi:10.1002/14651858.CD006489.pub4. PMC 9426996. PMID 25874613.
  20. ^ National Institute for Health and Clinical Excellence. . National Institute for Health and Care Excellence (NICE). Archived from the original on 5 December 2014. Retrieved 29 November 2014.
  21. ^ . US Food and Drug Administration. 16 June 2008. Archived from the original on 29 November 2014. Retrieved 29 November 2014.
  22. ^ Zhu D, Montagne A, Zhao Z (June 2021). "Alzheimer's pathogenic mechanisms and underlying sex difference". Cell Mol Life Sci. 78 (11): 4907–4920. doi:10.1007/s00018-021-03830-w. PMC 8720296. PMID 33844047.
  23. ^ a b c Berchtold NC, Cotman CW (1998). "Evolution in the conceptualization of dementia and Alzheimer's disease: Greco-Roman period to the 1960s". Neurobiology of Aging. 19 (3): 173–189. doi:10.1016/S0197-4580(98)00052-9. PMID 9661992. S2CID 24808582.
  24. ^ a b "Alzheimer's Disease Fact Sheet". National Institute on Aging. Retrieved 23 March 2022.
  25. ^ a b c "Alzheimer's disease – Symptoms". nhs.uk. 10 May 2018.
  26. ^ a b Waldemar G, Dubois B, Emre M, et al. (January 2007). "Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline". European Journal of Neurology. 14 (1): e1-26. doi:10.1111/j.1468-1331.2006.01605.x. PMID 17222085. S2CID 2725064.
  27. ^ a b c Bäckman L, Jones S, Berger AK, Laukka EJ, Small BJ (September 2004). "Multiple cognitive deficits during the transition to Alzheimer's disease". Journal of Internal Medicine. 256 (3): 195–204. doi:10.1111/j.1365-2796.2004.01386.x. PMID 15324363. S2CID 37005854.
  28. ^ Nygård L (2003). "Instrumental activities of daily living: a stepping-stone towards Alzheimer's disease diagnosis in subjects with mild cognitive impairment?". Acta Neurologica Scandinavica. Supplementum. 179 (s179): 42–46. doi:10.1034/j.1600-0404.107.s179.8.x. PMID 12603250. S2CID 25313065.
  29. ^ Deardorff WJ, Grossberg GT (2019). "Behavioral and psychological symptoms in Alzheimer's dementia and vascular dementia". Handbook of Clinical Neurology. 165: 5–32. doi:10.1016/B978-0-444-64012-3.00002-2. ISBN 978-0444640123. PMID 31727229. S2CID 208037448.
  30. ^ Murray ED, Buttner N, Price BH (2012). "Depression and Psychosis in Neurological Practice". In Bradley WG, Daroff RB, Fenichel GM, Jankovic J (eds.). Bradley's neurology in clinical practice (6th ed.). Philadelphia, PA: Elsevier/Saunders. ISBN 978-1-4377-0434-1.
  31. ^ a b Petersen RC, Lopez O, Armstrong MJ, Getchius TS, Ganguli M, Gloss D, et al. (January 2018). "Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology". Neurology. 90 (3): 126–135. doi:10.1212/WNL.0000000000004826. PMC 5772157. PMID 29282327.
  32. ^ a b c Atri A (March 2019). "The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management". The Medical Clinics of North America (Review). 103 (2): 263–293. doi:10.1016/j.mcna.2018.10.009. PMID 30704681. S2CID 73432842.
  33. ^ a b c d e f g h i j k l m n o p q r s Förstl H, Kurz A (1999). "Clinical features of Alzheimer's disease". European Archives of Psychiatry and Clinical Neuroscience. 249 (6): 288–290. doi:10.1007/s004060050101. PMID 10653284. S2CID 26142779.
  34. ^ Carlesimo GA, Oscar-Berman M (June 1992). "Memory deficits in Alzheimer's patients: a comprehensive review". Neuropsychology Review. 3 (2): 119–169. doi:10.1007/BF01108841. PMID 1300219. S2CID 19548915.
  35. ^ Jelicic M, Bonebakker AE, Bonke B (1995). "Implicit memory performance of patients with Alzheimer's disease: a brief review". International Psychogeriatrics. 7 (3): 385–392. doi:10.1017/S1041610295002134. PMID 8821346. S2CID 9419442.
  36. ^ a b Taler V, Phillips NA (July 2008). "Language performance in Alzheimer's disease and mild cognitive impairment: a comparative review". Journal of Clinical and Experimental Neuropsychology. 30 (5): 501–556. doi:10.1080/13803390701550128. PMID 18569251. S2CID 37153159.
  37. ^ a b c Frank EM (September 1994). "Effect of Alzheimer's disease on communication function". Journal of the South Carolina Medical Association. 90 (9): 417–423. PMID 7967534.
  38. ^ Volicer L, Harper DG, Manning BC, Goldstein R, Satlin A (May 2001). "Sundowning and circadian rhythms in Alzheimer's disease". The American Journal of Psychiatry. 158 (5): 704–711. doi:10.1176/appi.ajp.158.5.704. PMID 11329390. S2CID 10492607.
  39. ^ Gold DP, Reis MF, Markiewicz D, Andres D (January 1995). "When home caregiving ends: a longitudinal study of outcomes for caregivers of relatives with dementia". Journal of the American Geriatrics Society. 43 (1): 10–16. doi:10.1111/j.1532-5415.1995.tb06235.x. PMID 7806732. S2CID 29847950.
  40. ^ a b "Alzheimer's disease - Symptoms and causes". Mayo Clinic. Retrieved 23 March 2022.
  41. ^ Alzheimer's disease – Causes (NHS)
  42. ^ Tackenberg C, Kulic L, Nitsch RM (2020). "Familial Alzheimer's disease mutations at position 22 of the amyloid β-peptide sequence differentially affect synaptic loss, tau phosphorylation and neuronal cell death in an ex vivo system". PLOS ONE. 15 (9): e0239584. Bibcode:2020PLoSO..1539584T. doi:10.1371/journal.pone.0239584. PMC 7510992. PMID 32966331.
  43. ^ Wang H, Kulas JA, Wang C, Holtzman DM, Ferris HA, Hansen SB (August 2021). "Regulation of beta-amyloid production in neurons by astrocyte-derived cholesterol". Proceedings of the National Academy of Sciences of the United States of America. 118 (33): e2102191118. Bibcode:2021PNAS..11802191W. doi:10.1073/pnas.2102191118. ISSN 0027-8424. PMC 8379952. PMID 34385305. S2CID 236998499.
  44. ^ Vilchez D, Saez I, Dillin A (December 2014). "The role of protein clearance mechanisms in organismal ageing and age-related diseases". Nature Communications. 5: 5659. Bibcode:2014NatCo...5.5659V. doi:10.1038/ncomms6659. PMID 25482515.
  45. ^ Jacobson M, McCarthy N (2002). Apoptosis. Oxford, OX: Oxford University Press. p. 290. ISBN 0199638497.
  46. ^ Hardy J, Allsop D (October 1991). "Amyloid deposition as the central event in the aetiology of Alzheimer's disease". Trends in Pharmacological Sciences. 12 (10): 383–388. doi:10.1016/0165-6147(91)90609-V. PMID 1763432.
  47. ^ a b Mudher A, Lovestone S (January 2002). "Alzheimer's disease-do tauists and baptists finally shake hands?". Trends in Neurosciences. 25 (1): 22–26. doi:10.1016/S0166-2236(00)02031-2. PMID 11801334. S2CID 37380445.
  48. ^ Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, et al. (November 1995). "Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein". The New England Journal of Medicine. 333 (19): 1242–1247. doi:10.1056/NEJM199511093331902. PMID 7566000.
  49. ^ Selkoe DJ (June 1999). "Translating cell biology into therapeutic advances in Alzheimer's disease". Nature. 399 (6738 Suppl): A23–A31. doi:10.1038/19866. PMID 10392577. S2CID 42287088.
  50. ^ Borchelt DR, Thinakaran G, Eckman CB, Lee MK, Davenport F, Ratovitsky T, et al. (November 1996). "Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo". Neuron. 17 (5): 1005–1013. doi:10.1016/S0896-6273(00)80230-5. PMID 8938131. S2CID 18315650.
  51. ^ Kim JH (December 2018). "Genetics of Alzheimer's Disease". Dementia and Neurocognitive Disorders. 17 (4): 131–136. doi:10.12779/dnd.2018.17.4.131. PMC 6425887. PMID 30906402.
  52. ^ Perea JR, Bolós M, Avila J (October 2020). "Microglia in Alzheimer's Disease in the Context of Tau Pathology". Biomolecules. 10 (10): 1439. doi:10.3390/biom10101439. PMC 7602223. PMID 33066368.
  53. ^ Mahley RW, Weisgraber KH, Huang Y (April 2006). "Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease". Proceedings of the National Academy of Sciences of the United States of America. 103 (15): 5644–5651. Bibcode:2006PNAS..103.5644M. doi:10.1073/pnas.0600549103. PMC 1414631. PMID 16567625.
  54. ^ Blennow K, de Leon MJ, Zetterberg H (July 2006). "Alzheimer's disease". Lancet. 368 (9533): 387–403. doi:10.1016/S0140-6736(06)69113-7. PMID 16876668. S2CID 47544338.
  55. ^ Hall K, Murrell J, Ogunniyi A, Deeg M, Baiyewu O, Gao S, et al. (January 2006). "Cholesterol, APOE genotype, and Alzheimer disease: an epidemiologic study of Nigerian Yoruba". Neurology. 66 (2): 223–227. doi:10.1212/01.wnl.0000194507.39504.17. PMC 2860622. PMID 16434658.
  56. ^ Gureje O, Ogunniyi A, Baiyewu O, Price B, Unverzagt FW, Evans RM, et al. (January 2006). "APOE epsilon4 is not associated with Alzheimer's disease in elderly Nigerians". Annals of Neurology. 59 (1): 182–185. doi:10.1002/ana.20694. PMC 2855121. PMID 16278853.
  57. ^ Carmona S, Zahs K, Wu E, Dakin K, Bras J, Guerreiro R (August 2018). "The role of TREM2 in Alzheimer's disease and other neurodegenerative disorders". Lancet Neurol. 17 (8): 721–730. doi:10.1016/S1474-4422(18)30232-1. PMID 30033062. S2CID 51706988.
  58. ^ Tomiyama T (July 2010). "[Involvement of beta-amyloid in the etiology of Alzheimer's disease]". Brain and Nerve = Shinkei Kenkyu No Shinpo. 62 (7): 691–699. PMID 20675873.
  59. ^ Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. (March 2008). "A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia". Annals of Neurology. 63 (3): 377–387. doi:10.1002/ana.21321. PMID 18300294. S2CID 42311988.
  60. ^ Tomiyama T, Shimada H (February 2020). "APP Osaka Mutation in Familial Alzheimer's Disease-Its Discovery, Phenotypes, and Mechanism of Recessive Inheritance". International Journal of Molecular Sciences. 21 (4): 1413. doi:10.3390/ijms21041413. PMC 7073033. PMID 32093100.
  61. ^ Goedert M, Spillantini MG, Crowther RA (July 1991). "Tau proteins and neurofibrillary degeneration". Brain Pathology. 1 (4): 279–286. doi:10.1111/j.1750-3639.1991.tb00671.x. PMID 1669718. S2CID 33331924.
  62. ^ Iqbal K, Alonso A, Chen S, Chohan MO, El-Akkad E, Gong CX, et al. (January 2005). "Tau pathology in Alzheimer disease and other tauopathies". Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1739 (2–3): 198–210. doi:10.1016/j.bbadis.2004.09.008. PMID 15615638.
  63. ^ Sinyor B, Mineo J, Ochner C (June 2020). "Alzheimer's Disease, Inflammation, and the Role of Antioxidants". Journal of Alzheimer's Disease Reports. 4 (1): 175–183. doi:10.3233/ADR-200171. PMC 7369138. PMID 32715278.
  64. ^ Kinney JW, Bemiller SM, Murtishaw AS, Leisgang AM, Salazar AM, Lamb BT (2018). "Inflammation as a central mechanism in Alzheimer's disease". Alzheimer's & Dementia. 4: 575–590. doi:10.1016/j.trci.2018.06.014. PMC 6214864. PMID 30406177.
  65. ^ Lin X, Kapoor A, Gu Y, Chow MJ, Peng J, Zhao K, Tang D (February 2020). "Contributions of DNA Damage to Alzheimer's Disease". Int J Mol Sci. 21 (5): 1666. doi:10.3390/ijms21051666. PMC 7084447. PMID 32121304.
  66. ^ Irwin MR, Vitiello MV (March 2019). "Implications of sleep disturbance and inflammation for Alzheimer's disease dementia". The Lancet. Neurology. 18 (3): 296–306. doi:10.1016/S1474-4422(18)30450-2. PMID 30661858. S2CID 58546748.
  67. ^ Huat TJ, Camats-Perna J, Newcombe EA, Valmas N, Kitazawa M, Medeiros R (April 2019). "Metal Toxicity Links to Alzheimer's Disease and Neuroinflammation". J Mol Biol. 431 (9): 1843–1868. doi:10.1016/j.jmb.2019.01.018. PMC 6475603. PMID 30664867.
  68. ^ Eikelenboom P, van Exel E, Hoozemans JJ, Veerhuis R, Rozemuller AJ, van Gool WA (2010). "Neuroinflammation – an early event in both the history and pathogenesis of Alzheimer's disease". Neuro-Degenerative Diseases. 7 (1–3): 38–41. doi:10.1159/000283480. PMID 20160456. S2CID 40048333.
  69. ^ Bartzokis G (August 2011). "Alzheimer's disease as homeostatic responses to age-related myelin breakdown". Neurobiology of Aging. 32 (8): 1341–1371. doi:10.1016/j.neurobiolaging.2009.08.007. PMC 3128664. PMID 19775776.
  70. ^ Cai Z, Xiao M (2016). "Oligodendrocytes and Alzheimer's disease". The International Journal of Neuroscience. 126 (2): 97–104. doi:10.3109/00207454.2015.1025778. PMID 26000818. S2CID 21448714.
  71. ^ Alves GS, Oertel Knöchel V, Knöchel C, Carvalho AF, Pantel J, Engelhardt E, Laks J (2015). "Integrating retrogenesis theory to Alzheimer's disease pathology: insight from DTI-TBSS investigation of the white matter microstructural integrity". BioMed Research International. 2015: 291658. doi:10.1155/2015/291658. PMC 4320890. PMID 25685779.
  72. ^ Reisberg B, Franssen EH, Hasan SM, Monteiro I, Boksay I, Souren LE, et al. (1999). "Retrogenesis: clinical, physiologic, and pathologic mechanisms in brain aging, Alzheimer's and other dementing processes". European Archives of Psychiatry and Clinical Neuroscience. 249 (3): 28–36. doi:10.1007/pl00014170. PMID 10654097. S2CID 23410069.
  73. ^ Zis P, Hadjivassiliou M (February 2019). "Treatment of Neurological Manifestations of Gluten Sensitivity and Coeliac Disease". Current Treatment Options in Neurology. 21 (3): 10. doi:10.1007/s11940-019-0552-7. PMID 30806821. S2CID 73466457.
  74. ^ Makhlouf S, Messelmani M, Zaouali J, Mrissa R (March 2018). "Cognitive impairment in celiac disease and non-celiac gluten sensitivity: review of literature on the main cognitive impairments, the imaging and the effect of gluten free diet". Acta Neurologica Belgica (Review). 118 (1): 21–27. doi:10.1007/s13760-017-0870-z. PMID 29247390. S2CID 3943047.
  75. ^ Wenk GL (2003). "Neuropathologic changes in Alzheimer's disease". The Journal of Clinical Psychiatry. 64 (Suppl 9): 7–10. PMID 12934968.
  76. ^ Braak H, Del Tredici K (December 2012). "Where, when, and in what form does sporadic Alzheimer's disease begin?". Current Opinion in Neurology. 25 (6): 708–714. doi:10.1097/WCO.0b013e32835a3432. PMID 23160422.
  77. ^ Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW, et al. (August 2009). "Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer's disease". Brain. 132 (Pt 8): 2048–2057. doi:10.1093/brain/awp123. PMC 2714061. PMID 19460794.
  78. ^ Moan R (July 2009). "MRI Software Accurately IDs Preclinical Alzheimer's Disease". Diagnostic Imaging.
  79. ^ a b Tiraboschi P, Hansen LA, Thal LJ, Corey-Bloom J (June 2004). "The importance of neuritic plaques and tangles to the development and evolution of AD". Neurology. 62 (11): 1984–1989. doi:10.1212/01.WNL.0000129697.01779.0A. PMID 15184601. S2CID 25017332.
  80. ^ DeTure MA, Dickson DW (August 2019). "The neuropathological diagnosis of Alzheimer's disease". Molecular Neurodegeneration. 14 (1): 32. doi:10.1186/s13024-019-0333-5. PMC 6679484. PMID 31375134.
  81. ^ Tiraboschi P, Sabbagh MN, Hansen LA, Salmon DP, Merdes A, Gamst A, et al. (April 2004). "Alzheimer disease without neocortical neurofibrillary tangles: "a second look"". Neurology. 62 (7): 1141–1147. doi:10.1212/01.wnl.0000118212.41542.e7. PMID 15079014. S2CID 22832110.
  82. ^ Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH (1994). "Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital". Cerebral Cortex. 4 (2): 138–150. doi:10.1093/cercor/4.2.138. PMID 8038565.
  83. ^ Kotzbauer PT, Trojanowsk JQ, Lee VM (October 2001). "Lewy body pathology in Alzheimer's disease". Journal of Molecular Neuroscience. 17 (2): 225–232. doi:10.1385/JMN:17:2:225. PMID 11816795. S2CID 44407971.
  84. ^ Hashimoto M, Rockenstein E, Crews L, Masliah E (2003). "Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer's and Parkinson's diseases". Neuromolecular Medicine. 4 (1–2): 21–36. doi:10.1385/NMM:4:1-2:21. PMID 14528050. S2CID 20760249.
  85. ^ Priller C, Bauer T, Mitteregger G, Krebs B, Kretzschmar HA, Herms J (July 2006). "Synapse formation and function is modulated by the amyloid precursor protein". The Journal of Neuroscience. 26 (27): 7212–7221. doi:10.1523/JNEUROSCI.1450-06.2006. PMC 6673945. PMID 16822978.
  86. ^ Turner PR, O'Connor K, Tate WP, Abraham WC (May 2003). "Roles of amyloid precursor protein and its fragments in regulating neural activity, plasticity and memory". Progress in Neurobiology. 70 (1): 1–32. doi:10.1016/S0301-0082(03)00089-3. PMID 12927332. S2CID 25376584.
  87. ^ Hooper NM (April 2005). "Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein". Biochemical Society Transactions. 33 (Pt 2): 335–338. doi:10.1042/BST0330335. PMID 15787600. S2CID 14269634.
  88. ^ Ohnishi S, Takano K (March 2004). "Amyloid fibrils from the viewpoint of protein folding". Cellular and Molecular Life Sciences. 61 (5): 511–524. doi:10.1007/s00018-003-3264-8. PMID 15004691. S2CID 25739126.
  89. ^ Hernández F, Avila J (September 2007). "Tauopathies". Cellular and Molecular Life Sciences. 64 (17): 2219–2233. doi:10.1007/s00018-007-7220-x. PMID 17604998.
  90. ^ Sun W, Samimi H, Gamez M, Zare H, Frost B (August 2018). "Pathogenic tau-induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies". Nature Neuroscience. 21 (8): 1038–1048. doi:10.1038/s41593-018-0194-1. PMC 6095477. PMID 30038280.
  91. ^ Van Broeck B, Van Broeckhoven C, Kumar-Singh S (2007). "Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches". Neuro-Degenerative Diseases. 4 (5): 349–365. doi:10.1159/000105156. PMID 17622778. S2CID 7949658.
  92. ^ Huang Y, Mucke L (March 2012). "Alzheimer mechanisms and therapeutic strategies". Cell. 148 (6): 1204–1222. doi:10.1016/j.cell.2012.02.040. PMC 3319071. PMID 22424230.
  93. ^ Yankner BA, Duffy LK, Kirschner DA (October 1990). "Neurotrophic and neurotoxic effects of amyloid beta protein: reversal by tachykinin neuropeptides". Science. 250 (4978): 279–282. Bibcode:1990Sci...250..279Y. doi:10.1126/science.2218531. PMID 2218531.
  94. ^ Chen X, Yan SD (December 2006). "Mitochondrial Abeta: a potential cause of metabolic dysfunction in Alzheimer's disease". IUBMB Life. 58 (12): 686–694. doi:10.1080/15216540601047767. PMID 17424907. S2CID 85423830.
  95. ^ Greig NH, Mattson MP, Perry T, Chan SL, Giordano T, Sambamurti K, et al. (December 2004). "New therapeutic strategies and drug candidates for neurodegenerative diseases: p53 and TNF-alpha inhibitors, and GLP-1 receptor agonists". Annals of the New York Academy of Sciences. 1035: 290–315. doi:10.1196/annals.1332.018. PMID 15681814. S2CID 84659695.
  96. ^ Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. (April 2015). "Neuroinflammation in Alzheimer's disease". The Lancet. Neurology. 14 (4): 388–405. doi:10.1016/S1474-4422(15)70016-5. PMC 5909703. PMID 25792098.
  97. ^ Tapia-Arancibia L, Aliaga E, Silhol M, Arancibia S (November 2008). "New insights into brain BDNF function in normal aging and Alzheimer disease". Brain Research Reviews. 59 (1): 201–220. doi:10.1016/j.brainresrev.2008.07.007. hdl:10533/142174. PMID 18708092. S2CID 6589846.
  98. ^ Schindowski K, Belarbi K, Buée L (February 2008). "Neurotrophic factors in Alzheimer's disease: role of axonal transport". Genes, Brain and Behavior. 7 (Suppl 1): 43–56. doi:10.1111/j.1601-183X.2007.00378.x. PMC 2228393. PMID 18184369.
  99. ^ Khan S, Barve KH, Kumar MS (2020). "Recent Advancements in Pathogenesis, Diagnostics and Treatment of Alzheimer's Disease". Curr Neuropharmacol. 18 (11): 1106–1125. doi:10.2174/1570159X18666200528142429. PMC 7709159. PMID 32484110.
  100. ^ a b Gauthreaux K, Bonnett TA, Besser LM, et al. (May 2020). "Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy". J Neuropathol Exp Neurol. 79 (5): 465–473. doi:10.1093/jnen/nlaa014. PMC 7160616. PMID 32186726.
  101. ^ a b Sachdev PS, Blacker D, Blazer DG, Ganguli M, Jeste DV, Paulsen JS, Petersen RC (November 2014). "Classifying neurocognitive disorders: the DSM-5 approach". Nature Reviews. Neurology. 10 (11): 634–642. doi:10.1038/nrneurol.2014.181. PMID 25266297. S2CID 20635070.
  102. ^ Mendez MF (2006). "The accurate diagnosis of early-onset dementia". International Journal of Psychiatry in Medicine. 36 (4): 401–412. doi:10.2190/Q6J4-R143-P630-KW41. PMID 17407994. S2CID 43715976.
  103. ^ Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J (November 2006). "Therapeutic approaches to Alzheimer's disease". Brain. 129 (Pt 11): 2840–2855. doi:10.1093/brain/awl280. PMID 17018549.
  104. ^ (PDF). London: (UK) National Institute for Health and Clinical Excellence. 2006. ISBN 978-1-84629-312-2. Archived from the original (PDF) on 27 February 2008. Retrieved 22 February 2008.
  105. ^ Schroeter ML, Stein T, Maslowski N, Neumann J (October 2009). "Neural correlates of Alzheimer's disease and mild cognitive impairment: a systematic and quantitative meta-analysis involving 1351 patients". NeuroImage. 47 (4): 1196–1206. doi:10.1016/j.neuroimage.2009.05.037. PMC 2730171. PMID 19463961.
  106. ^ Jie CV, Treyer V, Schibli R, Mu L (January 2021). "Tauvid: The First FDA-Approved PET Tracer for Imaging Tau Pathology in Alzheimer's Disease". Pharmaceuticals. 14 (2): 110. doi:10.3390/ph14020110. PMC 7911942. PMID 33573211.
  107. ^ a b c d e Weller J, Budson A (2018). "Current understanding of Alzheimer's disease diagnosis and treatment". F1000Research (Review). 7: 1161. doi:10.12688/f1000research.14506.1. PMC 6073093. PMID 30135715.
  108. ^ Silva MV, Loures CM, Alves LC, de Souza LC, Borges KB, Carvalho MD (May 2019). "Alzheimer's disease: risk factors and potentially protective measures". Journal of Biomedical Science. 26 (1): 33. doi:10.1186/s12929-019-0524-y. PMC 6507104. PMID 31072403.
  109. ^ Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS (2017). "Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment". Journal of Alzheimer's Disease (Review). 57 (3): 645–665. doi:10.3233/JAD-160907. PMC 5389048. PMID 28269772.
  110. ^ Diagnostic and statistical manual of mental disorders: DSM-IV-TR (4th Text Revision ed.). Washington, DC: American Psychiatric Association. 2000. ISBN 978-0-89042-025-6.
  111. ^ a b c Diagnostic and statistical manual of mental disorders: DSM-5. Washington, D.C: American Psychiatric Association. 2013. p. 611. ISBN 978-0890425558.
  112. ^ Sachs-Ericsson N, Blazer DG (January 2015). "The new DSM-5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment". Aging & Mental Health. 19 (1): 2–12. doi:10.1080/13607863.2014.920303. PMID 24914889. S2CID 46244321.
  113. ^ Stokin GB, Krell-Roesch J, Petersen RC, Geda YE (2015). "Mild Neurocognitive Disorder: An Old Wine in a New Bottle". Harvard Review of Psychiatry (Review). 23 (5): 368–376. doi:10.1097/HRP.0000000000000084. PMC 4894762. PMID 26332219.
  114. ^ Sperry L, Carlson J, Sauerheber J, Sperry J, eds. (2014). Psychopathology and Psychotherapy: DSM-5 Diagnosis, Case Conceptualization, and Treatment (3 ed.). New York: Routledge. pp. 342–343. doi:10.4324/9780203772287. ISBN 978-0-203-77228-7.
  115. ^ Fink HA, Hemmy LS, Linskens EJ, et al. (2020). Diagnosis and Treatment of Clinical Alzheimer's-Type Dementia: A Systematic Review. AHRQ Comparative Effectiveness Reviews. Rockville (MD): Agency for Healthcare Research and Quality (US). PMID 32369312.
  116. ^ Stokin GB, Krell-Roesch J, Petersen RC, Geda YE (September 2015). "Mild Neurocognitive Disorder: An Old Wine in a New Bottle". Harvard Review of Psychiatry. Wolters Kluwer Health. 23 (5): 368–376. doi:10.1097/HRP.0000000000000084. PMC 4894762. PMID 26332219.
  117. ^ Bradfield NI, Ames D (April 2020). "Mild cognitive impairment: narrative review of taxonomies and systematic review of their prediction of incident Alzheimer's disease dementia". BJPsych Bulletin (Review). 44 (2): 67–74. doi:10.1192/bjb.2019.77. PMC 7283119. PMID 31724527.
  118. ^ a b Vega JN, Newhouse PA (October 2014). "Mild cognitive impairment: diagnosis, longitudinal course, and emerging treatments". Current Psychiatry Reports. SpringerLink. 16 (10): 490. doi:10.1007/s11920-014-0490-8. PMC 4169219. PMID 25160795.
  119. ^ Parnetti L, Chipi E, Salvadori N, D'Andrea K, Eusebi P (January 2019). "Prevalence and risk of progression of preclinical Alzheimer's disease stages: a systematic review and meta-analysis". Alzheimer's Research & Therapy. Springer Nature. 11 (1): 7. doi:10.1186/s13195-018-0459-7. PMC 6334406. PMID 30646955.
  120. ^ a b c d e Jack CR, Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. (April 2018). "NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease". Alzheimer's & Dementia. Wiley Online Library. 14 (4): 535–562. doi:10.1016/j.jalz.2018.02.018. PMC 5958625. PMID 29653606.
  121. ^ Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. (May 2011). "Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease". Alzheimer's & Dementia. Wiley Online Library. 7 (3): 280–292. doi:10.1016/j.jalz.2011.03.003. PMC 3220946. PMID 21514248.
  122. ^ Cheng YW, Chen TF, Chiu MJ (16 February 2017). "From mild cognitive impairment to subjective cognitive decline: conceptual and methodological evolution". Neuropsychiatric Disease and Treatment. Dove Medical Press Limited. 13: 491–498. doi:10.2147/NDT.S123428. PMC 5317337. PMID 28243102.
  123. ^ Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. (May 2011). "The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease". Alzheimer's & Dementia. Wiley Online Library. 7 (3): 270–279. doi:10.1016/j.jalz.2011.03.008. PMC 3312027. PMID 21514249.
  124. ^ a b c d Chertkow H, Feldman HH, Jacova C, Massoud F (July 2013). "Definitions of dementia and predementia states in Alzheimer's disease and vascular cognitive impairment: consensus from the Canadian conference on diagnosis of dementia". Alzheimer's Research & Therapy. BMC. 5 (Suppl 1): S2. doi:10.1186/alzrt198. PMC 3981054. PMID 24565215.
  125. ^ a b c Papadakis MA, McPhee SJ, Rabow MW (2021). Current medical diagnosis & treatment (Sixtieth ed.). New York: McGraw Hill. p. 1760. ISBN 978-1-260-46986-8. OCLC 1195972209.
  126. ^ Tombaugh TN, McIntyre NJ (September 1992). "The mini-mental state examination: a comprehensive review". Journal of the American Geriatrics Society. 40 (9): 922–935. doi:10.1111/j.1532-5415.1992.tb01992.x. PMID 1512391. S2CID 25169596.
  127. ^ Pasquier F (January 1999). "Early diagnosis of dementia: neuropsychology". Journal of Neurology. 246 (1): 6–15. doi:10.1007/s004150050299. PMID 9987708. S2CID 2108587.
  128. ^ Harvey PD, Moriarty PJ, Kleinman L, Coyne K, Sadowsky CH, Chen M, Mirski DF (2005). "The validation of a caregiver assessment of dementia: the Dementia Severity Scale". Alzheimer Disease and Associated Disorders. 19 (4): 186–194. doi:10.1097/01.wad.0000189034.43203.60. PMID 16327345. S2CID 20238911.
  129. ^ Antoine C, Antoine P, Guermonprez P, Frigard B (2004). "[Awareness of deficits and anosognosia in Alzheimer's disease]". L'Encéphale (in French). 30 (6): 570–577. doi:10.1016/S0013-7006(04)95472-3. PMID 15738860.
  130. ^ Cruz VT, Pais J, Teixeira A, Nunes B (2004). "[The initial symptoms of Alzheimer disease: caregiver perception]". Acta Médica Portuguesa (in Portuguese). 17 (6): 435–444. PMID 16197855.
  131. ^ a b c Stern SD (2020). Symptom to diagnosis: an evidence-based guide. Adam S. Cifu, Diane Altkorn (4th ed.). [New York]. pp. 209–210. ISBN 978-1260121117. OCLC 1121597721.
  132. ^ Jha A, Mukhopadhaya K (2021). Alzheimer's disease: diagnosis and treatment guide. Cham, Switzerland: Springer. p. 32. ISBN 978-3-030-56739-2. OCLC 1202472277.
  133. ^ Sun X, Steffens DC, Au R, Folstein M, Summergrad P, Yee J, et al. (May 2008). "Amyloid-associated depression: a prodromal depression of Alzheimer disease?". Archives of General Psychiatry. 65 (5): 542–550. doi:10.1001/archpsyc.65.5.542. PMC 3042807. PMID 18458206.
  134. ^ Geldmacher DS, Whitehouse PJ (May 1997). "Differential diagnosis of Alzheimer's disease". Neurology. 48 (5 Suppl 6): S2–S9. doi:10.1212/WNL.48.5_Suppl_6.2S. PMID 9153154. S2CID 30018544.
  135. ^ Potter GG, Steffens DC (May 2007). "Contribution of depression to cognitive impairment and dementia in older adults". The Neurologist. 13 (3): 105–117. doi:10.1097/01.nrl.0000252947.15389.a9. PMID 17495754. S2CID 24569198.
  136. ^ Zhang S, Smailagic N, Hyde C, Noel-Storr AH, Takwoingi Y, McShane R, Feng J (July 2014). "(11)C-PIB-PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". The Cochrane Database of Systematic Reviews. 2014 (7): CD010386. doi:10.1002/14651858.CD010386.pub2. PMC 6464750. PMID 25052054.
  137. ^ Smailagic N, Vacante M, Hyde C, Martin S, Ukoumunne O, Sachpekidis C (January 2015). "18F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)". The Cochrane Database of Systematic Reviews. 1 (1): CD010632. doi:10.1002/14651858.CD010632.pub2. PMC 7081123. PMID 25629415.
  138. ^ Viña J, Sanz-Ros J (October 2018). "Alzheimer's disease: Only prevention makes sense". European Journal of Clinical Investigation. 48 (10): e13005. doi:10.1111/eci.13005. PMID 30028503. S2CID 51703879.
  139. ^ Patterson C, Feightner JW, Garcia A, Hsiung GY, MacKnight C, Sadovnick AD (February 2008). "Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease". CMAJ. 178 (5): 548–556. doi:10.1503/cmaj.070796. PMC 2244657. PMID 18299540.
  140. ^ Rosendorff C, Beeri MS, Silverman JM (2007). "Cardiovascular risk factors for Alzheimer's disease". The American Journal of Geriatric Cardiology. 16 (3): 143–149. doi:10.1111/j.1076-7460.2007.06696.x. PMID 17483665.
  141. ^ Chu CS, Tseng PT, Stubbs B, et al. (April 2018). "Use of statins and the risk of dementia and mild cognitive impairment: A systematic review and meta-analysis". Scientific Reports. 8 (1): 5804. Bibcode:2018NatSR...8.5804C. doi:10.1038/s41598-018-24248-8. PMC 5895617. PMID 29643479.
  142. ^ Ungvari Z, Toth P, Tarantini S, et al. (October 2021). "Hypertension-induced cognitive impairment: from pathophysiology to public health". Nat Rev Nephrol. 17 (10): 639–654. doi:10.1038/s41581-021-00430-6. PMC 8202227. PMID 34127835.
  143. ^ a b c d e f g Yu JT, Xu W, Tan CC, et al. (November 2020). "Evidence-based prevention of Alzheimer's disease: systematic review and meta-analysis of 243 observational prospective studies and 153 randomised controlled trials". J Neurol Neurosurg Psychiatry. 91 (11): 1201–1209. doi:10.1136/jnnp-2019-321913. PMC 7569385. PMID 32690803.
  144. ^ Lethaby A, Hogervorst E, Richards M, Yesufu A, Yaffe K (January 2008). "Hormone replacement therapy for cognitive function in postmenopausal women". Cochrane Database Syst Rev. 2008 (1): CD003122. doi:10.1002/14651858.CD003122.pub2. PMC 6599876. PMID 18254016.
  145. ^ Cheng ST (September 2016). "Cognitive Reserve and the Prevention of Dementia: the Role of Physical and Cognitive Activities". Current Psychiatry Reports (Review). 18 (9): 85. doi:10.1007/s11920-016-0721-2. PMC 4969323. PMID 27481112.
  146. ^ Farina N, Rusted J, Tabet N (January 2014). "The effect of exercise interventions on cognitive outcome in Alzheimer's disease: a systematic review". International Psychogeriatrics (Review). 26 (1): 9–18. doi:10.1017/S1041610213001385. PMID 23962667. S2CID 24936334.
  147. ^ Barnard ND, Bush AI, Ceccarelli A, et al. (September 2014). "Dietary and lifestyle guidelines for the prevention of Alzheimer's disease". Neurobiology of Aging (Review). 35 (Suppl 2): S74–S78. doi:10.1016/j.neurobiolaging.2014.03.033. PMID 24913896. S2CID 8265377.
  148. ^ a b Bhatti GK, Reddy AP, Reddy PH, Bhatti JS (2019). "Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease". Frontiers in Aging Neuroscience (Review). 11: 369. doi:10.3389/fnagi.2019.00369. PMC 6966236. PMID 31998117.
  149. ^ López-Ortiz S, Lista S, Valenzuela PL, Pinto-Fraga J, Carmona R, Caraci F, et al. (November 2022). "Effects of physical activity and exercise interventions on Alzheimer's disease: an umbrella review of existing meta-analyses". Journal of Neurology. doi:10.1007/s00415-022-11454-8. PMID 36342524. S2CID 253382289.
  150. ^ a b Viña J, Sanz-Ros J (October 2018). "Alzheimer's disease: Only prevention makes sense". European Journal of Clinical Investigation (Review). 48 (10): e13005. doi:10.1111/eci.13005. PMID 30028503. S2CID 51703879.
  151. ^ Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H (April 2014). "Future directions in Alzheimer's disease from risk factors to prevention". Biochemical Pharmacology (Review). 88 (4): 661–670. doi:10.1016/j.bcp.2014.01.003. PMID 24418410.
  152. ^ Imtiaz B, Tolppanen AM, Kivipelto M, Soininen H (April 2014). "Future directions in Alzheimer's disease from risk factors to prevention". Biochem Pharmacol. 88 (4): 661–70. doi:10.1016/j.bcp.2014.01.003. PMID 24418410.
  153. ^ Kivipelto M, Mangialasche F, Ngandu T (November 2018). "Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease". Nat Rev Neurol. 14 (11): 653–666. doi:10.1038/s41582-018-0070-3. PMID 30291317. S2CID 52925352.
  154. ^ a b c d Borges CR, Poyares D, Piovezan R, Nitrini R, Brucki S (November 2019). "Alzheimer's disease and sleep disturbances: a review". Arq Neuropsiquiatr. 77 (11): 815–824. doi:10.1590/0004-282X20190149. PMID 31826138. S2CID 209327994.
  155. ^ a b Uddin MS, Tewari D, Mamun AA, et al. (July 2020). "Circadian and sleep dysfunction in Alzheimer's disease". Ageing Res Rev. 60: 101046. doi:10.1016/j.arr.2020.101046. PMID 32171783. S2CID 212729131.
  156. ^ Rasmussen MK, Mestre H, Nedergaard M (November 2018). "The glymphatic pathway in neurological disorders". Lancet Neurol. 17 (11): 1016–1024. doi:10.1016/S1474-4422(18)30318-1. PMC 6261373. PMID 30353860.
  157. ^ Irwin MR, Vitiello MV (March 2019). "Implications of sleep disturbance and inflammation for Alzheimer's disease dementia". Lancet Neurol. 18 (3): 296–306. doi:10.1016/S1474-4422(18)30450-2. PMID 30661858. S2CID 58546748.
  158. ^ Hampel H, Vergallo A, Aguilar LF, et al. (April 2018). "Precision pharmacology for Alzheimer's disease". Pharmacol Res. 130: 331–365. doi:10.1016/j.phrs.2018.02.014. PMC 8505114. PMID 29458203.
  159. ^ Chen Y, Zhang J, Zhang T, et al. (March 2020). "Meditation treatment of Alzheimer disease and mild cognitive impairment: A protocol for systematic review". Medicine (Baltimore). 99 (10): e19313. doi:10.1097/MD.0000000000019313. PMC 7478420. PMID 32150066.
  160. ^ Drislane F, Hovauimian A, Tarulli A, Boegle AK, McIiduff C, Caplan LR (2019). Blueprints neurology (Fifth ed.). Philadelphia: Wolters Kluwer. p. 146. ISBN 978-1-4963-8739-4. OCLC 1048659425.
  161. ^ a b c Birks JS, Harvey RJ (June 2018). "Donepezil for dementia due to Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2018 (6): CD001190. doi:10.1002/14651858.CD001190.pub3. PMC 6513124. PMID 29923184.
  162. ^ Fink HA, Linskens EJ, MacDonald R, et al. (May 2020). "Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer-Type Dementia". Annals of Internal Medicine. 172 (10): 656–668. doi:10.7326/M19-3887. PMID 32340037. S2CID 216595473.
  163. ^ Berkowitz A (2017). Clinical neurology and neuroanatomy: a localization-based approach. New York: McGraw Hill. p. 236. ISBN 978-1-259-83440-0. OCLC 948547621.
  164. ^ Geula C, Mesulam MM (1995). "Cholinesterases and the pathology of Alzheimer disease". Alzheimer Disease and Associated Disorders. 9 (Suppl 2): 23–28. doi:10.1097/00002093-199501002-00005. PMID 8534419.
  165. ^ Stahl SM (November 2000). "The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action". The Journal of Clinical Psychiatry. 61 (11): 813–814. doi:10.4088/JCP.v61n1101. PMID 11105732.
  166. ^ a b Birks J (January 2006). Birks J (ed.). "Cholinesterase inhibitors for Alzheimer's disease". The Cochrane Database of Systematic Reviews. 2016 (1): CD005593. doi:10.1002/14651858.CD005593. PMC 9006343. PMID 16437532.
  167. ^ Raschetti R, Albanese E, Vanacore N, Maggini M (November 2007). "Cholinesterase inhibitors in mild cognitive impairment: a systematic review of randomised trials". PLOS Medicine. 4 (11): e338. doi:10.1371/journal.pmed.0040338. PMC 2082649. PMID 18044984.
  168. ^ Alldredge BK, Corelli RL, Ernst ME, Guglielmo BJ, Jacobson PA, Kradjan WA, Williams BR (2013). Applied therapeutics : the clinical use of drugs (10th ed.). Baltimore: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 2385. ISBN 978-1-60913-713-7.
  169. ^ a b Lipton SA (February 2006). "Paradigm shift in neuroprotection by NMDA receptor blockade: memantine and beyond". Nature Reviews. Drug Discovery. 5 (2): 160–170. doi:10.1038/nrd1958. PMID 16424917. S2CID 21379258.
  170. ^ "Memantine". US National Library of Medicine (Medline). 4 January 2004. from the original on 22 February 2010. Retrieved 3 February 2010.
  171. ^ McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, et al. (March 2019). "Memantine for dementia". The Cochrane Database of Systematic Reviews. 3 (3): CD003154. doi:10.1002/14651858.CD003154.pub6. PMC 6425228. PMID 30891742.
  172. ^ "Namenda- memantine hydrochloride tablet Namenda- memantine hydrochloride kit". DailyMed. 15 November 2018. Retrieved 20 February 2022.
  173. ^ "Namenda XR- memantine hydrochloride capsule, extended release Namenda XR- memantine hydrochloride kit". DailyMed. 15 November 2019. Retrieved 20 February 2022.
  174. ^ "Namzaric- memantine hydrochloride and donepezil hydrochloride capsule Namzaric- memantine hydrochloride and donepezil hydrochloride kit". DailyMed. 22 January 2019. Retrieved 20 February 2022.
  175. ^ Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. (March 2008). "Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline". Annals of Internal Medicine. 148 (5): 379–397. doi:10.7326/0003-4819-148-5-200803040-00009. PMID 18316756. S2CID 22235353.
  176. ^ a b Kandiah N, Ong PA, Yuda T, Ng LL, Mamun K, Merchant RA, et al. (February 2019). "Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease: Expert consensus on the use of Ginkgo biloba extract, EGb 761". CNS Neuroscience & Therapeutics. 25 (2): 288–298. doi:10.1111/cns.13095. PMC 6488894. PMID 30648358.
  177. ^ McKeage K, Lyseng-Williamson KA (2018). "Ginkgo biloba extract EGb 761 in the symptomatic treatment of mild-to-moderate dementia: a profile of its use". Drugs & Therapy Perspectives. 34 (8): 358–366. doi:10.1007/s40267-018-0537-8. PMC 6267544. PMID 30546253.
  178. ^ Yang G, Wang Y, Sun J, Zhang K, Liu J (22 October 2015). "Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials". Current Topics in Medicinal Chemistry. 16 (5): 520–528. doi:10.2174/1568026615666150813143520. PMID 26268332.
  179. ^ Ballard C, Waite J (January 2006). Ballard CG (ed.). "The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease". The Cochrane Database of Systematic Reviews (1): CD003476. doi:10.1002/14651858.CD003476.pub2. PMID 16437455.
  180. ^ Ballard C, Hanney ML, Theodoulou M, Douglas S, McShane R, Kossakowski K, et al. (February 2009). "The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial". The Lancet. Neurology. 8 (2): 151–157. doi:10.1016/S1474-4422(08)70295-3. PMID 19138567. S2CID 23000439. See , January 2009.
  181. ^ Declercq T, Petrovic M, Azermai M, Vander Stichele R, De Sutter AI, van Driel ML, Christiaens T (March 2013). "Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia". The Cochrane Database of Systematic Reviews. 3 (3): CD007726. doi:10.1002/14651858.CD007726.pub2. hdl:1854/LU-3109108. PMID 23543555.
  182. ^ a b c d e [needs update] Rabins PV, Blacker D, Rovner BW, et al. (Steering Committee on Practice Guidelines) (December 2007). "American Psychiatric Association practice guideline for the treatment of patients with Alzheimer's disease and other dementias. Second edition". The American Journal of Psychiatry. 164 (12 Suppl): 5–56. PMID 18340692.
  183. ^ Bottino CM, Carvalho IA, Alvarez AM, Avila R, Zukauskas PR, Bustamante SE, et al. (December 2005). "Cognitive rehabilitation combined with drug treatment in Alzheimer's disease patients: a pilot study". Clinical Rehabilitation. 19 (8): 861–869. doi:10.1191/0269215505cr911oa. PMID 16323385. S2CID 21290731.
  184. ^ Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. (May 2001). "Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology". Neurology. 56 (9): 1154–1166. doi:10.1212/WNL.56.9.1154. PMID 11342679. S2CID 10711725.
  185. ^ Hermans DG, Htay UH, McShane R (January 2007). "Non-pharmacological interventions for wandering of people with dementia in the domestic setting". The Cochrane Database of Systematic Reviews. 2010 (1): CD005994. doi:10.1002/14651858.CD005994.pub2. PMC 6669244. PMID 17253573.
  186. ^ Robinson L, Hutchings D, Dickinson HO, Corner L, Beyer F, Finch T, et al. (January 2007). "Effectiveness and acceptability of non-pharmacological interventions to reduce wandering in dementia: a systematic review". International Journal of Geriatric Psychiatry. 22 (1): 9–22. doi:10.1002/gps.1643. PMID 17096455. S2CID 45660235.
  187. ^ Abraha I, Rimland JM, Trotta FM, Dell'Aquila G, Cruz-Jentoft A, Petrovic M, et al. (March 2017). "Systematic review of systematic reviews of non-pharmacological interventions to treat behavioural disturbances in older patients with dementia. The SENATOR-OnTop series". BMJ Open. 7 (3): e012759. doi:10.1136/bmjopen-2016-012759. PMC 5372076. PMID 28302633.
  188. ^ Chung JC, Lai CK, Chung PM, French HP (2002). "Snoezelen for dementia". The Cochrane Database of Systematic Reviews. 2010 (4): CD003152. doi:10.1002/14651858.CD003152. PMC 9002239. PMID 12519587.
  189. ^ Woods B, O'Philbin L, Farrell EM, Spector AE, Orrell M (March 2018). "Reminiscence therapy for dementia". The Cochrane Database of Systematic Reviews. 2018 (3): CD001120. doi:10.1002/14651858.CD001120.pub3. PMC 6494367. PMID 29493789.
  190. ^ Zetteler J (November 2008). "Effectiveness of simulated presence therapy for individuals with dementia: a systematic review and meta-analysis". Aging & Mental Health. 12 (6): 779–785. doi:10.1080/13607860802380631. PMID 19023729. S2CID 39529938.
  191. ^ Spector A, Thorgrimsen L, Woods B, Royan L, Davies S, Butterworth M, Orrell M (September 2003). "Efficacy of an evidence-based cognitive stimulation therapy programme for people with dementia: randomised controlled trial". The British Journal of Psychiatry. 183 (3): 248–254. doi:10.1192/bjp.183.3.248. PMID 12948999.
  192. ^ Gitlin LN, Corcoran M, Winter L, Boyce A, Hauck WW (February 2001). "A randomized, controlled trial of a home environmental intervention: effect on efficacy and upset in caregivers and on daily function of persons with dementia". The Gerontologist. 41 (1): 4–14. doi:10.1093/geront/41.1.4. PMID 11220813.
  193. ^ Gitlin LN, Hauck WW, Dennis MP, Winter L (March 2005). "Maintenance of effects of the home environmental skill-building program for family caregivers and individuals with Alzheimer's disease and related disorders". The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences. 60 (3): 368–374. doi:10.1093/gerona/60.3.368. PMID 15860476.
  194. ^ . Alzheimer's Association. 2006. Archived from the original on 25 September 2006. Retrieved 25 September 2006.
  195. ^ Dunne TE, Neargarder SA, Cipolloni PB, Cronin-Golomb A (August 2004). "Visual contrast enhances food and liquid intake in advanced Alzheimer's disease". Clinical Nutrition. 23 (4): 533–538. doi:10.1016/j.clnu.2003.09.015. PMID 15297089.
  196. ^ Dudek SB (2007). Nutrition Essentials for Nursing Practice. Hagerstown, Maryland: Lippincott Williams & Wilkins. p. 360. ISBN 978-0-7817-6651-7. Retrieved 19 August 2008.
  197. ^ Dennehy C (2006). "Analysis of patients' rights: dementia and PEG insertion". British Journal of Nursing. 15 (1): 18–20. doi:10.12968/bjon.2006.15.1.20303. PMID 16415742.
  198. ^ Chernoff R (April 2006). "Tube feeding patients with dementia". Nutrition in Clinical Practice. 21 (2): 142–146. doi:10.1177/0115426506021002142. PMID 16556924. S2CID 20841502.
  199. ^ Shega JW, Levin A, Hougham GW, Cox-Hayley D, Luchins D, Hanrahan P, et al. (April 2003). "Palliative Excellence in Alzheimer Care Efforts (PEACE): a program description". Journal of Palliative Medicine. 6 (2): 315–320. doi:10.1089/109662103764978641. PMID 12854952. S2CID 6072807.
  200. ^ a b Dominguez LJ, Barbagallo M (June 2018). "Nutritional prevention of cognitive decline and dementia". Acta Bio-Medica. 89 (2): 276–290. doi:10.23750/abm.v89i2.7401. PMC 6179018. PMID 29957766.
  201. ^ Hu N, Yu JT, Tan L, Wang YL, Sun L, Tan L (2013). "Nutrition and the risk of Alzheimer's disease". BioMed Research International (Review). 2013: 524820. doi:10.1155/2013/524820. PMC 3705810. PMID 23865055.
  202. ^ Bhatti GK, Reddy AP, Reddy PH, Bhatti JS (2019). "Lifestyle Modifications and Nutritional Interventions in Aging-Associated Cognitive Decline and Alzheimer's Disease". Front Aging Neurosci. 11: 369. doi:10.3389/fnagi.2019.00369. PMC 6966236. PMID 31998117.
  203. ^ a b Zanetti O, Solerte SB, Cantoni F (2009). "Life expectancy in Alzheimer's disease (AD)". Archives of Gerontology and Geriatrics. 49 (Suppl 1): 237–243. doi:10.1016/j.archger.2009.09.035. PMID 19836639.
  204. ^ "United States Life Tables, 2017" (PDF). National Vital Statistics Reports, CDC. Retrieved 10 June 2021.
  205. ^ a b Mölsä PK, Marttila RJ, Rinne UK (March 1995). "Long-term survival and predictors of mortality in Alzheimer's disease and multi-infarct dementia". Acta Neurologica Scandinavica. 91 (3): 159–164. doi:10.1111/j.1600-0404.1995.tb00426.x. PMID 7793228. S2CID 19724937.
  206. ^ Bowen JD, Malter AD, Sheppard L, Kukull WA, McCormick WC, Teri L, Larson EB (August 1996). "Predictors of mortality in patients diagnosed with probable Alzheimer's disease". Neurology. 47 (2): 433–439. doi:10.1212/wnl.47.2.433. PMID 8757016. S2CID 24961809.
  207. ^ Larson EB, Shadlen MF, Wang L, McCormick WC, Bowen JD, Teri L, Kukull WA (April 2004). "Survival after initial diagnosis of Alzheimer disease". Annals of Internal Medicine. 140 (7): 501–509. doi:10.7326/0003-4819-140-7-200404060-00008. PMID 15068977. S2CID 27410149.
  208. ^ Jagger C, Clarke M, Stone A (January 1995). "Predictors of survival with Alzheimer's disease: a community-based study". Psychological Medicine. 25 (1): 171–177. doi:10.1017/S0033291700028191. PMID 7792352. S2CID 34066330.
  209. ^ Dodge HH, Shen C, Pandav R, DeKosky ST, Ganguli M (February 2003). "Functional transitions and active life expectancy associated with Alzheimer disease". Archives of Neurology. 60 (2): 253–259. doi:10.1001/archneur.60.2.253. PMID 12580712.
  210. ^ a b Bermejo-Pareja F, Benito-León J, Vega S, Medrano MJ, Román GC (January 2008). "Incidence and subtypes of dementia in three elderly populations of central Spain". Journal of the Neurological Sciences. 264 (1–2): 63–72. doi:10.1016/j.jns.2007.07.021. PMID 17727890. S2CID 34341344.
  211. ^ a b Di Carlo A, Baldereschi M, Amaducci L, Lepore V, Bracco L, Maggi S, et al. (January 2002). "Incidence of dementia, Alzheimer's disease, and vascular dementia in Italy. The ILSA Study". Journal of the American Geriatrics Society. 50 (1): 41–48. doi:10.1046/j.1532-5415.2002.50006.x. PMID 12028245. S2CID 22576935.
  212. ^ Tejada-Vera B. (2013). Mortality from Alzheimer's Disease in the United States: Data for 2000 and 2010. Hyattsville, MD: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics.
  213. ^ Reitz C, Rogaeva E, Beecham GW (October 2020). "Late-onset vs nonmendelian early-onset Alzheimer disease: A distinction without a difference?". Neurology. Genetics. 6 (5): e512. doi:10.1212/NXG.0000000000000512. PMC 7673282. PMID 33225065.
  214. ^ a b Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G (February 2013). "Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy". Nature Reviews. Neurology. 9 (2): 106–118. doi:10.1038/nrneurol.2012.263. PMC 3726719. PMID 23296339.
  215. ^ Massett HA, Mitchell AK, Alley L, Simoneau E, Burke P, Han SH, et al. (29 June 2021). "Facilitators, Challenges, and Messaging Strategies for Hispanic/Latino Populations Participating in Alzheimer's Disease and Related Dementias Clinical Research: A Literature Review". Journal of Alzheimer's Disease. 82 (1): 107–127. doi:10.3233/JAD-201463. PMID 33998537. S2CID 234745473.
  216. ^ Huynh RA, Mohan C (2017). "Alzheimer's Disease: Biomarkers in the Genome, Blood, and Cerebrospinal Fluid". Frontiers in Neurology. 8: 102. doi:10.3389/fneur.2017.00102. PMC 5357660. PMID 28373857.
  217. ^ Rajan KB, Weuve J, Barnes LL, McAninch EA, Wilson RS, Evans DA (May 2021). "Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060)". Alzheimer's & Dementia. 17 (12): 1966–1975. doi:10.1002/alz.12362. PMC 9013315. PMID 34043283. S2CID 235215290.
  218. ^ Rizzi L, Rosset I, Roriz-Cruz M (2014). "Global epidemiology of dementia: Alzheimer's and vascular types". Biomed Res Int. 2014: 908915. doi:10.1155/2014/908915. PMC 4095986. PMID 25089278.
  219. ^ Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, et al. (December 2005). "Global prevalence of dementia: a Delphi consensus study". Lancet. 366 (9503): 2112–2117. doi:10.1016/S0140-6736(05)67889-0. PMC 2850264. PMID 16360788.
  220. ^ Li F, Qin W, Zhu M, Jia J (1 January 2021). "Model-Based Projection of Dementia Prevalence in China and Worldwide: 2020-2050". Journal of Alzheimer's Disease. IOS Press. 82 (4): 1823–1831. doi:10.3233/JAD-210493. PMID 34219732. S2CID 235735045.
  221. ^ Auguste D.:
    • Alzheimer A (1907). "Über eine eigenartige Erkrankung der Hirnrinde" [About a peculiar disease of the cerebral cortex]. Allgemeine Zeitschrift für Psychiatrie und Psychisch-Gerichtlich Medizin (in German). 64 (1–2): 146–148.
    • Translated by H. Greenson. "About a peculiar disease of the cerebral cortex. By Alois Alzheimer, 1907 (Translated by L. Jarvik and H. Greenson)". Alzheimer Disease and Associated Disorders. 1 (1): 3–8. 1987. PMID 3331112.
    • Maurer U, Maurer K (2003). Alzheimer: The Life of a Physician and the Career of a Disease. New Yor

January 29, 2023
alzheimer, disease, alzheimer, redirects, here, other, uses, alzheimer, disambiguation, this, article, needs, updated, please, help, update, this, article, reflect, recent, events, newly, available, information, march, 2021, neurodegenerative, disease, that, u. Alzheimer redirects here For other uses see Alzheimer disambiguation This article needs to be updated Please help update this article to reflect recent events or newly available information March 2021 Alzheimer s disease AD is a neurodegenerative disease that usually starts slowly and progressively worsens 2 It is the cause of 60 70 of cases of dementia 2 11 The most common early symptom is difficulty in remembering recent events 1 As the disease advances symptoms can include problems with language disorientation including easily getting lost mood swings loss of motivation self neglect and behavioral issues 2 As a person s condition declines they often withdraw from family and society 12 Gradually bodily functions are lost ultimately leading to death 13 Although the speed of progression can vary the typical life expectancy following diagnosis is three to nine years 9 14 Alzheimer s diseaseDiagram of a normal brain compared to the brain of a person with Alzheimer sPronunciationˈaltshʌɪmezSpecialtyNeurologySymptomsMemory loss problems with language disorientation mood swings 1 2 ComplicationsDehydration and pneumonia in the terminal stage 3 Usual onsetOver 65 years old 4 DurationLong term 2 CausesPoorly understood 1 Risk factorsGenetics head injuries depression hypertension 1 Diagnostic methodBased on symptoms and cognitive testing after ruling out other possible causes 5 Differential diagnosisNormal aging 1 Lewy body dementia 6 Trisomy 21 7 MedicationAcetylcholinesterase inhibitors NMDA receptor antagonists small benefit 8 PrognosisLife expectancy 3 9 years 9 Frequency50 million 2020 10 The cause of Alzheimer s disease is poorly understood 12 There are many environmental and genetic risk factors associated with its development The strongest genetic risk factor is from an allele of APOE 15 16 Other risk factors include a history of head injury clinical depression and high blood pressure 1 The disease process is largely associated with amyloid plaques neurofibrillary tangles and loss of neuronal connections in the brain 13 A probable diagnosis is based on the history of the illness and cognitive testing with medical imaging and blood tests to rule out other possible causes 5 Initial symptoms are often mistaken for normal aging 12 Examination of brain tissue is needed for a definite diagnosis but this can only take place after death 13 Good nutrition physical activity and engaging socially are known to be of benefit generally in aging and these may help in reducing the risk of cognitive decline and Alzheimer s in 2019 clinical trials were underway to look at these possibilities 13 There are no medications or supplements that have been shown to decrease risk 17 No treatments stop or reverse its progression though some may temporarily improve symptoms 2 Affected people increasingly rely on others for assistance often placing a burden on the caregiver 18 The pressures can include social psychological physical and economic elements 18 Exercise programs may be beneficial with respect to activities of daily living and can potentially improve outcomes 19 Behavioral problems or psychosis due to dementia are often treated with antipsychotics but this is not usually recommended as there is little benefit and an increased risk of early death 20 21 As of 2020 there were approximately 50 million people worldwide with Alzheimer s disease 10 It most often begins in people over 65 years of age although up to 10 of cases are early onset affecting those in their 30s to mid 60s 13 4 It affects about 6 of people 65 years and older 12 and women more often than men 22 The disease is named after German psychiatrist and pathologist Alois Alzheimer who first described it in 1906 23 Alzheimer s financial burden on society is large with an estimated global annual cost of US 1 trillion 10 Alzheimer s disease is currently ranked as the seventh leading cause of death in the United States 24 Contents 1 Signs and symptoms 1 1 First symptoms 1 2 Early stage 1 3 Middle stage 1 4 Late stage 2 Causes 2 1 Genetic 2 2 Other hypotheses 3 Pathophysiology 3 1 Neuropathology 3 2 Biochemistry 3 3 Disease mechanism 4 Diagnosis 4 1 Criteria 4 2 Techniques 5 Prevention 5 1 Medication 5 2 Lifestyle 6 Management 6 1 Pharmaceutical 6 2 Psychosocial 6 3 Caregiving 6 4 Diet 7 Prognosis 8 Epidemiology 9 History 10 Society and culture 10 1 Social costs 10 2 Caregiving burden 10 3 Media 11 Research directions 11 1 Emerging theories 11 2 Treatment and prevention 12 References 13 Further reading 14 External linksSigns and symptomsThe course of Alzheimer s is generally described in three stages with a progressive pattern of cognitive and functional impairment 25 13 The three stages are described as early or mild middle or moderate and late or severe 25 13 The disease is known to target the hippocampus which is associated with memory and this is responsible for the first symptoms of memory impairment As the disease progresses so does the degree of memory impairment 13 First symptoms Stages of atrophy in Alzheimer s The first symptoms are often mistakenly attributed to aging or stress 26 Detailed neuropsychological testing can reveal mild cognitive difficulties up to eight years before a person fulfills the clinical criteria for diagnosis of Alzheimer s disease 27 These early symptoms can affect the most complex activities of daily living 28 The most noticeable deficit is short term memory loss which shows up as difficulty in remembering recently learned facts and inability to acquire new information 27 Subtle problems with the executive functions of attentiveness planning flexibility and abstract thinking or impairments in semantic memory memory of meanings and concept relationships can also be symptomatic of the early stages of Alzheimer s disease 27 Apathy and depression can be seen at this stage with apathy remaining as the most persistent symptom throughout the course of the disease 29 30 Mild cognitive impairment MCI is often found to be a transitional stage between normal aging and dementia MCI can present with a variety of symptoms and when memory loss is the predominant symptom it is termed amnestic MCI and is frequently seen as a prodromal stage of Alzheimer s disease 31 Amnestic MCI has a greater than 90 likelihood of being associated with Alzheimer s 32 Early stage In people with Alzheimer s disease the increasing impairment of learning and memory eventually leads to a definitive diagnosis In a small percentage difficulties with language executive functions perception agnosia or execution of movements apraxia are more prominent than memory problems 33 Alzheimer s disease does not affect all memory capacities equally Older memories of the person s life episodic memory facts learned semantic memory and implicit memory the memory of the body on how to do things such as using a fork to eat or how to drink from a glass are affected to a lesser degree than new facts or memories 34 35 Language problems are mainly characterised by a shrinking vocabulary and decreased word fluency leading to a general impoverishment of oral and written language 33 36 In this stage the person with Alzheimer s is usually capable of communicating basic ideas adequately 33 36 37 While performing fine motor tasks such as writing drawing or dressing certain movement coordination and planning difficulties apraxia may be present but they are commonly unnoticed 33 As the disease progresses people with Alzheimer s disease can often continue to perform many tasks independently but may need assistance or supervision with the most cognitively demanding activities 33 Middle stage Progressive deterioration eventually hinders independence with subjects being unable to perform most common activities of daily living 33 Speech difficulties become evident due to an inability to recall vocabulary which leads to frequent incorrect word substitutions paraphasias Reading and writing skills are also progressively lost 33 37 Complex motor sequences become less coordinated as time passes and Alzheimer s disease progresses so the risk of falling increases 33 During this phase memory problems worsen and the person may fail to recognise close relatives 33 Long term memory which was previously intact becomes impaired 33 Behavioral and neuropsychiatric changes become more prevalent Common manifestations are wandering irritability and emotional lability leading to crying outbursts of unpremeditated aggression or resistance to caregiving 33 Sundowning can also appear 38 Approximately 30 of people with Alzheimer s disease develop illusionary misidentifications and other delusional symptoms 33 Subjects also lose insight of their disease process and limitations anosognosia 33 Urinary incontinence can develop 33 These symptoms create stress for relatives and caregivers which can be reduced by moving the person from home care to other long term care facilities 33 39 Late stage A normal brain on the left and a late stage Alzheimer s brain on the right During the final stage known as the late stage or severe stage there is complete dependence on caregivers 13 25 33 Language is reduced to simple phrases or even single words eventually leading to complete loss of speech 33 37 Despite the loss of verbal language abilities people can often understand and return emotional signals Although aggressiveness can still be present extreme apathy and exhaustion are much more common symptoms People with Alzheimer s disease will ultimately not be able to perform even the simplest tasks independently muscle mass and mobility deteriorates to the point where they are bedridden and unable to feed themselves The cause of death is usually an external factor such as infection of pressure ulcers or pneumonia not the disease itself 33 CausesProteins fail to function normally This disrupts the work of the brain cells affected and triggers a toxic cascade ultimately leading to cell death and later brain shrinkage 40 Alzheimer s disease is believed to occur when abnormal amounts of amyloid beta Ab accumulating extracellularly as amyloid plaques and tau proteins or intracellularly as neurofibrillary tangles form in the brain affecting neuronal functioning and connectivity resulting in a progressive loss of brain function 41 42 This altered protein clearance ability is age related regulated by brain cholesterol 43 and associated with other neurodegenerative diseases 44 45 Advances in brain imaging techniques allow researchers to see the development and spread of abnormal amyloid and tau proteins in the living brain as well as changes in brain structure and function 24 Beta amyloid is a fragment of a larger protein When these fragments cluster together a toxic effect appears on neurons and disrupt cell to cell communication Larger deposits called amyloid plaques are thus further formed 40 Tau proteins are responsible in neuron s internal support and transport system to carry nutrients and other essential materials In Alzheimer s disease the shape of tau proteins is altered and thus organize themselves into structures called neurofibrillary tangles The tangles disrupt the transport system and are toxic to cells The cause for most Alzheimer s cases is still mostly unknown 10 except for 1 2 of cases where deterministic genetic differences have been identified 15 Several competing hypotheses attempt to explain the underlying cause the two predominant hypotheses are the amyloid beta Ab hypothesis and the cholinergic hypothesis 10 The oldest hypothesis on which most drug therapies are based is the cholinergic hypothesis which proposes that Alzheimer s disease is caused by reduced synthesis of the neurotransmitter acetylcholine 10 The loss of cholinergic neurons noted in the limbic system and cerebral cortex is a key feature in the progression of Alzheimer s 31 The 1991 amyloid hypothesis postulated that extracellular amyloid beta Ab deposits are the fundamental cause of the disease 46 47 Support for this postulate comes from the location of the gene for the amyloid precursor protein APP on chromosome 21 together with the fact that people with trisomy 21 Down syndrome who have an extra gene copy almost universally exhibit at least the earliest symptoms of Alzheimer s disease by 40 years of age 7 A specific isoform of apolipoprotein APOE4 is a major genetic risk factor for Alzheimer s disease 11 While apolipoproteins enhance the breakdown of beta amyloid some isoforms are not very effective at this task such as APOE4 leading to excess amyloid buildup in the brain 48 Genetic Only 1 2 of Alzheimer s cases are inherited autosomal dominant These types are known as early onset familial Alzheimer s disease can have a very early onset and a faster rate of progression 15 Early onset familial Alzheimer s disease can be attributed to mutations in one of three genes those encoding amyloid beta precursor protein APP and presenilins PSEN1 and PSEN2 32 Most mutations in the APP and presenilin genes increase the production of a small protein called amyloid beta Ab 42 which is the main component of amyloid plaques 49 Some of the mutations merely alter the ratio between Ab42 and the other major forms particularly Ab40 without increasing Ab42 levels 50 Two other genes associated with autosomal dominant Alzheimer s disease are ABCA7 and SORL1 51 Most cases of Alzheimer s are not inherited and are termed sporadic Alzheimer s disease in which environmental and genetic differences may act as risk factors Most cases of sporadic Alzheimer s disease in contrast to familial Alzheimer s disease are late onset Alzheimer s disease LOAD developing after the age of 65 years Less than 5 of sporadic Alzheimer s disease have an earlier onset 15 The strongest genetic risk factor for sporadic Alzheimer s disease is APOEe4 16 APOEe4 is one of four alleles of apolipoprotein E APOE APOE plays a major role in lipid binding proteins in lipoprotein particles and the epsilon4 allele disrupts this function 52 Between 40 and 80 of people with Alzheimer s disease possess at least one APOEe4 allele 53 The APOEe4 allele increases the risk of the disease by three times in heterozygotes and by 15 times in homozygotes 54 Like many human diseases environmental effects and genetic modifiers result in incomplete penetrance For example certain Nigerian populations do not show the relationship between dose of APOEe4 and incidence or age of onset for Alzheimer s disease seen in other human populations 55 56 Alleles in the TREM2 gene have been associated with a 3 to 5 times higher risk of developing Alzheimer s disease 57 A Japanese pedigree of familial Alzheimer s disease was found to be associated with a deletion mutation of codon 693 of APP 58 This mutation and its association with Alzheimer s disease was first reported in 2008 59 and is known as the Osaka mutation Only homozygotes with this mutation have an increased risk of developing Alzheimer s disease This mutation accelerates Ab oligomerization but the proteins do not form the amyloid fibrils that aggregate into amyloid plaques suggesting that it is the Ab oligomerization rather than the fibrils that may be the cause of this disease Mice expressing this mutation have all the usual pathologies of Alzheimer s disease 60 Other hypotheses In Alzheimer s disease changes in tau protein lead to the disintegration of microtubules in brain cells The tau hypothesis proposes that tau protein abnormalities initiate the disease cascade 47 In this model hyperphosphorylated tau begins to pair with other threads of tau as paired helical filaments Eventually they form neurofibrillary tangles inside nerve cell bodies 61 When this occurs the microtubules disintegrate destroying the structure of the cell s cytoskeleton which collapses the neuron s transport system 62 A number of studies connect the misfolded amyloid beta and tau proteins associated with the pathology of Alzheimer s disease as bringing about oxidative stress that leads to chronic inflammation 63 Sustained inflammation neuroinflammation is also a feature of other neurodegenerative diseases including Parkinson s disease and ALS 64 Spirochete infections have also been linked to dementia 10 DNA damages accumulate in AD brains reactive oxygen species may be the major source of this DNA damage 65 Sleep disturbances are seen as a possible risk factor for inflammation in Alzheimer s disease Sleep problems have been seen as a consequence of Alzheimer s disease but studies suggest that they may instead be a causal factor Sleep disturbances are thought to be linked to persistent inflammation 66 The cellular homeostasis of biometals such as ionic copper iron and zinc is disrupted in Alzheimer s disease though it remains unclear whether this is produced by or causes the changes in proteins 10 67 Smoking is a significant Alzheimer s disease risk factor 1 Systemic markers of the innate immune system are risk factors for late onset Alzheimer s disease 68 Exposure to air pollution may be a contributing factor to the development of Alzheimer s disease 10 One hypothesis posits that dysfunction of oligodendrocytes and their associated myelin during aging contributes to axon damage which then causes amyloid production and tau hyper phosphorylation as a side effect 69 70 Retrogenesis is a medical hypothesis that just as the fetus goes through a process of neurodevelopment beginning with neurulation and ending with myelination the brains of people with Alzheimer s disease go through a reverse neurodegeneration process starting with demyelination and death of axons white matter and ending with the death of grey matter 71 Likewise the hypothesis is that as infants go through states of cognitive development people with Alzheimer s disease go through the reverse process of progressive cognitive impairment 72 The association with celiac disease is unclear with a 2019 study finding no increase in dementia overall in those with CD while a 2018 review found an association with several types of dementia including Alzheimer s disease 73 74 Pathophysiology Histopathologic images of Alzheimer s disease in the CA3 area of the hippocampus showing an amyloid plaque top right neurofibrillary tangles bottom left and granulovacuolar degeneration bodies bottom center Neuropathology Alzheimer s disease is characterised by loss of neurons and synapses in the cerebral cortex and certain subcortical regions This loss results in gross atrophy of the affected regions including degeneration in the temporal lobe and parietal lobe and parts of the frontal cortex and cingulate gyrus 75 Degeneration is also present in brainstem nuclei particularly the locus coeruleus in the pons 76 Studies using MRI and PET have documented reductions in the size of specific brain regions in people with Alzheimer s disease as they progressed from mild cognitive impairment to Alzheimer s disease and in comparison with similar images from healthy older adults 77 78 Both Ab plaques and neurofibrillary tangles are clearly visible by microscopy in brains of those with Alzheimer s disease 79 especially in the hippocampus 80 However Alzheimer s disease may occur without neurofibrillary tangles in the neocortex 81 Plaques are dense mostly insoluble deposits of beta amyloid peptide and cellular material outside and around neurons Tangles neurofibrillary tangles are aggregates of the microtubule associated protein tau which has become hyperphosphorylated and accumulate inside the cells themselves Although many older individuals develop some plaques and tangles as a consequence of aging the brains of people with Alzheimer s disease have a greater number of them in specific brain regions such as the temporal lobe 82 Lewy bodies are not rare in the brains of people with Alzheimer s disease 83 Biochemistry Main article Biochemistry of Alzheimer s disease Enzymes act on the APP amyloid beta precursor protein and cut it into fragments The beta amyloid fragment is crucial in the formation of amyloid plaques in Alzheimer s disease Alzheimer s disease has been identified as a protein misfolding disease a proteopathy caused by the accumulation of abnormally folded amyloid beta protein into amyloid plaques and tau protein into neurofibrillary tangles in the brain 84 Plaques are made up of small peptides 39 43 amino acids in length called amyloid beta Ab Amyloid beta is a fragment from the larger amyloid beta precursor protein APP a transmembrane protein that penetrates the neuron s membrane APP is critical to neuron growth survival and post injury repair 85 86 In Alzheimer s disease gamma secretase and beta secretase act together in a proteolytic process which causes APP to be divided into smaller fragments 87 One of these fragments gives rise to fibrils of amyloid beta which then form clumps that deposit outside neurons in dense formations known as amyloid plaques 79 88 Alzheimer s disease is also considered a tauopathy due to abnormal aggregation of the tau protein Every neuron has a cytoskeleton an internal support structure partly made up of structures called microtubules These microtubules act like tracks guiding nutrients and molecules from the body of the cell to the ends of the axon and back A protein called tau stabilises the microtubules when phosphorylated and is therefore called a microtubule associated protein In Alzheimer s disease tau undergoes chemical changes becoming hyperphosphorylated it then begins to pair with other threads creating neurofibrillary tangles and disintegrating the neuron s transport system 89 Pathogenic tau can also cause neuronal death through transposable element dysregulation 90 Disease mechanism Exactly how disturbances of production and aggregation of the beta amyloid peptide give rise to the pathology of Alzheimer s disease is not known 91 92 The amyloid hypothesis traditionally points to the accumulation of beta amyloid peptides as the central event triggering neuron degeneration Accumulation of aggregated amyloid fibrils which are believed to be the toxic form of the protein responsible for disrupting the cell s calcium ion homeostasis induces programmed cell death apoptosis 93 It is also known that Ab selectively builds up in the mitochondria in the cells of Alzheimer s affected brains and it also inhibits certain enzyme functions and the utilisation of glucose by neurons 94 Various inflammatory processes and cytokines may also have a role in the pathology of Alzheimer s disease Inflammation is a general marker of tissue damage in any disease and may be either secondary to tissue damage in Alzheimer s disease or a marker of an immunological response 95 There is increasing evidence of a strong interaction between the neurons and the immunological mechanisms in the brain Obesity and systemic inflammation may interfere with immunological processes which promote disease progression 96 Alterations in the distribution of different neurotrophic factors and in the expression of their receptors such as the brain derived neurotrophic factor BDNF have been described in Alzheimer s disease 97 98 DiagnosisSee also Early onset Alzheimer s disease Diagnosis PET scan of the brain of a person with Alzheimer s disease showing a loss of function in the temporal lobe Alzheimer s disease can only be definitively diagnosed with autopsy findings in the absence of autopsy clinical diagnoses of AD are possible or probable based on other findings 99 100 101 Up to 23 of those clinically diagnosed with AD may be misdiagnosed and may have pathology suggestive of another condition with symptoms that mimic those of AD 100 AD is usually clinically diagnosed based on the person s medical history history from relatives and behavioral observations The presence of characteristic neurological and neuropsychological features and the absence of alternative conditions supports the diagnosis needs update 102 103 Advanced medical imaging with computed tomography CT or magnetic resonance imaging MRI and with single photon emission computed tomography SPECT or positron emission tomography PET can be used to help exclude other cerebral pathology or subtypes of dementia 104 Moreover it may predict conversion from prodromal stages mild cognitive impairment to Alzheimer s disease 105 FDA approved radiopharmaceutical diagnostic agents used in PET for Alzheimer s disease are florbetapir 2012 flutemetamol 2013 florbetaben 2014 and flortaucipir 2020 106 Because many insurance companies in the United States do not cover this procedure its use in clinical practice is largely limited to clinical trials as of 2018 update 107 Assessment of intellectual functioning including memory testing can further characterise the state of the disease 1 Medical organizations have created diagnostic criteria to ease and standardise the diagnostic process for practising physicians Definitive diagnosis can only be confirmed with post mortem evaluations when brain material is available and can be examined histologically for senile plaques and neurofibrillary tangles 107 108 Criteria There are three sets of criteria for the clinical diagnoses of the spectrum of Alzheimer s disease the 2013 fifth edition of the Diagnostic and Statistical Manual of Mental Disorders DSM 5 the National Institute on Aging Alzheimer s Association NIA AA definition as revised in 2011 and the International Working Group criteria as revised in 2010 32 107 Three broad time periods which can span decades define the progression of Alzheimer s disease from the preclinical phase to mild cognitive impairment MCI followed by Alzheimer s disease dementia 109 Eight intellectual domains are most commonly impaired in AD memory language perceptual skills attention motor skills orientation problem solving and executive functional abilities as listed in the fourth text revision of the DSM DSM IV TR 110 The DSM 5 defines criteria for probable or possible Alzheimer s for both major and mild neurocognitive disorder 111 112 101 Major or mild neurocognitive disorder must be present along with at least one cognitive deficit for a diagnosis of either probable or possible AD 111 113 For major neurocognitive disorder due to Alzheimer s disease probable Alzheimer s disease can be diagnosed if the individual has genetic evidence of Alzheimer s 114 or if two or more acquired cognitive deficits and a functional disability that is not from another disorder are present 115 Otherwise possible Alzheimer s disease can be diagnosed as the diagnosis follows an atypical route 116 For mild neurocognitive disorder due to Alzheimer s probable Alzheimer s disease can be diagnosed if there is genetic evidence whereas possible Alzheimer s disease can be met if all of the following are present no genetic evidence decline in both learning and memory two or more cognitive deficits and a functional disability not from another disorder 111 117 The NIA AA criteria are used mainly in research rather than in clinical assessments 118 They define Alzheimer s disease through three major stages preclinical mild cognitive impairment MCI and Alzheimer s dementia 119 120 Diagnosis in the preclinical stage is complex and focuses on asymptomatic individuals 120 121 the latter two stages describe individuals experiencing symptoms 120 The core clinical criteria for MCI is used along with identification of biomarkers 122 predominantly those for neuronal injury mainly tau related and amyloid beta deposition 118 120 The core clinical criteria itself rests on the presence of cognitive impairment 120 without the presence of comorbidities 123 124 The third stage is divided into probable and possible Alzheimer s disease dementia 124 In probable Alzheimer s disease dementia there is steady impairment of cognition over time and a memory related or non memory related cognitive dysfunction 124 In possible Alzheimer s disease dementia another causal disease such as cerebrovascular disease is present 124 Techniques Cognitive tests such as the Mini Mental State Examination MMSE can help in the diagnosis of Alzheimer s disease In this test instructions are given to copy drawings like the one shown remember some words read and subtract numbers serially Neuropsychological tests including cognitive tests such as the Mini Mental State Examination MMSE the Montreal Cognitive Assessment MoCA and the Mini Cog are widely used to aid in diagnosis of the cognitive impairments in AD 125 These tests may not always be accurate as they lack sensitivity to mild cognitive impairment and can be biased by language or attention problems 125 more comprehensive test arrays are necessary for high reliability of results particularly in the earliest stages of the disease 126 127 Further neurological examinations are crucial in the differential diagnosis of Alzheimer s disease and other diseases 26 Interviews with family members are used in assessment caregivers can supply important information on daily living abilities and on the decrease in the person s mental function 128 A caregiver s viewpoint is particularly important since a person with Alzheimer s disease is commonly unaware of their deficits 129 Many times families have difficulties in the detection of initial dementia symptoms and may not communicate accurate information to a physician 130 Supplemental testing can rule out other potentially treatable diagnoses and help avoid misdiagnoses 131 Common supplemental tests include blood tests thyroid function tests as well as tests to assess vitamin B12 levels rule out neurosyphilis and rule out metabolic problems including tests for kidney function electrolyte levels and for diabetes 131 MRI or CT scans might also be used to rule out other potential causes of the symptoms including tumors or strokes 125 Delirium and depression can be common among individuals and are important to rule out 132 Psychological tests for depression are used since depression can either be concurrent with Alzheimer s disease see Depression of Alzheimer disease an early sign of cognitive impairment 133 or even the cause 134 135 Due to low accuracy the C PIB PET scan is not recommended as an early diagnostic tool or for predicting the development of Alzheimer s disease when people show signs of mild cognitive impairment MCI 136 The use of 18F FDG PET scans as a single test to identify people who may develop Alzheimer s disease is not supported by evidence 137 Prevention Intellectual activities such as playing chess or regular social interaction have been linked to a reduced risk of Alzheimer s disease in epidemiological studies although no causal relationship has been found There are no disease modifying treatments available to cure Alzheimer s disease and because of this AD research has focused on interventions to prevent the onset and progression 138 There is no evidence that supports any particular measure in preventing Alzheimer s 1 and studies of measures to prevent the onset or progression have produced inconsistent results Epidemiological studies have proposed relationships between an individual s likelihood of developing AD and modifiable factors such as medications lifestyle and diet There are some challenges in determining whether interventions for Alzheimer s disease act as a primary prevention method preventing the disease itself or a secondary prevention method identifying the early stages of the disease 17 These challenges include duration of intervention different stages of disease at which intervention begins and lack of standardization of inclusion criteria regarding biomarkers specific for Alzheimer s disease 17 Further research is needed to determine factors that can help prevent Alzheimer s disease 17 Medication Cardiovascular risk factors such as hypercholesterolaemia hypertension diabetes and smoking are associated with a higher risk of onset and worsened course of AD 139 140 The use of statins to lower cholesterol may be of benefit in Alzheimer s 141 Antihypertensive and antidiabetic medications in individuals without overt cognitive impairment may decrease the risk of dementia by influencing cerebrovascular pathology 1 142 More research is needed to examine the relationship with Alzheimer s disease specifically clarification of the direct role medications play versus other concurrent lifestyle changes diet exercise smoking is needed 1 Depression is associated with an increased risk for Alzheimer s disease management with antidepressants may provide a preventative measure 143 Historically long term usage of non steroidal anti inflammatory drugs NSAIDs were thought to be associated with a reduced likelihood of developing Alzheimer s disease as it reduces inflammation however NSAIDs do not appear to be useful as a treatment 107 Additionally because women have a higher incidence of Alzheimer s disease than men it was once thought that estrogen deficiency during menopause was a risk factor However there is a lack of evidence to show that hormone replacement therapy HRT in menopause decreases risk of cognitive decline 144 Lifestyle Further information Neurobiological effects of physical exercise Certain lifestyle activities such as physical and cognitive exercises higher education and occupational attainment cigarette smoking stress sleep and the management of other comorbidities including diabetes and hypertension may affect the risk of developing Alzheimer s 143 Physical exercise is associated with a decreased rate of dementia 145 and is effective in reducing symptom severity in those with AD 146 Memory and cognitive functions can be improved with aerobic exercises including brisk walking three times weekly for forty minutes 147 It may also induce neuroplasticity of the brain 148 Participating in mental exercises such as reading crossword puzzles and chess have shown a potential to be preventative 143 Meeting the WHO recommendations for physical activity is associated with a lower risk of AD 149 Higher education and occupational attainment and participation in leisure activities contribute to a reduced risk of developing Alzheimer s 150 or of delaying the onset of symptoms This is compatible with the cognitive reserve theory which states that some life experiences result in more efficient neural functioning providing the individual a cognitive reserve that delays the onset of dementia manifestations 150 Education delays the onset of Alzheimer s disease syndrome without changing the duration of the disease 151 Cessation in smoking may reduce risk of developing Alzheimer s disease specifically in those who carry APOE ɛ4 allele 152 143 The increased oxidative stress caused by smoking results in downstream inflammatory or neurodegenerative processes that may increase risk of developing AD 153 Avoidance of smoking counseling and pharmacotherapies to quit smoking are used and avoidance of environmental tobacco smoke is recommended 143 Alzheimer s disease is associated with sleep disorders but the precise relationship is unclear 154 155 It was once thought that as people get older the risk of developing sleep disorders and AD independently increase but research is examining whether sleep disorders may increase the prevalence of AD 154 One theory is that the mechanisms to increase clearance of toxic substances including Ab are active during sleep 154 156 With decreased sleep a person is increasing Ab production and decreasing Ab clearance resulting in Ab accumulation 157 154 155 Receiving adequate sleep approximately 7 8 hours every night has become a potential lifestyle intervention to prevent the development of AD 143 Stress is a risk factor for the development of Alzheimer s 143 The mechanism by which stress predisposes someone to development of Alzheimer s is unclear but it is suggested that lifetime stressors may affect a person s epigenome leading to an overexpression or under expression of specific genes 158 Although the relationship of stress and Alzheimer s is unclear strategies to reduce stress and relax the mind may be helpful strategies in preventing the progression or Alzheimer s disease 159 Meditation for instance is a helpful lifestyle change to support cognition and well being though further research is needed to assess long term effects 148 ManagementThere is no cure for Alzheimer s disease available treatments offer relatively small symptomatic benefits but remain palliative in nature 10 160 Treatments can be divided into pharmaceutical psychosocial and caregiving Pharmaceutical This section needs to be updated Please help update this article to reflect recent events or newly available information February 2022 Three dimensional molecular model of donepezil an acetylcholinesterase inhibitor used in the treatment of Alzheimer s disease symptoms Molecular structure of memantine a medication approved for advanced Alzheimer s disease symptoms Medications used to treat the cognitive problems of Alzheimer s disease include four acetylcholinesterase inhibitors tacrine rivastigmine galantamine and donepezil and memantine an NMDA receptor antagonist The acetylcholinesterase inhibitors are intended for those with mild to severe Alzheimer s whereas memantine is intended for those with moderate or severe Alzheimer s disease 107 The benefit from their use is small 161 162 163 11 Reduction in the activity of the cholinergic neurons is a well known feature of Alzheimer s disease 164 Acetylcholinesterase inhibitors are employed to reduce the rate at which acetylcholine ACh is broken down thereby increasing the concentration of ACh in the brain and combating the loss of ACh caused by the death of cholinergic neurons 165 There is evidence for the efficacy of these medications in mild to moderate Alzheimer s disease 166 161 and some evidence for their use in the advanced stage 161 The use of these drugs in mild cognitive impairment has not shown any effect in a delay of the onset of Alzheimer s disease 167 The most common side effects are nausea and vomiting both of which are linked to cholinergic excess These side effects arise in approximately 10 20 of users are mild to moderate in severity and can be managed by slowly adjusting medication doses 168 Less common secondary effects include muscle cramps decreased heart rate bradycardia decreased appetite and weight and increased gastric acid production 166 Glutamate is an excitatory neurotransmitter of the nervous system although excessive amounts in the brain can lead to cell death through a process called excitotoxicity which consists of the overstimulation of glutamate receptors Excitotoxicity occurs not only in Alzheimer s disease but also in other neurological diseases such as Parkinson s disease and multiple sclerosis 169 Memantine is a noncompetitive NMDA receptor antagonist first used as an anti influenza agent It acts on the glutamatergic system by blocking NMDA receptors and inhibiting their overstimulation by glutamate 169 170 Memantine has been shown to have a small benefit in the treatment of moderate to severe Alzheimer s disease 171 Reported adverse events with memantine are infrequent and mild including hallucinations confusion dizziness headache and fatigue 172 173 The combination of memantine and donepezil 174 has been shown to be of statistically significant but clinically marginal effectiveness 175 An extract of Ginkgo biloba known as EGb 761 has been used for treating Alzheimer s and other neuropsychiatric disorders 176 Its use is approved throughout Europe 177 The World Federation of Biological Psychiatry guidelines lists EGb 761 with the same weight of evidence level B given to acetylcholinesterase inhibitors and memantine EGb 761 is the only one that showed improvement of symptoms in both Alzheimer s disease and vascular dementia EGb 761 may have a role either on its own or as an add on if other therapies prove ineffective 176 A 2016 review concluded that the quality of evidence from clinical trials on Ginkgo biloba has been insufficient to warrant its use for treating Alzheimer s disease 178 Atypical antipsychotics are modestly useful in reducing aggression and psychosis in people with Alzheimer s disease but their advantages are offset by serious adverse effects such as stroke movement difficulties or cognitive decline 179 When used in the long term they have been shown to associate with increased mortality 180 Stopping antipsychotic use in this group of people appears to be safe 181 Psychosocial Psychosocial interventions are used as an adjunct to pharmaceutical treatment and can be classified within behavior emotion cognition or stimulation oriented approaches needs update 182 Behavioral interventions attempt to identify and reduce the antecedents and consequences of problem behaviors This approach has not shown success in improving overall functioning 183 but can help to reduce some specific problem behaviors such as incontinence 184 There is a lack of high quality data on the effectiveness of these techniques in other behavior problems such as wandering 185 186 Music therapy is effective in reducing behavioral and psychological symptoms 187 Emotion oriented interventions include reminiscence therapy validation therapy supportive psychotherapy sensory integration also called snoezelen and simulated presence therapy A Cochrane review has found no evidence that this is effective 188 Reminiscence therapy RT involves the discussion of past experiences individually or in group many times with the aid of photographs household items music and sound recordings or other familiar items from the past A 2018 review of the effectiveness of RT found that effects were inconsistent small in size and of doubtful clinical significance and varied by setting 189 Simulated presence therapy SPT is based on attachment theories and involves playing a recording with voices of the closest relatives of the person with Alzheimer s disease There is partial evidence indicating that SPT may reduce challenging behaviors 190 The aim of cognition oriented treatments which include reality orientation and cognitive retraining is the reduction of cognitive deficits Reality orientation consists of the presentation of information about time place or person to ease the understanding of the person about its surroundings and his or her place in them On the other hand cognitive retraining tries to improve impaired capacities by exercising mental abilities Both have shown some efficacy improving cognitive capacities 191 Stimulation oriented treatments include art music and pet therapies exercise and any other kind of recreational activities Stimulation has modest support for improving behavior mood and to a lesser extent function Nevertheless as important as these effects are the main support for the use of stimulation therapies is the change in the person s routine 182 Caregiving Further information Caring for people with dementia and Palliative care Since Alzheimer s has no cure and it gradually renders people incapable of tending to their own needs caregiving is essentially the treatment and must be carefully managed over the course of the disease During the early and moderate stages modifications to the living environment and lifestyle can increase safety and reduce caretaker burden 192 193 Examples of such modifications are the adherence to simplified routines the placing of safety locks the labeling of household items to cue the person with the disease or the use of modified daily life objects 182 194 195 If eating becomes problematic food will need to be prepared in smaller pieces or even pureed 196 When swallowing difficulties arise the use of feeding tubes may be required In such cases the medical efficacy and ethics of continuing feeding is an important consideration of the caregivers and family members 197 198 The use of physical restraints is rarely indicated in any stage of the disease although there are situations when they are necessary to prevent harm to the person with Alzheimer s disease or their caregivers 182 During the final stages of the disease treatment is centred on relieving discomfort until death often with the help of hospice 199 Diet Diet may be a modifiable risk factor for the development of Alzheimer s disease The Mediterranean diet and the DASH diet are both associated with less cognitive decline A different approach has been to incorporate elements of both of these diets into one known as the MIND diet 200 Studies of individual dietary components minerals and supplements are conflicting as to whether they prevent AD or cognitive decline 200 201 202 PrognosisThe early stages of Alzheimer s disease are difficult to diagnose A definitive diagnosis is usually made once cognitive impairment compromises daily living activities although the person may still be living independently The symptoms will progress from mild cognitive problems such as memory loss through increasing stages of cognitive and non cognitive disturbances eliminating any possibility of independent living especially in the late stages of the disease 33 Life expectancy of people with Alzheimer s disease is reduced 203 The normal life expectancy for 60 to 70 years old is 23 to 15 years for 90 years old it is 4 5 years 204 Following Alzheimer s disease diagnosis it ranges from 7 to 10 years for those in their 60s and early 70s a loss of 13 to 8 years to only about 3 years or less a loss of 1 5 years for those in their 90s 203 Fewer than 3 of people live more than fourteen years 205 Disease features significantly associated with reduced survival are an increased severity of cognitive impairment decreased functional level history of falls and disturbances in the neurological examination Other coincident diseases such as heart problems diabetes or history of alcohol abuse are also related with shortened survival 206 207 208 While the earlier the age at onset the higher the total survival years life expectancy is particularly reduced when compared to the healthy population among those who are younger 209 Men have a less favourable survival prognosis than women 205 3 Pneumonia and dehydration are the most frequent immediate causes of death brought by Alzheimer s disease while cancer is a less frequent cause of death than in the general population 3 EpidemiologyTwo main measures are used in epidemiological studies incidence and prevalence Incidence is the number of new cases per unit of person time at risk usually number of new cases per thousand person years while prevalence is the total number of cases of the disease in the population at any given time Deaths per million persons in 2012 due to dementias including Alzheimer s disease 0 4 5 8 9 10 11 13 14 17 18 24 25 45 46 114 115 375 376 1266 Regarding incidence cohort longitudinal studies studies where a disease free population is followed over the years provide rates between 10 and 15 per thousand person years for all dementias and 5 8 for Alzheimer s disease 210 211 which means that half of new dementia cases each year are Alzheimer s disease Advancing age is a primary risk factor for the disease and incidence rates are not equal for all ages every 5 years after the age of 65 the risk of acquiring the disease approximately doubles increasing from 3 to as much as 69 per thousand person years 210 211 Females with Alzheimer s disease are more common than males but this difference is likely due to women s longer life spans When adjusted for age both sexes are affected by Alzheimer s at equal rates 11 In the United States the risk of dying from Alzheimer s disease in 2010 was 26 higher among the non Hispanic white population than among the non Hispanic black population and the Hispanic population had a 30 lower risk than the non Hispanic white population 212 However much Alzheimer s research remains to be done in minority groups such as the African American and the Hispanic Latino populations 213 214 Studies have shown that these groups are underrepresented in clinical trials and do not have the same risk of developing Alzheimer s when carrying certain genetic risk factors i e APOE4 compared to their caucasian counterparts 214 215 216 The prevalence of Alzheimer s disease in populations is dependent upon factors including incidence and survival Since the incidence of Alzheimer s disease increases with age prevalence depends on the mean age of the population for which prevalence is given In the United States in 2020 Alzheimer s dementia prevalence was estimated to be 5 3 for those in the 60 74 age group with the rate increasing to 13 8 in the 74 84 group and to 34 6 in those greater than 85 217 Prevalence rates in some less developed regions around the globe are lower 218 219 As the incidence and prevalence are steadily increasing the prevalence itself is projected to triple by 2050 clarification needed 220 As of 2020 50 million people globally have AD with this number expected to increase to 152 million by 2050 10 See also Alzheimer s disease in African AmericansHistory Alois Alzheimer s patient Auguste Deter in 1902 Hers was the first described case of what became known as Alzheimer s disease The ancient Greek and Roman philosophers and physicians associated old age with increasing dementia 23 It was not until 1901 that German psychiatrist Alois Alzheimer identified the first case of what became known as Alzheimer s disease named after him in a fifty year old woman he called Auguste D He followed her case until she died in 1906 when he first reported publicly on it 221 During the next five years eleven similar cases were reported in the medical literature some of them already using the term Alzheimer s disease 23 The disease was first described as a distinctive disease by Emil Kraepelin after suppressing some of the clinical delusions and hallucinations and pathological features arteriosclerotic changes contained in the original report of Auguste D 222 He included Alzheimer s disease also named presenile dementia by Kraepelin as a subtype of senile dementia in the eighth edition of his Textbook of Psychiatry published on 15 July 1910 223 For most of the 20th century the diagnosis of Alzheimer s disease was reserved for individuals between the ages of 45 and 65 who developed symptoms of dementia The terminology changed after 1977 when a conference on Alzheimer s disease concluded that the clinical and pathological manifestations of presenile and senile dementia were almost identical although the authors also added that this did not rule out the possibility that they had different causes 224 This eventually led to the diagnosis of Alzheimer s disease independent of age 225 The term senile dementia of the Alzheimer type SDAT was used for a time to describe the condition in those over 65 with classical Alzheimer s disease being used to describe those who were younger Eventually the term Alzheimer s disease was formally adopted in medical nomenclature to describe individuals of all ages with a characteristic common symptom pattern disease course and neuropathology 226 The National Institute of Neurological and Communicative Disorders and Stroke NINCDS and the Alzheimer s Disease and Related Disorders Association ADRDA now known as the Alzheimer s Association established the most commonly used NINCDS ADRDA Alzheimer s Criteria for diagnosis in 1984 227 extensively updated in 2007 228 131 These criteria require that the presence of cognitive impairment and a suspected dementia syndrome be confirmed by neuropsychological testing for a clinical diagnosis of possible or probable Alzheimer s disease A histopathologic confirmation including a microscopic examination of brain tissue is required for a definitive diagnosis Good statistical reliability and validity have been shown between the diagnostic criteria and definitive histopathological confirmation 229 Society and cultureSee also Alzheimer s disease organizations Social costs Dementia and specifically Alzheimer s disease may be among the most costly diseases for societies worldwide 230 As populations age these costs will probably increase and become an important social problem and economic burden 231 Costs associated with AD include direct and indirect medical costs which vary between countries depending on social care for a person with AD 230 232 233 Direct costs include doctor visits hospital care medical treatments nursing home care specialized equipment and household expenses 230 231 Indirect costs include the cost of informal care and the loss in productivity of informal caregivers 231 In the United States as of 2019 update informal family care is estimated to constitute nearly three fourths of caregiving for people with AD at a cost of US 234 billion per year and approximately 18 5 billion hours of care 230 The cost to society worldwide to care for individuals with AD is projected to increase nearly ten fold and reach about US 9 1 trillion by 2050 232 Costs for those with more severe dementia or behavioral disturbances are higher and are related to the additional caregiving time to provide physical care 233 Caregiving burden Further information Caregiving and dementia This section needs to be updated Please help update this article to reflect recent events or newly available information February 2022 The role of the main caregiver is often taken by the spouse or a close relative 234 Alzheimer s disease is known for placing a great burden on caregivers which includes social psychological physical or economic aspects 18 235 236 Home care is usually preferred by people with Alzheimer s disease and their families 237 This option also delays or eliminates the need for more professional and costly levels of care 237 238 Nevertheless two thirds of nursing home residents have dementias 182 Dementia caregivers are subject to high rates of physical and mental disorders 239 Factors associated with greater psychosocial problems of the primary caregivers include having an affected person at home the carer being a spouse demanding behaviors of the cared person such as depression behavioral disturbances hallucinations sleep problems or walking disruptions and social isolation 240 241 Regarding economic problems family caregivers often give up time from work to spend 47 hours per week on average with the person with Alzheimer s disease while the costs of caring for them are high Direct and indirect costs of caring for somebody with Alzheimer s average between 18 000 and 77 500 per year in the United States depending on the study 242 234 Cognitive behavioral therapy and the teaching of coping strategies either individually or in group have demonstrated their efficacy in improving caregivers psychological health 18 243 Media Main article Alzheimer s disease in the media Alzheimer s disease has been portrayed in films such as Iris 2001 based on John Bayley s memoir of his wife Iris Murdoch 244 The Notebook 2004 based on Nicholas Sparks s 1996 novel of the same name 245 A Moment to Remember 2004 Thanmathra 2005 246 Memories of Tomorrow Ashita no Kioku 2006 based on Hiroshi Ogiwara s novel of the same name 247 Away from Her 2006 based on Alice Munro s short story The Bear Came over the Mountain 248 Still Alice 2014 about a Columbia University professor who has early onset Alzheimer s disease based on Lisa Genova s 2007 novel of the same name and featuring Julianne Moore in the title role Documentaries on Alzheimer s disease include Malcolm and Barbara A Love Story 1999 and Malcolm and Barbara Love s Farewell 2007 both featuring Malcolm Pointon 249 250 251 Alzheimer s disease has also been portrayed in music by English musician the Caretaker in releases such as Persistent Repetition of Phrases 2008 An Empty Bliss Beyond This World 2011 and Everywhere at the End of Time 2016 2019 252 253 254 Paintings depicting the disorder include the late works by American artist William Utermohlen who drew self portraits from 1995 to 2000 as an experiment of showing his disease through art 255 256 Research directionsAdditional research on the lifestyle effect may provide insight into neuroimaging biomarkers and better understanding of the mechanisms causing both Alzheimer s disease and early onset AD 257 Emerging theories Alzheimer s disease is associated with neuroinflammation and loss of function of microglia the resident immune cells of the central nervous system 258 Microglia become progressively dysfunctional following exposure to amyloid plaques and exposure to pro inflammatory cytokines e g TNFa IL 1b IL 12 has been hypothesized to sustain this dysfunction Aberrant synaptic pruning via microglial phagocytosis may also contribute to AD pathology 259 The complement system which is involved in some forms of typical microglial pruning during development 260 is implicated in animal models of AD by way of dysregulation of the activation e g C1q C3b and terminal e g MAC pathways in synapses with proximity to amyloid plaques 261 4 Astrocytes may also contribute to AD pathology via their reactive states Under typical conditions astrocytes can surround amyloid beta plaques and can function to remove these species which may be dysregulated under pathological conditions Additionally the activation of astrocytes following the release of APOE has been found to be vitally important in microglia function especially in their ability to remove amyloid beta In AD disease pathology atrophy of astrocytes may prevent these functions and further contribute to the prevalence of AD pathological species such as amyloid beta plaques 258 Treatment and prevention There is ongoing research examining the role of specific medications in reducing the prevalence primary prevention and or progression secondary prevention of Alzheimer s disease 262 The research trials investigating medications generally impact Ab plaques inflammation APOE neurotransmitter receptors neurogenesis epigenetic regulators growth factors and hormones 262 263 264 These studies have led to a better understanding of the disease but none identified a prevention strategy 262 263 Experimental models are commonly used by researchers in order to understand disease mechanisms as well develop and test novel therapeutics aimed at treating Alzheimer s disease Antibodies are being developed that may have the ability to alter the disease course by targeting amyloid beta such as donanemab and aducanumab Aducanumab was approved by the FDA in 2021 but its use and effectiveness remain unclear and controversial 265 Although it received FDA approval aducanumab failed to show effectiveness in people who already had Alzheimer s symptoms 266 References a b c d e f g h i j k Knopman DS Amieva H Petersen RC et al May 2021 Alzheimer disease Nat Rev Dis Primers 7 1 33 doi 10 1038 s41572 021 00269 y PMC 8574196 PMID 33986301 a b c d e f Dementia Fact sheet World Health Organization September 2020 a b c Ganguli M Dodge HH Shen C Pandav RS DeKosky ST May 2005 Alzheimer disease and mortality a 15 year epidemiological study Archives of Neurology 62 5 779 784 doi 10 1001 archneur 62 5 779 PMID 15883266 a b Mendez MF November 2012 Early onset Alzheimer s disease nonamnestic subtypes and type 2 AD Archives of Medical Research 43 8 677 685 doi 10 1016 j arcmed 2012 11 009 PMC 3532551 PMID 23178565 a b Dementia diagnosis and assessment PDF National Institute for Health and Care Excellence NICE Archived from the original PDF on 5 December 2014 Retrieved 30 November 2014 Gomperts SN April 2016 Lewy Body Dementias Dementia With Lewy Bodies and Parkinson Disease Dementia Continuum Review 22 2 Dementia 435 463 doi 10 1212 CON 0000000000000309 PMC 5390937 PMID 27042903 a b Lott IT Head E March 2019 Dementia in Down syndrome unique insights for Alzheimer disease research Nat Rev Neurol 15 3 135 147 doi 10 1038 s41582 018 0132 6 PMC 8061428 PMID 30733618 Commission de la transparence June 2012 Drugs for Alzheimer s disease best avoided No therapeutic advantage Drugs for Alzheimer s disease best avoided No therapeutic advantage Prescrire International 21 128 150 PMID 22822592 a b Querfurth HW LaFerla FM January 2010 Alzheimer s disease The New England Journal of Medicine 362 4 329 344 doi 10 1056 NEJMra0909142 PMID 20107219 S2CID 205115756 a b c d e f g h i j k Breijyeh Z Karaman R December 2020 Comprehensive Review on Alzheimer s Disease Causes and Treatment Molecules Review 25 24 5789 doi 10 3390 molecules25245789 PMC 7764106 PMID 33302541 a b c d Simon RP Greenberg DA Aminoff MJ 2018 Clinical neurology Tenth ed New York McGraw Hill p 111 ISBN 978 1 259 86173 4 OCLC 1012400314 a b c d Burns A Iliffe S February 2009 Alzheimer s disease BMJ 338 b158 doi 10 1136 bmj b158 PMID 19196745 S2CID 8570146 a b c d e f g h i Alzheimer s Disease Fact Sheet National Institute on Aging Retrieved 25 January 2021 Todd S Barr S Roberts M Passmore AP November 2013 Survival in dementia and predictors of mortality a review International Journal of Geriatric Psychiatry 28 11 1109 1124 doi 10 1002 gps 3946 PMID 23526458 S2CID 25445595 a b c d Long JM Holtzman DM October 2019 Alzheimer Disease An Update on Pathobiology and Treatment Strategies Cell 179 2 312 339 doi 10 1016 j cell 2019 09 001 PMC 6778042 PMID 31564456 a b Study reveals how APOE4 gene may increase risk for dementia National Institute on Aging Retrieved 17 March 2021 a b c d Hsu D Marshall GA 2017 Primary and secondary prevention trials in Alzheimer disease looking back moving forward Curr Alzheimer Res 14 4 426 440 doi 10 2174 1567205013666160930112125 PMC 5329133 PMID 27697063 a b c d Thompson CA Spilsbury K Hall J Birks Y Barnes C Adamson J July 2007 Systematic review of information and support interventions for caregivers of people with dementia BMC Geriatrics 7 18 doi 10 1186 1471 2318 7 18 PMC 1951962 PMID 17662119 Forbes D Forbes SC Blake CM Thiessen EJ Forbes S April 2015 Exercise programs for people with dementia The Cochrane Database of Systematic Reviews Submitted manuscript 132 4 CD006489 doi 10 1002 14651858 CD006489 pub4 PMC 9426996 PMID 25874613 National Institute for Health and Clinical Excellence Low dose antipsychotics in people with dementia National Institute for Health and Care Excellence NICE Archived from the original on 5 December 2014 Retrieved 29 November 2014 Information for Healthcare Professionals Conventional Antipsychotics US Food and Drug Administration 16 June 2008 Archived from the original on 29 November 2014 Retrieved 29 November 2014 Zhu D Montagne A Zhao Z June 2021 Alzheimer s pathogenic mechanisms and underlying sex difference Cell Mol Life Sci 78 11 4907 4920 doi 10 1007 s00018 021 03830 w PMC 8720296 PMID 33844047 a b c Berchtold NC Cotman CW 1998 Evolution in the conceptualization of dementia and Alzheimer s disease Greco Roman period to the 1960s Neurobiology of Aging 19 3 173 189 doi 10 1016 S0197 4580 98 00052 9 PMID 9661992 S2CID 24808582 a b Alzheimer s Disease Fact Sheet National Institute on Aging Retrieved 23 March 2022 a b c Alzheimer s disease Symptoms nhs uk 10 May 2018 a b Waldemar G Dubois B Emre M et al January 2007 Recommendations for the diagnosis and management of Alzheimer s disease and other disorders associated with dementia EFNS guideline European Journal of Neurology 14 1 e1 26 doi 10 1111 j 1468 1331 2006 01605 x PMID 17222085 S2CID 2725064 a b c Backman L Jones S Berger AK Laukka EJ Small BJ September 2004 Multiple cognitive deficits during the transition to Alzheimer s disease Journal of Internal Medicine 256 3 195 204 doi 10 1111 j 1365 2796 2004 01386 x PMID 15324363 S2CID 37005854 Nygard L 2003 Instrumental activities of daily living a stepping stone towards Alzheimer s disease diagnosis in subjects with mild cognitive impairment Acta Neurologica Scandinavica Supplementum 179 s179 42 46 doi 10 1034 j 1600 0404 107 s179 8 x PMID 12603250 S2CID 25313065 Deardorff WJ Grossberg GT 2019 Behavioral and psychological symptoms in Alzheimer s dementia and vascular dementia Handbook of Clinical Neurology 165 5 32 doi 10 1016 B978 0 444 64012 3 00002 2 ISBN 978 0444640123 PMID 31727229 S2CID 208037448 Murray ED Buttner N Price BH 2012 Depression and Psychosis in Neurological Practice In Bradley WG Daroff RB Fenichel GM Jankovic J eds Bradley s neurology in clinical practice 6th ed Philadelphia PA Elsevier Saunders ISBN 978 1 4377 0434 1 a b Petersen RC Lopez O Armstrong MJ Getchius TS Ganguli M Gloss D et al January 2018 Practice guideline update summary Mild cognitive impairment Report of the Guideline Development Dissemination and Implementation Subcommittee of the American Academy of Neurology Neurology 90 3 126 135 doi 10 1212 WNL 0000000000004826 PMC 5772157 PMID 29282327 a b c Atri A March 2019 The Alzheimer s Disease Clinical Spectrum Diagnosis and Management The Medical Clinics of North America Review 103 2 263 293 doi 10 1016 j mcna 2018 10 009 PMID 30704681 S2CID 73432842 a b c d e f g h i j k l m n o p q r s Forstl H Kurz A 1999 Clinical features of Alzheimer s disease European Archives of Psychiatry and Clinical Neuroscience 249 6 288 290 doi 10 1007 s004060050101 PMID 10653284 S2CID 26142779 Carlesimo GA Oscar Berman M June 1992 Memory deficits in Alzheimer s patients a comprehensive review Neuropsychology Review 3 2 119 169 doi 10 1007 BF01108841 PMID 1300219 S2CID 19548915 Jelicic M Bonebakker AE Bonke B 1995 Implicit memory performance of patients with Alzheimer s disease a brief review International Psychogeriatrics 7 3 385 392 doi 10 1017 S1041610295002134 PMID 8821346 S2CID 9419442 a b Taler V Phillips NA July 2008 Language performance in Alzheimer s disease and mild cognitive impairment a comparative review Journal of Clinical and Experimental Neuropsychology 30 5 501 556 doi 10 1080 13803390701550128 PMID 18569251 S2CID 37153159 a b c Frank EM September 1994 Effect of Alzheimer s disease on communication function Journal of the South Carolina Medical Association 90 9 417 423 PMID 7967534 Volicer L Harper DG Manning BC Goldstein R Satlin A May 2001 Sundowning and circadian rhythms in Alzheimer s disease The American Journal of Psychiatry 158 5 704 711 doi 10 1176 appi ajp 158 5 704 PMID 11329390 S2CID 10492607 Gold DP Reis MF Markiewicz D Andres D January 1995 When home caregiving ends a longitudinal study of outcomes for caregivers of relatives with dementia Journal of the American Geriatrics Society 43 1 10 16 doi 10 1111 j 1532 5415 1995 tb06235 x PMID 7806732 S2CID 29847950 a b Alzheimer s disease Symptoms and causes Mayo Clinic Retrieved 23 March 2022 Alzheimer s disease Causes NHS Tackenberg C Kulic L Nitsch RM 2020 Familial Alzheimer s disease mutations at position 22 of the amyloid b peptide sequence differentially affect synaptic loss tau phosphorylation and neuronal cell death in an ex vivo system PLOS ONE 15 9 e0239584 Bibcode 2020PLoSO 1539584T doi 10 1371 journal pone 0239584 PMC 7510992 PMID 32966331 Wang H Kulas JA Wang C Holtzman DM Ferris HA Hansen SB August 2021 Regulation of beta amyloid production in neurons by astrocyte derived cholesterol Proceedings of the National Academy of Sciences of the United States of America 118 33 e2102191118 Bibcode 2021PNAS 11802191W doi 10 1073 pnas 2102191118 ISSN 0027 8424 PMC 8379952 PMID 34385305 S2CID 236998499 Vilchez D Saez I Dillin A December 2014 The role of protein clearance mechanisms in organismal ageing and age related diseases Nature Communications 5 5659 Bibcode 2014NatCo 5 5659V doi 10 1038 ncomms6659 PMID 25482515 Jacobson M McCarthy N 2002 Apoptosis Oxford OX Oxford University Press p 290 ISBN 0199638497 Hardy J Allsop D October 1991 Amyloid deposition as the central event in the aetiology of Alzheimer s disease Trends in Pharmacological Sciences 12 10 383 388 doi 10 1016 0165 6147 91 90609 V PMID 1763432 a b Mudher A Lovestone S January 2002 Alzheimer s disease do tauists and baptists finally shake hands Trends in Neurosciences 25 1 22 26 doi 10 1016 S0166 2236 00 02031 2 PMID 11801334 S2CID 37380445 Polvikoski T Sulkava R Haltia M Kainulainen K Vuorio A Verkkoniemi A et al November 1995 Apolipoprotein E dementia and cortical deposition of beta amyloid protein The New England Journal of Medicine 333 19 1242 1247 doi 10 1056 NEJM199511093331902 PMID 7566000 Selkoe DJ June 1999 Translating cell biology into therapeutic advances in Alzheimer s disease Nature 399 6738 Suppl A23 A31 doi 10 1038 19866 PMID 10392577 S2CID 42287088 Borchelt DR Thinakaran G Eckman CB Lee MK Davenport F Ratovitsky T et al November 1996 Familial Alzheimer s disease linked presenilin 1 variants elevate Abeta1 42 1 40 ratio in vitro and in vivo Neuron 17 5 1005 1013 doi 10 1016 S0896 6273 00 80230 5 PMID 8938131 S2CID 18315650 Kim JH December 2018 Genetics of Alzheimer s Disease Dementia and Neurocognitive Disorders 17 4 131 136 doi 10 12779 dnd 2018 17 4 131 PMC 6425887 PMID 30906402 Perea JR Bolos M Avila J October 2020 Microglia in Alzheimer s Disease in the Context of Tau Pathology Biomolecules 10 10 1439 doi 10 3390 biom10101439 PMC 7602223 PMID 33066368 Mahley RW Weisgraber KH Huang Y April 2006 Apolipoprotein E4 a causative factor and therapeutic target in neuropathology including Alzheimer s disease Proceedings of the National Academy of Sciences of the United States of America 103 15 5644 5651 Bibcode 2006PNAS 103 5644M doi 10 1073 pnas 0600549103 PMC 1414631 PMID 16567625 Blennow K de Leon MJ Zetterberg H July 2006 Alzheimer s disease Lancet 368 9533 387 403 doi 10 1016 S0140 6736 06 69113 7 PMID 16876668 S2CID 47544338 Hall K Murrell J Ogunniyi A Deeg M Baiyewu O Gao S et al January 2006 Cholesterol APOE genotype and Alzheimer disease an epidemiologic study of Nigerian Yoruba Neurology 66 2 223 227 doi 10 1212 01 wnl 0000194507 39504 17 PMC 2860622 PMID 16434658 Gureje O Ogunniyi A Baiyewu O Price B Unverzagt FW Evans RM et al January 2006 APOE epsilon4 is not associated with Alzheimer s disease in elderly Nigerians Annals of Neurology 59 1 182 185 doi 10 1002 ana 20694 PMC 2855121 PMID 16278853 Carmona S Zahs K Wu E Dakin K Bras J Guerreiro R August 2018 The role of TREM2 in Alzheimer s disease and other neurodegenerative disorders Lancet Neurol 17 8 721 730 doi 10 1016 S1474 4422 18 30232 1 PMID 30033062 S2CID 51706988 Tomiyama T July 2010 Involvement of beta amyloid in the etiology of Alzheimer s disease Brain and Nerve Shinkei Kenkyu No Shinpo 62 7 691 699 PMID 20675873 Tomiyama T Nagata T Shimada H Teraoka R Fukushima A Kanemitsu H et al March 2008 A new amyloid beta variant favoring oligomerization in Alzheimer s type dementia Annals of Neurology 63 3 377 387 doi 10 1002 ana 21321 PMID 18300294 S2CID 42311988 Tomiyama T Shimada H February 2020 APP Osaka Mutation in Familial Alzheimer s Disease Its Discovery Phenotypes and Mechanism of Recessive Inheritance International Journal of Molecular Sciences 21 4 1413 doi 10 3390 ijms21041413 PMC 7073033 PMID 32093100 Goedert M Spillantini MG Crowther RA July 1991 Tau proteins and neurofibrillary degeneration Brain Pathology 1 4 279 286 doi 10 1111 j 1750 3639 1991 tb00671 x PMID 1669718 S2CID 33331924 Iqbal K Alonso A Chen S Chohan MO El Akkad E Gong CX et al January 2005 Tau pathology in Alzheimer disease and other tauopathies Biochimica et Biophysica Acta BBA Molecular Basis of Disease 1739 2 3 198 210 doi 10 1016 j bbadis 2004 09 008 PMID 15615638 Sinyor B Mineo J Ochner C June 2020 Alzheimer s Disease Inflammation and the Role of Antioxidants Journal of Alzheimer s Disease Reports 4 1 175 183 doi 10 3233 ADR 200171 PMC 7369138 PMID 32715278 Kinney JW Bemiller SM Murtishaw AS Leisgang AM Salazar AM Lamb BT 2018 Inflammation as a central mechanism in Alzheimer s disease Alzheimer s amp Dementia 4 575 590 doi 10 1016 j trci 2018 06 014 PMC 6214864 PMID 30406177 Lin X Kapoor A Gu Y Chow MJ Peng J Zhao K Tang D February 2020 Contributions of DNA Damage to Alzheimer s Disease Int J Mol Sci 21 5 1666 doi 10 3390 ijms21051666 PMC 7084447 PMID 32121304 Irwin MR Vitiello MV March 2019 Implications of sleep disturbance and inflammation for Alzheimer s disease dementia The Lancet Neurology 18 3 296 306 doi 10 1016 S1474 4422 18 30450 2 PMID 30661858 S2CID 58546748 Huat TJ Camats Perna J Newcombe EA Valmas N Kitazawa M Medeiros R April 2019 Metal Toxicity Links to Alzheimer s Disease and Neuroinflammation J Mol Biol 431 9 1843 1868 doi 10 1016 j jmb 2019 01 018 PMC 6475603 PMID 30664867 Eikelenboom P van Exel E Hoozemans JJ Veerhuis R Rozemuller AJ van Gool WA 2010 Neuroinflammation an early event in both the history and pathogenesis of Alzheimer s disease Neuro Degenerative Diseases 7 1 3 38 41 doi 10 1159 000283480 PMID 20160456 S2CID 40048333 Bartzokis G August 2011 Alzheimer s disease as homeostatic responses to age related myelin breakdown Neurobiology of Aging 32 8 1341 1371 doi 10 1016 j neurobiolaging 2009 08 007 PMC 3128664 PMID 19775776 Cai Z Xiao M 2016 Oligodendrocytes and Alzheimer s disease The International Journal of Neuroscience 126 2 97 104 doi 10 3109 00207454 2015 1025778 PMID 26000818 S2CID 21448714 Alves GS Oertel Knochel V Knochel C Carvalho AF Pantel J Engelhardt E Laks J 2015 Integrating retrogenesis theory to Alzheimer s disease pathology insight from DTI TBSS investigation of the white matter microstructural integrity BioMed Research International 2015 291658 doi 10 1155 2015 291658 PMC 4320890 PMID 25685779 Reisberg B Franssen EH Hasan SM Monteiro I Boksay I Souren LE et al 1999 Retrogenesis clinical physiologic and pathologic mechanisms in brain aging Alzheimer s and other dementing processes European Archives of Psychiatry and Clinical Neuroscience 249 3 28 36 doi 10 1007 pl00014170 PMID 10654097 S2CID 23410069 Zis P Hadjivassiliou M February 2019 Treatment of Neurological Manifestations of Gluten Sensitivity and Coeliac Disease Current Treatment Options in Neurology 21 3 10 doi 10 1007 s11940 019 0552 7 PMID 30806821 S2CID 73466457 Makhlouf S Messelmani M Zaouali J Mrissa R March 2018 Cognitive impairment in celiac disease and non celiac gluten sensitivity review of literature on the main cognitive impairments the imaging and the effect of gluten free diet Acta Neurologica Belgica Review 118 1 21 27 doi 10 1007 s13760 017 0870 z PMID 29247390 S2CID 3943047 Wenk GL 2003 Neuropathologic changes in Alzheimer s disease The Journal of Clinical Psychiatry 64 Suppl 9 7 10 PMID 12934968 Braak H Del Tredici K December 2012 Where when and in what form does sporadic Alzheimer s disease begin Current Opinion in Neurology 25 6 708 714 doi 10 1097 WCO 0b013e32835a3432 PMID 23160422 Desikan RS Cabral HJ Hess CP Dillon WP Glastonbury CM Weiner MW et al August 2009 Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer s disease Brain 132 Pt 8 2048 2057 doi 10 1093 brain awp123 PMC 2714061 PMID 19460794 Moan R July 2009 MRI Software Accurately IDs Preclinical Alzheimer s Disease Diagnostic Imaging a b Tiraboschi P Hansen LA Thal LJ Corey Bloom J June 2004 The importance of neuritic plaques and tangles to the development and evolution of AD Neurology 62 11 1984 1989 doi 10 1212 01 WNL 0000129697 01779 0A PMID 15184601 S2CID 25017332 DeTure MA Dickson DW August 2019 The neuropathological diagnosis of Alzheimer s disease Molecular Neurodegeneration 14 1 32 doi 10 1186 s13024 019 0333 5 PMC 6679484 PMID 31375134 Tiraboschi P Sabbagh MN Hansen LA Salmon DP Merdes A Gamst A et al April 2004 Alzheimer disease without neocortical neurofibrillary tangles a second look Neurology 62 7 1141 1147 doi 10 1212 01 wnl 0000118212 41542 e7 PMID 15079014 S2CID 22832110 Bouras C Hof PR Giannakopoulos P Michel JP Morrison JH 1994 Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients a quantitative evaluation of a one year autopsy population from a geriatric hospital Cerebral Cortex 4 2 138 150 doi 10 1093 cercor 4 2 138 PMID 8038565 Kotzbauer PT Trojanowsk JQ Lee VM October 2001 Lewy body pathology in Alzheimer s disease Journal of Molecular Neuroscience 17 2 225 232 doi 10 1385 JMN 17 2 225 PMID 11816795 S2CID 44407971 Hashimoto M Rockenstein E Crews L Masliah E 2003 Role of protein aggregation in mitochondrial dysfunction and neurodegeneration in Alzheimer s and Parkinson s diseases Neuromolecular Medicine 4 1 2 21 36 doi 10 1385 NMM 4 1 2 21 PMID 14528050 S2CID 20760249 Priller C Bauer T Mitteregger G Krebs B Kretzschmar HA Herms J July 2006 Synapse formation and function is modulated by the amyloid precursor protein The Journal of Neuroscience 26 27 7212 7221 doi 10 1523 JNEUROSCI 1450 06 2006 PMC 6673945 PMID 16822978 Turner PR O Connor K Tate WP Abraham WC May 2003 Roles of amyloid precursor protein and its fragments in regulating neural activity plasticity and memory Progress in Neurobiology 70 1 1 32 doi 10 1016 S0301 0082 03 00089 3 PMID 12927332 S2CID 25376584 Hooper NM April 2005 Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein Biochemical Society Transactions 33 Pt 2 335 338 doi 10 1042 BST0330335 PMID 15787600 S2CID 14269634 Ohnishi S Takano K March 2004 Amyloid fibrils from the viewpoint of protein folding Cellular and Molecular Life Sciences 61 5 511 524 doi 10 1007 s00018 003 3264 8 PMID 15004691 S2CID 25739126 Hernandez F Avila J September 2007 Tauopathies Cellular and Molecular Life Sciences 64 17 2219 2233 doi 10 1007 s00018 007 7220 x PMID 17604998 Sun W Samimi H Gamez M Zare H Frost B August 2018 Pathogenic tau induced piRNA depletion promotes neuronal death through transposable element dysregulation in neurodegenerative tauopathies Nature Neuroscience 21 8 1038 1048 doi 10 1038 s41593 018 0194 1 PMC 6095477 PMID 30038280 Van Broeck B Van Broeckhoven C Kumar Singh S 2007 Current insights into molecular mechanisms of Alzheimer disease and their implications for therapeutic approaches Neuro Degenerative Diseases 4 5 349 365 doi 10 1159 000105156 PMID 17622778 S2CID 7949658 Huang Y Mucke L March 2012 Alzheimer mechanisms and therapeutic strategies Cell 148 6 1204 1222 doi 10 1016 j cell 2012 02 040 PMC 3319071 PMID 22424230 Yankner BA Duffy LK Kirschner DA October 1990 Neurotrophic and neurotoxic effects of amyloid beta protein reversal by tachykinin neuropeptides Science 250 4978 279 282 Bibcode 1990Sci 250 279Y doi 10 1126 science 2218531 PMID 2218531 Chen X Yan SD December 2006 Mitochondrial Abeta a potential cause of metabolic dysfunction in Alzheimer s disease IUBMB Life 58 12 686 694 doi 10 1080 15216540601047767 PMID 17424907 S2CID 85423830 Greig NH Mattson MP Perry T Chan SL Giordano T Sambamurti K et al December 2004 New therapeutic strategies and drug candidates for neurodegenerative diseases p53 and TNF alpha inhibitors and GLP 1 receptor agonists Annals of the New York Academy of Sciences 1035 290 315 doi 10 1196 annals 1332 018 PMID 15681814 S2CID 84659695 Heneka MT Carson MJ El Khoury J Landreth GE Brosseron F Feinstein DL et al April 2015 Neuroinflammation in Alzheimer s disease The Lancet Neurology 14 4 388 405 doi 10 1016 S1474 4422 15 70016 5 PMC 5909703 PMID 25792098 Tapia Arancibia L Aliaga E Silhol M Arancibia S November 2008 New insights into brain BDNF function in normal aging and Alzheimer disease Brain Research Reviews 59 1 201 220 doi 10 1016 j brainresrev 2008 07 007 hdl 10533 142174 PMID 18708092 S2CID 6589846 Schindowski K Belarbi K Buee L February 2008 Neurotrophic factors in Alzheimer s disease role of axonal transport Genes Brain and Behavior 7 Suppl 1 43 56 doi 10 1111 j 1601 183X 2007 00378 x PMC 2228393 PMID 18184369 Khan S Barve KH Kumar MS 2020 Recent Advancements in Pathogenesis Diagnostics and Treatment of Alzheimer s Disease Curr Neuropharmacol 18 11 1106 1125 doi 10 2174 1570159X18666200528142429 PMC 7709159 PMID 32484110 a b Gauthreaux K Bonnett TA Besser LM et al May 2020 Concordance of Clinical Alzheimer Diagnosis and Neuropathological Features at Autopsy J Neuropathol Exp Neurol 79 5 465 473 doi 10 1093 jnen nlaa014 PMC 7160616 PMID 32186726 a b Sachdev PS Blacker D Blazer DG Ganguli M Jeste DV Paulsen JS Petersen RC November 2014 Classifying neurocognitive disorders the DSM 5 approach Nature Reviews Neurology 10 11 634 642 doi 10 1038 nrneurol 2014 181 PMID 25266297 S2CID 20635070 Mendez MF 2006 The accurate diagnosis of early onset dementia International Journal of Psychiatry in Medicine 36 4 401 412 doi 10 2190 Q6J4 R143 P630 KW41 PMID 17407994 S2CID 43715976 Klafki HW Staufenbiel M Kornhuber J Wiltfang J November 2006 Therapeutic approaches to Alzheimer s disease Brain 129 Pt 11 2840 2855 doi 10 1093 brain awl280 PMID 17018549 Dementia Quick Reference Guide PDF London UK National Institute for Health and Clinical Excellence 2006 ISBN 978 1 84629 312 2 Archived from the original PDF on 27 February 2008 Retrieved 22 February 2008 Schroeter ML Stein T Maslowski N Neumann J October 2009 Neural correlates of Alzheimer s disease and mild cognitive impairment a systematic and quantitative meta analysis involving 1351 patients NeuroImage 47 4 1196 1206 doi 10 1016 j neuroimage 2009 05 037 PMC 2730171 PMID 19463961 Jie CV Treyer V Schibli R Mu L January 2021 Tauvid The First FDA Approved PET Tracer for Imaging Tau Pathology in Alzheimer s Disease Pharmaceuticals 14 2 110 doi 10 3390 ph14020110 PMC 7911942 PMID 33573211 a b c d e Weller J Budson A 2018 Current understanding of Alzheimer s disease diagnosis and treatment F1000Research Review 7 1161 doi 10 12688 f1000research 14506 1 PMC 6073093 PMID 30135715 Silva MV Loures CM Alves LC de Souza LC Borges KB Carvalho MD May 2019 Alzheimer s disease risk factors and potentially protective measures Journal of Biomedical Science 26 1 33 doi 10 1186 s12929 019 0524 y PMC 6507104 PMID 31072403 Hane FT Robinson M Lee BY Bai O Leonenko Z Albert MS 2017 Recent Progress in Alzheimer s Disease Research Part 3 Diagnosis and Treatment Journal of Alzheimer s Disease Review 57 3 645 665 doi 10 3233 JAD 160907 PMC 5389048 PMID 28269772 Diagnostic and statistical manual of mental disorders DSM IV TR 4th Text Revision ed Washington DC American Psychiatric Association 2000 ISBN 978 0 89042 025 6 a b c Diagnostic and statistical manual of mental disorders DSM 5 Washington D C American Psychiatric Association 2013 p 611 ISBN 978 0890425558 Sachs Ericsson N Blazer DG January 2015 The new DSM 5 diagnosis of mild neurocognitive disorder and its relation to research in mild cognitive impairment Aging amp Mental Health 19 1 2 12 doi 10 1080 13607863 2014 920303 PMID 24914889 S2CID 46244321 Stokin GB Krell Roesch J Petersen RC Geda YE 2015 Mild Neurocognitive Disorder An Old Wine in a New Bottle Harvard Review of Psychiatry Review 23 5 368 376 doi 10 1097 HRP 0000000000000084 PMC 4894762 PMID 26332219 Sperry L Carlson J Sauerheber J Sperry J eds 2014 Psychopathology and Psychotherapy DSM 5 Diagnosis Case Conceptualization and Treatment 3 ed New York Routledge pp 342 343 doi 10 4324 9780203772287 ISBN 978 0 203 77228 7 Fink HA Hemmy LS Linskens EJ et al 2020 Diagnosis and Treatment of Clinical Alzheimer s Type Dementia A Systematic Review AHRQ Comparative Effectiveness Reviews Rockville MD Agency for Healthcare Research and Quality US PMID 32369312 Stokin GB Krell Roesch J Petersen RC Geda YE September 2015 Mild Neurocognitive Disorder An Old Wine in a New Bottle Harvard Review of Psychiatry Wolters Kluwer Health 23 5 368 376 doi 10 1097 HRP 0000000000000084 PMC 4894762 PMID 26332219 Bradfield NI Ames D April 2020 Mild cognitive impairment narrative review of taxonomies and systematic review of their prediction of incident Alzheimer s disease dementia BJPsych Bulletin Review 44 2 67 74 doi 10 1192 bjb 2019 77 PMC 7283119 PMID 31724527 a b Vega JN Newhouse PA October 2014 Mild cognitive impairment diagnosis longitudinal course and emerging treatments Current Psychiatry Reports SpringerLink 16 10 490 doi 10 1007 s11920 014 0490 8 PMC 4169219 PMID 25160795 Parnetti L Chipi E Salvadori N D Andrea K Eusebi P January 2019 Prevalence and risk of progression of preclinical Alzheimer s disease stages a systematic review and meta analysis Alzheimer s Research amp Therapy Springer Nature 11 1 7 doi 10 1186 s13195 018 0459 7 PMC 6334406 PMID 30646955 a b c d e Jack CR Bennett DA Blennow K Carrillo MC Dunn B Haeberlein SB et al April 2018 NIA AA Research Framework Toward a biological definition of Alzheimer s disease Alzheimer s amp Dementia Wiley Online Library 14 4 535 562 doi 10 1016 j jalz 2018 02 018 PMC 5958625 PMID 29653606 Sperling RA Aisen PS Beckett LA Bennett DA Craft S Fagan AM et al May 2011 Toward defining the preclinical stages of Alzheimer s disease recommendations from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease Alzheimer s amp Dementia Wiley Online Library 7 3 280 292 doi 10 1016 j jalz 2011 03 003 PMC 3220946 PMID 21514248 Cheng YW Chen TF Chiu MJ 16 February 2017 From mild cognitive impairment to subjective cognitive decline conceptual and methodological evolution Neuropsychiatric Disease and Treatment Dove Medical Press Limited 13 491 498 doi 10 2147 NDT S123428 PMC 5317337 PMID 28243102 Albert MS DeKosky ST Dickson D Dubois B Feldman HH Fox NC et al May 2011 The diagnosis of mild cognitive impairment due to Alzheimer s disease recommendations from the National Institute on Aging Alzheimer s Association workgroups on diagnostic guidelines for Alzheimer s disease Alzheimer s amp Dementia Wiley Online Library 7 3 270 279 doi 10 1016 j jalz 2011 03 008 PMC 3312027 PMID 21514249 a b c d Chertkow H Feldman HH Jacova C Massoud F July 2013 Definitions of dementia and predementia states in Alzheimer s disease and vascular cognitive impairment consensus from the Canadian conference on diagnosis of dementia Alzheimer s Research amp Therapy BMC 5 Suppl 1 S2 doi 10 1186 alzrt198 PMC 3981054 PMID 24565215 a b c Papadakis MA McPhee SJ Rabow MW 2021 Current medical diagnosis amp treatment Sixtieth ed New York McGraw Hill p 1760 ISBN 978 1 260 46986 8 OCLC 1195972209 Tombaugh TN McIntyre NJ September 1992 The mini mental state examination a comprehensive review Journal of the American Geriatrics Society 40 9 922 935 doi 10 1111 j 1532 5415 1992 tb01992 x PMID 1512391 S2CID 25169596 Pasquier F January 1999 Early diagnosis of dementia neuropsychology Journal of Neurology 246 1 6 15 doi 10 1007 s004150050299 PMID 9987708 S2CID 2108587 Harvey PD Moriarty PJ Kleinman L Coyne K Sadowsky CH Chen M Mirski DF 2005 The validation of a caregiver assessment of dementia the Dementia Severity Scale Alzheimer Disease and Associated Disorders 19 4 186 194 doi 10 1097 01 wad 0000189034 43203 60 PMID 16327345 S2CID 20238911 Antoine C Antoine P Guermonprez P Frigard B 2004 Awareness of deficits and anosognosia in Alzheimer s disease L Encephale in French 30 6 570 577 doi 10 1016 S0013 7006 04 95472 3 PMID 15738860 Cruz VT Pais J Teixeira A Nunes B 2004 The initial symptoms of Alzheimer disease caregiver perception Acta Medica Portuguesa in Portuguese 17 6 435 444 PMID 16197855 a b c Stern SD 2020 Symptom to diagnosis an evidence based guide Adam S Cifu Diane Altkorn 4th ed New York pp 209 210 ISBN 978 1260121117 OCLC 1121597721 Jha A Mukhopadhaya K 2021 Alzheimer s disease diagnosis and treatment guide Cham Switzerland Springer p 32 ISBN 978 3 030 56739 2 OCLC 1202472277 Sun X Steffens DC Au R Folstein M Summergrad P Yee J et al May 2008 Amyloid associated depression a prodromal depression of Alzheimer disease Archives of General Psychiatry 65 5 542 550 doi 10 1001 archpsyc 65 5 542 PMC 3042807 PMID 18458206 Geldmacher DS Whitehouse PJ May 1997 Differential diagnosis of Alzheimer s disease Neurology 48 5 Suppl 6 S2 S9 doi 10 1212 WNL 48 5 Suppl 6 2S PMID 9153154 S2CID 30018544 Potter GG Steffens DC May 2007 Contribution of depression to cognitive impairment and dementia in older adults The Neurologist 13 3 105 117 doi 10 1097 01 nrl 0000252947 15389 a9 PMID 17495754 S2CID 24569198 Zhang S Smailagic N Hyde C Noel Storr AH Takwoingi Y McShane R Feng J July 2014 11 C PIB PET for the early diagnosis of Alzheimer s disease dementia and other dementias in people with mild cognitive impairment MCI The Cochrane Database of Systematic Reviews 2014 7 CD010386 doi 10 1002 14651858 CD010386 pub2 PMC 6464750 PMID 25052054 Smailagic N Vacante M Hyde C Martin S Ukoumunne O Sachpekidis C January 2015 18F FDG PET for the early diagnosis of Alzheimer s disease dementia and other dementias in people with mild cognitive impairment MCI The Cochrane Database of Systematic Reviews 1 1 CD010632 doi 10 1002 14651858 CD010632 pub2 PMC 7081123 PMID 25629415 Vina J Sanz Ros J October 2018 Alzheimer s disease Only prevention makes sense European Journal of Clinical Investigation 48 10 e13005 doi 10 1111 eci 13005 PMID 30028503 S2CID 51703879 Patterson C Feightner JW Garcia A Hsiung GY MacKnight C Sadovnick AD February 2008 Diagnosis and treatment of dementia 1 Risk assessment and primary prevention of Alzheimer disease CMAJ 178 5 548 556 doi 10 1503 cmaj 070796 PMC 2244657 PMID 18299540 Rosendorff C Beeri MS Silverman JM 2007 Cardiovascular risk factors for Alzheimer s disease The American Journal of Geriatric Cardiology 16 3 143 149 doi 10 1111 j 1076 7460 2007 06696 x PMID 17483665 Chu CS Tseng PT Stubbs B et al April 2018 Use of statins and the risk of dementia and mild cognitive impairment A systematic review and meta analysis Scientific Reports 8 1 5804 Bibcode 2018NatSR 8 5804C doi 10 1038 s41598 018 24248 8 PMC 5895617 PMID 29643479 Ungvari Z Toth P Tarantini S et al October 2021 Hypertension induced cognitive impairment from pathophysiology to public health Nat Rev Nephrol 17 10 639 654 doi 10 1038 s41581 021 00430 6 PMC 8202227 PMID 34127835 a b c d e f g Yu JT Xu W Tan CC et al November 2020 Evidence based prevention of Alzheimer s disease systematic review and meta analysis of 243 observational prospective studies and 153 randomised controlled trials J Neurol Neurosurg Psychiatry 91 11 1201 1209 doi 10 1136 jnnp 2019 321913 PMC 7569385 PMID 32690803 Lethaby A Hogervorst E Richards M Yesufu A Yaffe K January 2008 Hormone replacement therapy for cognitive function in postmenopausal women Cochrane Database Syst Rev 2008 1 CD003122 doi 10 1002 14651858 CD003122 pub2 PMC 6599876 PMID 18254016 Cheng ST September 2016 Cognitive Reserve and the Prevention of Dementia the Role of Physical and Cognitive Activities Current Psychiatry Reports Review 18 9 85 doi 10 1007 s11920 016 0721 2 PMC 4969323 PMID 27481112 Farina N Rusted J Tabet N January 2014 The effect of exercise interventions on cognitive outcome in Alzheimer s disease a systematic review International Psychogeriatrics Review 26 1 9 18 doi 10 1017 S1041610213001385 PMID 23962667 S2CID 24936334 Barnard ND Bush AI Ceccarelli A et al September 2014 Dietary and lifestyle guidelines for the prevention of Alzheimer s disease Neurobiology of Aging Review 35 Suppl 2 S74 S78 doi 10 1016 j neurobiolaging 2014 03 033 PMID 24913896 S2CID 8265377 a b Bhatti GK Reddy AP Reddy PH Bhatti JS 2019 Lifestyle Modifications and Nutritional Interventions in Aging Associated Cognitive Decline and Alzheimer s Disease Frontiers in Aging Neuroscience Review 11 369 doi 10 3389 fnagi 2019 00369 PMC 6966236 PMID 31998117 Lopez Ortiz S Lista S Valenzuela PL Pinto Fraga J Carmona R Caraci F et al November 2022 Effects of physical activity and exercise interventions on Alzheimer s disease an umbrella review of existing meta analyses Journal of Neurology doi 10 1007 s00415 022 11454 8 PMID 36342524 S2CID 253382289 a b Vina J Sanz Ros J October 2018 Alzheimer s disease Only prevention makes sense European Journal of Clinical Investigation Review 48 10 e13005 doi 10 1111 eci 13005 PMID 30028503 S2CID 51703879 Imtiaz B Tolppanen AM Kivipelto M Soininen H April 2014 Future directions in Alzheimer s disease from risk factors to prevention Biochemical Pharmacology Review 88 4 661 670 doi 10 1016 j bcp 2014 01 003 PMID 24418410 Imtiaz B Tolppanen AM Kivipelto M Soininen H April 2014 Future directions in Alzheimer s disease from risk factors to prevention Biochem Pharmacol 88 4 661 70 doi 10 1016 j bcp 2014 01 003 PMID 24418410 Kivipelto M Mangialasche F Ngandu T November 2018 Lifestyle interventions to prevent cognitive impairment dementia and Alzheimer disease Nat Rev Neurol 14 11 653 666 doi 10 1038 s41582 018 0070 3 PMID 30291317 S2CID 52925352 a b c d Borges CR Poyares D Piovezan R Nitrini R Brucki S November 2019 Alzheimer s disease and sleep disturbances a review Arq Neuropsiquiatr 77 11 815 824 doi 10 1590 0004 282X20190149 PMID 31826138 S2CID 209327994 a b Uddin MS Tewari D Mamun AA et al July 2020 Circadian and sleep dysfunction in Alzheimer s disease Ageing Res Rev 60 101046 doi 10 1016 j arr 2020 101046 PMID 32171783 S2CID 212729131 Rasmussen MK Mestre H Nedergaard M November 2018 The glymphatic pathway in neurological disorders Lancet Neurol 17 11 1016 1024 doi 10 1016 S1474 4422 18 30318 1 PMC 6261373 PMID 30353860 Irwin MR Vitiello MV March 2019 Implications of sleep disturbance and inflammation for Alzheimer s disease dementia Lancet Neurol 18 3 296 306 doi 10 1016 S1474 4422 18 30450 2 PMID 30661858 S2CID 58546748 Hampel H Vergallo A Aguilar LF et al April 2018 Precision pharmacology for Alzheimer s disease Pharmacol Res 130 331 365 doi 10 1016 j phrs 2018 02 014 PMC 8505114 PMID 29458203 Chen Y Zhang J Zhang T et al March 2020 Meditation treatment of Alzheimer disease and mild cognitive impairment A protocol for systematic review Medicine Baltimore 99 10 e19313 doi 10 1097 MD 0000000000019313 PMC 7478420 PMID 32150066 Drislane F Hovauimian A Tarulli A Boegle AK McIiduff C Caplan LR 2019 Blueprints neurology Fifth ed Philadelphia Wolters Kluwer p 146 ISBN 978 1 4963 8739 4 OCLC 1048659425 a b c Birks JS Harvey RJ June 2018 Donepezil for dementia due to Alzheimer s disease The Cochrane Database of Systematic Reviews 2018 6 CD001190 doi 10 1002 14651858 CD001190 pub3 PMC 6513124 PMID 29923184 Fink HA Linskens EJ MacDonald R et al May 2020 Benefits and Harms of Prescription Drugs and Supplements for Treatment of Clinical Alzheimer Type Dementia Annals of Internal Medicine 172 10 656 668 doi 10 7326 M19 3887 PMID 32340037 S2CID 216595473 Berkowitz A 2017 Clinical neurology and neuroanatomy a localization based approach New York McGraw Hill p 236 ISBN 978 1 259 83440 0 OCLC 948547621 Geula C Mesulam MM 1995 Cholinesterases and the pathology of Alzheimer disease Alzheimer Disease and Associated Disorders 9 Suppl 2 23 28 doi 10 1097 00002093 199501002 00005 PMID 8534419 Stahl SM November 2000 The new cholinesterase inhibitors for Alzheimer s disease Part 2 illustrating their mechanisms of action The Journal of Clinical Psychiatry 61 11 813 814 doi 10 4088 JCP v61n1101 PMID 11105732 a b Birks J January 2006 Birks J ed Cholinesterase inhibitors for Alzheimer s disease The Cochrane Database of Systematic Reviews 2016 1 CD005593 doi 10 1002 14651858 CD005593 PMC 9006343 PMID 16437532 Raschetti R Albanese E Vanacore N Maggini M November 2007 Cholinesterase inhibitors in mild cognitive impairment a systematic review of randomised trials PLOS Medicine 4 11 e338 doi 10 1371 journal pmed 0040338 PMC 2082649 PMID 18044984 Alldredge BK Corelli RL Ernst ME Guglielmo BJ Jacobson PA Kradjan WA Williams BR 2013 Applied therapeutics the clinical use of drugs 10th ed Baltimore Wolters Kluwer Health Lippincott Williams amp Wilkins p 2385 ISBN 978 1 60913 713 7 a b Lipton SA February 2006 Paradigm shift in neuroprotection by NMDA receptor blockade memantine and beyond Nature Reviews Drug Discovery 5 2 160 170 doi 10 1038 nrd1958 PMID 16424917 S2CID 21379258 Memantine US National Library of Medicine Medline 4 January 2004 Archived from the original on 22 February 2010 Retrieved 3 February 2010 McShane R Westby MJ Roberts E Minakaran N Schneider L Farrimond LE et al March 2019 Memantine for dementia The Cochrane Database of Systematic Reviews 3 3 CD003154 doi 10 1002 14651858 CD003154 pub6 PMC 6425228 PMID 30891742 Namenda memantine hydrochloride tablet Namenda memantine hydrochloride kit DailyMed 15 November 2018 Retrieved 20 February 2022 Namenda XR memantine hydrochloride capsule extended release Namenda XR memantine hydrochloride kit DailyMed 15 November 2019 Retrieved 20 February 2022 Namzaric memantine hydrochloride and donepezil hydrochloride capsule Namzaric memantine hydrochloride and donepezil hydrochloride kit DailyMed 22 January 2019 Retrieved 20 February 2022 Raina P Santaguida P Ismaila A Patterson C Cowan D Levine M et al March 2008 Effectiveness of cholinesterase inhibitors and memantine for treating dementia evidence review for a clinical practice guideline Annals of Internal Medicine 148 5 379 397 doi 10 7326 0003 4819 148 5 200803040 00009 PMID 18316756 S2CID 22235353 a b Kandiah N Ong PA Yuda T Ng LL Mamun K Merchant RA et al February 2019 Treatment of dementia and mild cognitive impairment with or without cerebrovascular disease Expert consensus on the use of Ginkgo biloba extract EGb 761 CNS Neuroscience amp Therapeutics 25 2 288 298 doi 10 1111 cns 13095 PMC 6488894 PMID 30648358 McKeage K Lyseng Williamson KA 2018 Ginkgo biloba extract EGb 761 in the symptomatic treatment of mild to moderate dementia a profile of its use Drugs amp Therapy Perspectives 34 8 358 366 doi 10 1007 s40267 018 0537 8 PMC 6267544 PMID 30546253 Yang G Wang Y Sun J Zhang K Liu J 22 October 2015 Ginkgo Biloba for Mild Cognitive Impairment and Alzheimer s Disease A Systematic Review and Meta Analysis of Randomized Controlled Trials Current Topics in Medicinal Chemistry 16 5 520 528 doi 10 2174 1568026615666150813143520 PMID 26268332 Ballard C Waite J January 2006 Ballard CG ed The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer s disease The Cochrane Database of Systematic Reviews 1 CD003476 doi 10 1002 14651858 CD003476 pub2 PMID 16437455 Ballard C Hanney ML Theodoulou M Douglas S McShane R Kossakowski K et al February 2009 The dementia antipsychotic withdrawal trial DART AD long term follow up of a randomised placebo controlled trial The Lancet Neurology 8 2 151 157 doi 10 1016 S1474 4422 08 70295 3 PMID 19138567 S2CID 23000439 See lay summary January 2009 Declercq T Petrovic M Azermai M Vander Stichele R De Sutter AI van Driel ML Christiaens T March 2013 Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia The Cochrane Database of Systematic Reviews 3 3 CD007726 doi 10 1002 14651858 CD007726 pub2 hdl 1854 LU 3109108 PMID 23543555 a b c d e needs update Rabins PV Blacker D Rovner BW et al Steering Committee on Practice Guidelines December 2007 American Psychiatric Association practice guideline for the treatment of patients with Alzheimer s disease and other dementias Second edition The American Journal of Psychiatry 164 12 Suppl 5 56 PMID 18340692 Bottino CM Carvalho IA Alvarez AM Avila R Zukauskas PR Bustamante SE et al December 2005 Cognitive rehabilitation combined with drug treatment in Alzheimer s disease patients a pilot study Clinical Rehabilitation 19 8 861 869 doi 10 1191 0269215505cr911oa PMID 16323385 S2CID 21290731 Doody RS Stevens JC Beck C Dubinsky RM Kaye JA Gwyther L et al May 2001 Practice parameter management of dementia an evidence based review Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology 56 9 1154 1166 doi 10 1212 WNL 56 9 1154 PMID 11342679 S2CID 10711725 Hermans DG Htay UH McShane R January 2007 Non pharmacological interventions for wandering of people with dementia in the domestic setting The Cochrane Database of Systematic Reviews 2010 1 CD005994 doi 10 1002 14651858 CD005994 pub2 PMC 6669244 PMID 17253573 Robinson L Hutchings D Dickinson HO Corner L Beyer F Finch T et al January 2007 Effectiveness and acceptability of non pharmacological interventions to reduce wandering in dementia a systematic review International Journal of Geriatric Psychiatry 22 1 9 22 doi 10 1002 gps 1643 PMID 17096455 S2CID 45660235 Abraha I Rimland JM Trotta FM Dell Aquila G Cruz Jentoft A Petrovic M et al March 2017 Systematic review of systematic reviews of non pharmacological interventions to treat behavioural disturbances in older patients with dementia The SENATOR OnTop series BMJ Open 7 3 e012759 doi 10 1136 bmjopen 2016 012759 PMC 5372076 PMID 28302633 Chung JC Lai CK Chung PM French HP 2002 Snoezelen for dementia The Cochrane Database of Systematic Reviews 2010 4 CD003152 doi 10 1002 14651858 CD003152 PMC 9002239 PMID 12519587 Woods B O Philbin L Farrell EM Spector AE Orrell M March 2018 Reminiscence therapy for dementia The Cochrane Database of Systematic Reviews 2018 3 CD001120 doi 10 1002 14651858 CD001120 pub3 PMC 6494367 PMID 29493789 Zetteler J November 2008 Effectiveness of simulated presence therapy for individuals with dementia a systematic review and meta analysis Aging amp Mental Health 12 6 779 785 doi 10 1080 13607860802380631 PMID 19023729 S2CID 39529938 Spector A Thorgrimsen L Woods B Royan L Davies S Butterworth M Orrell M September 2003 Efficacy of an evidence based cognitive stimulation therapy programme for people with dementia randomised controlled trial The British Journal of Psychiatry 183 3 248 254 doi 10 1192 bjp 183 3 248 PMID 12948999 Gitlin LN Corcoran M Winter L Boyce A Hauck WW February 2001 A randomized controlled trial of a home environmental intervention effect on efficacy and upset in caregivers and on daily function of persons with dementia The Gerontologist 41 1 4 14 doi 10 1093 geront 41 1 4 PMID 11220813 Gitlin LN Hauck WW Dennis MP Winter L March 2005 Maintenance of effects of the home environmental skill building program for family caregivers and individuals with Alzheimer s disease and related disorders The Journals of Gerontology Series A Biological Sciences and Medical Sciences 60 3 368 374 doi 10 1093 gerona 60 3 368 PMID 15860476 Treating Behavioral and Psychiatric Symptoms Alzheimer s Association 2006 Archived from the original on 25 September 2006 Retrieved 25 September 2006 Dunne TE Neargarder SA Cipolloni PB Cronin Golomb A August 2004 Visual contrast enhances food and liquid intake in advanced Alzheimer s disease Clinical Nutrition 23 4 533 538 doi 10 1016 j clnu 2003 09 015 PMID 15297089 Dudek SB 2007 Nutrition Essentials for Nursing Practice Hagerstown Maryland Lippincott Williams amp Wilkins p 360 ISBN 978 0 7817 6651 7 Retrieved 19 August 2008 Dennehy C 2006 Analysis of patients rights dementia and PEG insertion British Journal of Nursing 15 1 18 20 doi 10 12968 bjon 2006 15 1 20303 PMID 16415742 Chernoff R April 2006 Tube feeding patients with dementia Nutrition in Clinical Practice 21 2 142 146 doi 10 1177 0115426506021002142 PMID 16556924 S2CID 20841502 Shega JW Levin A Hougham GW Cox Hayley D Luchins D Hanrahan P et al April 2003 Palliative Excellence in Alzheimer Care Efforts PEACE a program description Journal of Palliative Medicine 6 2 315 320 doi 10 1089 109662103764978641 PMID 12854952 S2CID 6072807 a b Dominguez LJ Barbagallo M June 2018 Nutritional prevention of cognitive decline and dementia Acta Bio Medica 89 2 276 290 doi 10 23750 abm v89i2 7401 PMC 6179018 PMID 29957766 Hu N Yu JT Tan L Wang YL Sun L Tan L 2013 Nutrition and the risk of Alzheimer s disease BioMed Research International Review 2013 524820 doi 10 1155 2013 524820 PMC 3705810 PMID 23865055 Bhatti GK Reddy AP Reddy PH Bhatti JS 2019 Lifestyle Modifications and Nutritional Interventions in Aging Associated Cognitive Decline and Alzheimer s Disease Front Aging Neurosci 11 369 doi 10 3389 fnagi 2019 00369 PMC 6966236 PMID 31998117 a b Zanetti O Solerte SB Cantoni F 2009 Life expectancy in Alzheimer s disease AD Archives of Gerontology and Geriatrics 49 Suppl 1 237 243 doi 10 1016 j archger 2009 09 035 PMID 19836639 United States Life Tables 2017 PDF National Vital Statistics Reports CDC Retrieved 10 June 2021 a b Molsa PK Marttila RJ Rinne UK March 1995 Long term survival and predictors of mortality in Alzheimer s disease and multi infarct dementia Acta Neurologica Scandinavica 91 3 159 164 doi 10 1111 j 1600 0404 1995 tb00426 x PMID 7793228 S2CID 19724937 Bowen JD Malter AD Sheppard L Kukull WA McCormick WC Teri L Larson EB August 1996 Predictors of mortality in patients diagnosed with probable Alzheimer s disease Neurology 47 2 433 439 doi 10 1212 wnl 47 2 433 PMID 8757016 S2CID 24961809 Larson EB Shadlen MF Wang L McCormick WC Bowen JD Teri L Kukull WA April 2004 Survival after initial diagnosis of Alzheimer disease Annals of Internal Medicine 140 7 501 509 doi 10 7326 0003 4819 140 7 200404060 00008 PMID 15068977 S2CID 27410149 Jagger C Clarke M Stone A January 1995 Predictors of survival with Alzheimer s disease a community based study Psychological Medicine 25 1 171 177 doi 10 1017 S0033291700028191 PMID 7792352 S2CID 34066330 Dodge HH Shen C Pandav R DeKosky ST Ganguli M February 2003 Functional transitions and active life expectancy associated with Alzheimer disease Archives of Neurology 60 2 253 259 doi 10 1001 archneur 60 2 253 PMID 12580712 a b Bermejo Pareja F Benito Leon J Vega S Medrano MJ Roman GC January 2008 Incidence and subtypes of dementia in three elderly populations of central Spain Journal of the Neurological Sciences 264 1 2 63 72 doi 10 1016 j jns 2007 07 021 PMID 17727890 S2CID 34341344 a b Di Carlo A Baldereschi M Amaducci L Lepore V Bracco L Maggi S et al January 2002 Incidence of dementia Alzheimer s disease and vascular dementia in Italy The ILSA Study Journal of the American Geriatrics Society 50 1 41 48 doi 10 1046 j 1532 5415 2002 50006 x PMID 12028245 S2CID 22576935 Tejada Vera B 2013 Mortality from Alzheimer s Disease in the United States Data for 2000 and 2010 Hyattsville MD U S Department of Health and Human Services Centers for Disease Control and Prevention National Center for Health Statistics Reitz C Rogaeva E Beecham GW October 2020 Late onset vs nonmendelian early onset Alzheimer disease A distinction without a difference Neurology Genetics 6 5 e512 doi 10 1212 NXG 0000000000000512 PMC 7673282 PMID 33225065 a b Liu CC Liu CC Kanekiyo T Xu H Bu G February 2013 Apolipoprotein E and Alzheimer disease risk mechanisms and therapy Nature Reviews Neurology 9 2 106 118 doi 10 1038 nrneurol 2012 263 PMC 3726719 PMID 23296339 Massett HA Mitchell AK Alley L Simoneau E Burke P Han SH et al 29 June 2021 Facilitators Challenges and Messaging Strategies for Hispanic Latino Populations Participating in Alzheimer s Disease and Related Dementias Clinical Research A Literature Review Journal of Alzheimer s Disease 82 1 107 127 doi 10 3233 JAD 201463 PMID 33998537 S2CID 234745473 Huynh RA Mohan C 2017 Alzheimer s Disease Biomarkers in the Genome Blood and Cerebrospinal Fluid Frontiers in Neurology 8 102 doi 10 3389 fneur 2017 00102 PMC 5357660 PMID 28373857 Rajan KB Weuve J Barnes LL McAninch EA Wilson RS Evans DA May 2021 Population estimate of people with clinical Alzheimer s disease and mild cognitive impairment in the United States 2020 2060 Alzheimer s amp Dementia 17 12 1966 1975 doi 10 1002 alz 12362 PMC 9013315 PMID 34043283 S2CID 235215290 Rizzi L Rosset I Roriz Cruz M 2014 Global epidemiology of dementia Alzheimer s and vascular types Biomed Res Int 2014 908915 doi 10 1155 2014 908915 PMC 4095986 PMID 25089278 Ferri CP Prince M Brayne C Brodaty H Fratiglioni L Ganguli M et al December 2005 Global prevalence of dementia a Delphi consensus study Lancet 366 9503 2112 2117 doi 10 1016 S0140 6736 05 67889 0 PMC 2850264 PMID 16360788 Li F Qin W Zhu M Jia J 1 January 2021 Model Based Projection of Dementia Prevalence in China and Worldwide 2020 2050 Journal of Alzheimer s Disease IOS Press 82 4 1823 1831 doi 10 3233 JAD 210493 PMID 34219732 S2CID 235735045 Auguste D Alzheimer A 1907 Uber eine eigenartige Erkrankung der Hirnrinde About a peculiar disease of the cerebral cortex Allgemeine Zeitschrift fur Psychiatrie und Psychisch Gerichtlich Medizin in German 64 1 2 146 148 Translated by H Greenson About a peculiar disease of the cerebral cortex By Alois Alzheimer 1907 Translated by L Jarvik and H Greenson Alzheimer Disease and Associated Disorders 1 1 3 8 1987 PMID 3331112 Maurer U Maurer K 2003 Alzheimer The Life of a Physician and the Career of a Disease New Yor, wikipedia, wiki, book, books, library,

article

, read, download, free, free download, mp3, video, mp4, 3gp, jpg, jpeg, gif, png, picture, music, song, movie, book, game, games.